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Abstract	
	
Distal	intestinal	obstruction	syndrome	(DIOS)	is	a	major	gastrointestinal	complication	in	
cystic	fibrosis	(CF).	It	arises	when	thick	mucus	and	viscid	faecal	material	combine	in	the	
bowel,	commonly	at	the	terminal	ileum	or	caecum,	leading	to	partial	obstruction	
(incomplete	DIOS)	or	complete	obstruction	(complete	DIOS).	There	is	limited	evidence	for	
the	efficacy	and	safety	of	laxatives	used	to	manage	DIOS	and	insufficient	knowledge	of	
current	practices	used	to	treat	it;	consequently,	this	thesis	aimed	to	evaluate	these	
matters	in	children	and	adults.		
	
A	Cochrane	review	was	conducted	to	evaluate	the	effectiveness	and	safety	of	laxatives	
used	for	the	prevention	of	DIOS.	Of	2631	studies	identified,	only	1	study	was	included	so	
meta-analysis	could	not	be	performed.	The	study	was	a	double-blind,	placebo-controlled,	
crossover	trial	investigating	the	efficacy	of	cisapride	(a	prokinetic	drug)	in	17	patients	with	
a	history	of	DIOS.	Radiograph	scores	revealed	no	difference	between	cisapride	and	
placebo.	There	were	no	adverse	effects.	However,	total	gastrointestinal	symptom	scores	
favoured	cisapride	with	a	mean	difference	of	-7.60(95%	CI	-14.73	to	-0.47).		
However,	cisapride	is	no	longer	licenced	due	to	cardiac	side	effects,	limiting	its	clinical	
applicability.		
	
A	quantitative	survey	was	conducted	to	establish	the	current	treatments	for	constipation	
and	DIOS	in	UK	CF	centres.	Results	varied	greatly,	especially	for	the	treatment	of	DIOS:		
incomplete	DIOS	had	23	different	1st	line	combinations	in	adults	and	22	in	children;	
	
vii	
complete	DIOS	had	25	1st	line	combinations	in	adults	and	17	in	children.	Over	99%	
respondents	recognised	limited	evidence	for	their	treatment	decisions.		
	
This	thesis	demonstrates	that	there	is	a	lack	of	evidence	for	the	prevention	of	DIOS	and	
little	consensus	for	the	treatment	of	DIOS,	highlighting	a	need	for	research,	which	at	
present	is	pitifully	lacking.		
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Chapter	1:	Aims	and	Objectives		
1.1	Overview	
This	section	describes	the	aims	and	objectives	for	this	thesis.	Chapter	2	provides	an	
overview	of	the	clinical	aspects	of	cystic	fibrosis	(CF)	and	the	present	management	of	
Distal	Intestinal	Obstruction	Syndrome	(DIOS).	
1.2	Aim	
This	thesis	aims	to	evaluate	the	effectiveness,	safety	and	current	practice	of	different	
laxative	agents	in	the	management	of	DIOS,	(complete	and	incomplete)	both	in	children	
and	in	adults	with	CF.		
1.3	Objectives	
1. Conduct	 a	 Cochrane	 systematic	 review	 to	 assess	 the	 evidence	 base	 for	 the	
management	of	distal	intestinal	obstruction	syndrome	in	cystic	fibrosis,	on	one	or	
both	of	the	following	subjects:	
i.)	 Interventions	 for	 preventing	 distal	 intestinal	 obstruction	 syndrome	 in	 cystic	
fibrosis.		
ii.)	 Interventions	 for	 treating	 distal	 intestinal	 obstruction	 syndrome	 in	 cystic	
fibrosis.			
2. Conduct	 a	 survey	 that	 investigates	 the	 current	 treatments	 for	 constipation	 and	
DIOS	used	in	children	and	adults	with	cystic	fibrosis	across	the	UK.		
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Chapter	2:	Background	of	Cystic	Fibrosis	
2.1	Overview	
This	 chapter	 provides	 information	 on	 CF,	 focussing	 on	 its	 epidemiology,	 historical	
background,	 aetiology,	 pathophysiology,	 diagnosis,	 clinical	 features,	 treatments	 and	
includes	a	brief	section	on	emerging	therapies.	Distal	intestinal	obstruction	syndrome,	the	
main	subject	of	this	thesis,	will	also	be	discussed	in	detail	later	in	this	chapter.			
2.2	Introduction	
CF	 is	 an	autosomal	 recessive,	 chronic,	progressive	disease	 in	which	 the	 sufferer	 is	born	
with	 a	 mutation	 in	 the	 gene	 encoding	 the	 Cystic	 Fibrosis	 Trans-membrane	 Regulator	
Protein	 (CFTR).	Normally,	 this	protein	 translates	 into	an	 ion	channel	 responsible	 for	 the	
movement	of	anions	 (notably	chloride	 ions	and	thiocyanate	 ions)	out	of	epithelial	 cells,	
which	 keeps	 the	 equilibrium	 of	 the	 positively	 charged	 sodium	 ions	 and	 water	 on	 the	
epithelial	cell	surface.		An	absence	or	mutation	in	the	CFTR	protein	results	in	the	build	up	
of	thick,	sticky	mucus	in	body	organs	where	the	protein	is	found,	particularly	in	the	lungs,	
pancreas,	gastrointestinal	tract	and	in	the	vas	deferens	in	males.		
	
Lung	disease	causes	most	of	the	morbidity	and	mortality	in	patients,	but	other	important	
complications	 include	pancreatic	 insufficiency,	 disturbances	 in	 gastrointestinal	 function,	
nutritional	deficiencies	and	 reproductive	 issues	 (1).	These	 result	 in	a	 reduced	quality	of	
life.	 However,	 not	 all	 CF	 patients	 will	 be	 affected	 in	 the	 same	 way.	 Different	 genetic	
mutations	may	present	with	different	phenotypic	severities;	however,	patients	with	the	
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same	mutation	may	also	present	differently	due	to	other	factors,	such	as	gene/gene	and	
gene/environmental	interactions.	This	will	be	discussed	in	more	detail	in	section	2.5.3.		
2.3	Historical	Background	
It	is	believed	that	CF	arose	between	4000	and	5000	years	ago	(2),	although	it	was	not	well	
documented	until	the	mid-17th	century.		In	an	era	when	supernatural	forces	were	blamed	
for	 diseases,	 CF	 sufferers	 were	 thought	 by	many	 to	 be	 cursed.	 The	 common	mode	 of	
diagnosis	 was	 to	 taste	 the	 sweat	 from	 the	 child’s	 forehead,	 and	 if	 discernibly	 salty,	 it	
would	predict	the	child’s	death	(3).	
	
There	was	very	little	progress	in	CF	until	the	20th	century.	However,	the	oldest	scientific	
record	 of	 the	 disease	 dates	 back	 to	 1838.	 This	 was	 a	 post-mortem	 report	 by	 Austrian	
pathologist,	 Carl	 Rokitansky,	 who	 conducted	 an	 autopsy	 on	 an	 infant	 with	 meconium	
peritonitis.	Then,	 in	1905,	Karl	Landsteiner	discovered	meconium	ileus	and	put	together	
the	first	report,	which	suggested	that	the	histological	changes	in	the	pancreas	could	affect	
the	digestion	of	the	meconium,	hence	leading	to	bowel	obstruction	(2,4).	
Before	the	mid-	20th	century,	 the	disease	was	not	known	as	CF.	 In	1888,	Samuel	Gee,	a	
London	 physician,	 titled	 it	 “the	 coeliac	 affection”.	 He	 described	 it	 as	 a	 “chronic	
indigestion”	 with	 stools	 being	 “pale	 in	 colour,	 as	 if	 devoid	 of	 bile”	 (5,4).	 Scientists	
eventually	discovered	that	coeliac	disease	and	CF	(or	mucoviscidosis,	an	earlier	name	for	
CF)	were	distinctly	different	 in	their	pathophysiology.	This	was	thanks	to	further	studies	
conducted	in	the	1900s,	one	of	the	most	notable	from	the	paediatric	pathologist,	Dorothy	
Anderson,	 in	 1938.	 	 Anderson	 observed	 that	 a	 few	 patients,	 who	 had	 seemingly	
responded	 to	 their	 treatment	 for	 coeliac	 disease,	 lacked	 healthy	 pancreatic	 tissue	 on	
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post-mortem	 examination.	 She	 therefore	 speculated	 that	 there	was	 a	 different	 kind	 of	
pathophysiology	occurring	in	these	patients	(6).	The	paper	was	entitled	“Cystic	Fibrosis	of	
the	Pancreas	and	its	relation	to	Coeliac	Disease”	and	it	crystallized	our	understanding	of	
CF	(4).	
In	 1953	 there	 was	 a	 significant	 breakthrough	 made	 by	 Dr	 Paul	 di	 Sant’Agnese,	 who	
revealed	the	phenomenon	of	salt	loss	in	the	sweat	of	patients	with	CF.	He	discovered	this	
during	the	heat	wave	of	New	York	in	1948,	where	he	found	that	his	CF	patients	became	
especially	 salt-depleted	 (7).	 Thereafter,	 tasting	 the	 sweat	 of	 patients	 was	 no	 longer	
carried	out.	A	new	mode	of	diagnosis	 (as	we	know	 it	 today)	was	developed:	 the	 sweat	
test	(see	diagnosis	section	below).	
	
Throughout	the	mid	20th	century,	the	number	of	care	centres	for	CF	grew	in	number,	as	
did	 CF	 research.	 Due	 to	 the	 expansion	 of	 CF	 care,	 a	 patient	 registry	 was	 launched	 to	
gather	information	about	CF	patients	(8).	
The	cause	of	CF	became	an	important	focus.	In	1989	a	group	of	scientists	discovered	the	
most	 common	 genetic	 mutation	 causing	 CF	 to	 be	 “a	 loss	 of	 phenylalanine	 residue	 at	
amino	acid	position	508”;	they	also	discovered	the	defective	protein	associated	with	the	
gene,	 CFTR	 (9).	 This	 critical	 finding	 enabled	 scientists	 to	 understand	 more	 about	 the	
aetiology	of	CF	and	paved	the	way	for	the	development	of	CF-specific	drugs	in	the	1990s.	
Examples	 of	 these	 include	 the	 development	 of	 recombinant	 human	 DNase	 (to	 break	
down	or	thin	the	thickened	mucus	in	the	lungs)	and	a	new	preparation	of	tobramycin	for	
inhalation	(4).	
As	the	understanding	of	genetics	in	CF	expanded	in	the	early	2000s,	so	did	the	number	of	
drugs	 available	 for	 treatment.	 	 The	 Food	 and	 Drug	 Administration	 (FDA)	 has	 recently	
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approved	a	new	medication	called	 Ivacaftor,	which	has	been	approved	for	a	number	of	
mutations	in	CF;	this	will	be	discussed	in	more	detail	later	in	this	review	(10).	
	
2.4	Epidemiology	
	Although	 it	 is	 a	 recessive	 condition,	 CF	 is	 still	 the	 commonest,	 life-limiting,	 genetically	
inherited	 disease	 found	 in	 white	 populations	 (11).	 Approximately	 1	 in	 25	 of	 the	 UK	
population	 are	 carriers	 of	 the	 faulty	 CFTR	 gene.	 The	 incidence	 of	 CF	 within	 the	 UK	 is	
around	1	in	2500	births.	According	to	the	most	recent	figures	available	in	the	CF	annual	
data	report	in	2015,	there	are	over	10,800	people	in	the	UK	currently	living	with	CF.	
	
The	percentage	of	males	with	CF	is	slightly	higher	than	females	(53%	compared	to	47%)	
and	 predominantly	 affects	 the	 white	 population;	 over	 90%	 of	 individuals	 with	 CF	 are	
white.	(8)	
There	 has	 been	 a	 persistent	 yearly	 increase	 in	 the	 number	 of	 adults	with	 CF	 since	 the	
1980s,	from	29.2%	in	1986	to	51.6%	in	2015.	In	contrast,	the	number	of	children	with	CF	
has	remained	stable.		The	increase	in	adults	is	likely	to	be	due	to	increased	life	expectancy	
as	a	result	of	greatly	improved	management	of	CF	since	the	1980s;	this	means	that	more	
children	 are	 progressing	 to	 adulthood.	 Children	 are	 usually	 diagnosed	 in	 one	 of	 three	
ways:	at	birth	with	meconium	ileus,	detection	through	newborn	screening	or	presenting	
with	 failure	 to	 thrive	and/or	 chronic	 infections.	 The	number	of	 children	has	most	 likely	
remained	 stable	 because	 newborn	 screening	 (described	 in	 more	 detail	 in	 2.7.2)	 has	
decreased	 the	 age	 at	 diagnosis.	 Furthermore,	 parents	 who	 are	 aware	 of	 their	 carrier	
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status	they	may	choose	to	go	down	the	route	of	pre-implantation	genetic	screening,	or	
terminate	the	pregnancy.		
2.5	Aetiology	
2.5.1	The	CFTR	protein	
CF	is	caused	by	a	genetic	mutation	in	the	CFTR	protein.	CFTR	is	a	very	large	gene,	located	
on	the	long	arm	of	chromosome	7	(7q31)	and	comprises	27	exons	(12).		
The	protein	works	as	an	ATP	(adenosine	triphosphate)	dependent	chloride	channel,	found	
on	the	surface	of	epithelial	cells	of	most	exocrine	glands.	On	opening,	 it	allows	chloride	
and	 bicarbonate	 anions	 to	 pass	 out	 of	 the	 cells	 (13).	 The	 movement	 of	 these	 anions	
maintains	the	electrochemical	balance	and	hydration	of	various	epithelial	surfaces	in	the	
body,	such	as	the	lungs,	pancreas,	liver,	gastrointestinal	tract,	reproductive	tract	and	skin	
(14).	
	
2.5.2	Mutations	in	CFTR	
There	 are	 currently	 over	 2000	mutations	 discovered	 in	 the	 CFTR	 gene	 (1),	 which	 have	
been	divided	into	five	classes,	according	to	how	they	affect	CFTR	function	(15).	These	are	
described	below:	
		
1. Class	I	mutations	disturb	protein	synthesis	caused	by	a	premature	Stop	codon,	due	
to	 nonsense	 mutations,	 frame-shift	 mutations	 and	 deletions.	 This	 results	 in	 an	
unstable	 protein	 that	 is	 easily	 degraded,	 leading	 to	 no	 expression	 of	 the	 CFTR	
protein.	Examples	include	G542X,	W1282X	and	R553X.	
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2. Class	II,	the	most	common	form	of	mutation,	disrupts	protein	maturation	so	that	it	
cannot	be	correctly	folded	and	processed	in	the	endoplasmic	reticulum	before	it	is	
taken	 to	 the	 cell	 surface.	 These	 defects	 are	 caused	 by	missense	mutations	 and	
deletions.	The	most	common	mutation,	Phe508del,	falls	into	this	class.	It	accounts	
for	 almost	 two	 thirds	 of	 mutations	 in	 CF.	 It	 is	 a	 deletion	 of	 three	 nucleotides,	
coding	for	phenylalanine,	at	position	508	in	the	amino	acid	sequence	(16).	Other	
examples	of	class	II	mutations	include	N1303K	and	I507del.	
3. Class	III	mutations	affect	the	nucleotide	binding	domains	and	are	mostly	missense	
mutations	 that	 alter	 the	 chloride	 channel	 itself,	 interrupting	 channel	 regulation	
and	 function.	 They	 result	 in	 reduced	 or	 no	 channel	 opening.	 Examples	 include	
G551D,	G551S	and	G1349D.	
4. Class	 IV	 mutations	 are	 usually	 missense	 mutations	 that	 affect	 the	 structure	
chloride	channel	pore,	hence	 reducing	 the	anion	conductance.	Examples	 include	
R117H,	R334W	and	R347P.	
5. Class	 V	 mutations	 are	 also	 missense	 mutations	 caused	 by	 a	 defect	 in	 the	 pre-
MRNA	 splicing	 of	 the	 nascent	 protein.	 Consequently,	 there	 will	 be	 reduced	
synthesis	of	the	protein,	providing	less	CFTR	protein	at	the	cell	surface.	Examples	
include	2789+5G>A	and	A455E.		
6. There	 is	also	a	sixth	class	of	CFTR	mutation,	which	 increases	the	turnover	of	 the	
CFTR	 protein	 at	 the	 cell	 surface,	 reducing	 its	 stability	 (14,17).	 However	 this	
mutation	has	not	been	as	 thoroughly	 investigated	as	 the	other	 five	defects	 (18)	
and	therefore	 it	 is	often	grouped	with	the	Class	V	mutations,	as	both	result	 in	a	
reduced	quantity	of	protein	(17).		
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2.5.3	Clinical	consequences	of	CFTR	mutations	
In	 addition	 to	 assigning	 the	 mutations	 to	 the	 effect	 they	 have	 on	 a	 cellular	 level,	 CF	
mutations	can	also	be	categorised	according	 to	 their	 clinical	 consequences.	Historically,	
the	 two	 categories	 were	 “classic”	 CF	 and	 “non-classic”	 CF,	 with	 “classic”	 CF	 describing	
those	 patients	with	multi-organ	 disease.	However,	 this	 distinction	 is	 not	 very	 useful	 in	
practice,	which	is	why	it	is	no	longer	used	(18).	Children	within	one	family	with	the	same	
genotype	 can	 present	with	 different	 clinical	 features.	 There	 are	 areas	 in	 CF	where	 the	
genotype-phenotype	 relationship	 is	 strong,	 such	 as	 in	 pancreatic	 sufficiency	 status.	
However,	 for	 characteristics	 such	 as	 pulmonary	 function,	 or	 whether	 a	 patient	 will	
develop	diabetes,	genotype	does	not	usually	predict	phenotype.			
There	are	many	factors	(other	than	the	type	of	CFTR	mutation)	contributing	to	the	health	
of	 CF	 patients,	 including	 lifestyle,	 environment,	 modifier	 genes,	 treatment	 and	 age.	
However,	at	present,	we	have	limited	knowledge	of	how	these	elements	interact	(19).		
It	 is	also	 important	to	note	that	not	all	CFTR	mutations	actually	cause	CF.	These	can	be	
referred	to	as	“polymorphisms”	or	“neutral	variants”	(20).	
	
2.6	Pathophysiology	
At	the	pathophysiological	centre	of	CF	is	the	defective	ion	transport	across	epithelial	cells.	
This	 affects	 multiple	 body	 organs	 including	 the	 lungs,	 sweat	 glands,	 pancreas,	 liver,	
gastrointestinal	tract	and	reproductive	organs.		
	2.6.1	Respiratory	System	
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An	individual	with	CF	does	not	have	lung	disease	at	birth.	It	is	throughout	childhood	that	
the	lungs	become	infected,	first	intermittently	and	then	chronically	(21,	22).	The	sections	
below	explain	some	of	the	pathophysiology	and	hypotheses	behind	lung	disease	in	CF.	
a)	Existing	hypotheses		
The	 pathophysiology	 of	 CF	 lung	 disease	 is	 very	 complex	 and	 not	 fully	 understood.	 CF	
produces	 a	 cycle	 of	 inflammation	 and	 infection	 leading	 to	 lasting	 airway	 damage,	 but	
there	 is	 still	 debate	 as	 to	 how	 this	 occurs	 (23)	 and	whether	 inflammation	 or	 infection	
comes	 first.	 Poor	 bacterial	 elimination	 is	 thought	 to	 play	 an	 important	 role	 in	 the	
inflammatory	 response	 in	 CF	 lungs	 and	 there	 have	 been	 3	main	 hypotheses	 that	 have	
been	 put	 forward	 to	 explain	 why	 this	 occurs:	 the	 “high	 salt”,	 “low	 volume”	 and	 “pH”	
hypotheses.	The	“high	salt”	hypothesis	proposes	that	a	high	salt	concentration	at	the	cell	
surface	inhibits	the	activity	of	an	important	antimicrobial	protein	(human	beta	defensin-
1)	which	normally	acts	as	a	defence	mechanism	against	bacteria.	 	Without	 this	protein,	
the	epithelial	cells	are	more	vulnerable	to	infection	(24,25).	However,	other	studies	have	
found	 that,	 in	 both	 normal	 and	 CF	 patients,	 the	 airway	 surface	 liquid	 (ASL)	 is	 actually	
isotonic,	rather	than	hypertonic	(26).	
The	 second	 theory,	 the	 “low	 volume”	 hypothesis,	 suggests	 that	 the	 defective	 chloride	
channels	prevents	an	osmotic	gradient	occurring,	so	there	will	be	very	little	water	moving	
out	 of	 the	 epithelial	 cells.	 As	 such,	 the	 epithelial	 surface	 becomes	 dehydrated	 and	 the	
airway	 surface	 liquid	 (ASL)	 will	 be	 viscous	 and	 sticky.	 This	 results	 in	 an	 ineffective	
mucociliary	 clearance	 and	 hence	 higher	 susceptibility	 to	 infection	 (24).	 In	 vitro	 studies	
have	 shown	 that	 the	 ASL	 volume	 in	 CF	 epithelia	 is	much	 lower	 than	 normal	 epithelia;	
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mouse	models	and	human	subject	studies	have	also	supported	this	hypothesis	in	the	past	
decade.	(27,	28,	24).	
However,	despite	murine	models	supporting	the	“low	volume”	hypothesis,	it	is	generally	
accepted	that	CF	mice	do	not	acquire	spontaneous	and	chronic	bacterial	infections	as	
seen	in	CF	patients;	therefore	this	animal	model	is	unable	to	fully	demonstrate	
respiratory	pathology	in	CF	(29).	
	
The	“pH”	hypothesis	proposes	that	as	the	faulty	CFTR	cannot	transport	chloride	ions	and	
bicarbonate	 ions	 sufficiently,	 the	 ASL	 is	 relatively	 acidic.	 This	 acidity	 diminishes	
antimicrobial	activity	in	the	ASL,	impairing	the	killing	of	bacteria	(30).		
This	hypothesis	gained	support	after	a	2010	study	in	which	pigs	were	generated	to	have	
CFTR	mutations;	the	pigs	had	a	reduced	ASL	pH.	The	CF	pig	model	revealed	a	great	deal	
about	 the	 course	 of	 CF	 lung	 disease.	 At	 birth,	 the	 pigs’	 lungs	 did	 not	 show	 signs	 of	
inflammation,	 much	 like	 humans	 with	 CF.	 However,	 after	 an	 intrapulmonary	 bacterial	
challenge,	the	CF	pigs	could	not	eliminate	the	pathogens	as	the	healthy	pigs	could.	This	
signified	that	the	pig	model	also	supported	the	theory	that	it	is	poor	bacterial	elimination	
which	 triggers	 the	 inflammatory	cascade	 in	CF,	and	hence	the	mucus	accumulation	and	
airway	remodelling	in	CF	lungs	(23).			
	
b)	Inflammatory	processes	in	the	airways	
When	 the	 inflammatory	 response	 occurs,	 there	 is	 a	 high	 production	 of	 inflammatory	
mediators	 such	 as	 interleukin-8	 (IL-8).	 IL-8	 attracts	 vast	 numbers	 of	 neutrophils	 to	 the	
lungs,	 which	 produce	 enzymes	 such	 as	 oxidases	 and	 proteases.	 The	 neutrophils	 are	
thought	 to	be	 the	main	cause	of	pathology	 in	CF	 lung	disease,	but	 the	 loss	of	 immune-
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regulatory	mediators	such	as	 IL-10	are	also	thought	to	play	a	part	 (31).	Chronically,	 this	
cycle	of	infection	and	inflammation	causes	lasting	damage	to	the	structure	of	the	airways.		
The	broncho-alveolar	lavage	(BAL)	results	from	CF	pig	models	showed	changes	consistent	
with	 chronic	 inflammation;	 these	 include	 airway	 remodelling	 with	 wall	 thickening	 and	
infiltration,	goblet	cell	hyperplasia	and	mucus	accumulation	(23).		
The	CF	pig	model	has	therefore	proposed	that	the	introduction	of	infection	leads	to	
inflammation,	but	there	is	some	indirect	evidence	that	there	may	be	an	innate	
inflammatory	process	before	the	first	bacterial	infection	occurs.	One	study	found	high	
numbers	of	macrophages	(which	are	responsible	for	attracting	neutrophils)	in	CF	foetus	
lungs	(32)	and	another	study	found	increased	numbers	of	neutrophils	in	the	lungs	of	
seven	CF	infants	who	had	no	infections	at	the	time	of	BAL	(33).		
	
These	conflicting	theories	demonstrate	how	complex	the	pathophysiology	of	CF	really	 is	
and	 show	 that	 the	 inflammation/infection	debate	 is	 far	 from	settled.	 The	CF	pig	model	
has	 provided	 some	 valuable	 insight	 into	 the	 pathogenesis	 of	 CF	 and	 has	 shown	 the	
consequences	 of	 spontaneous	 and	 chronic	 infections	 in	 CF	 lung	disease.	 But	 of	 course,	
there	are	 limitations	 to	animal	models.	We	cannot	 replicate	CF	 in	other	animals	 just	as	
the	 disease	 would	 present	 in	 humans.	 Furthermore,	 these	 models	 cannot	 fully	
incorporate	phenotypic	and	environmental	variation	that	occurs	in	human	subjects.		
	
2.6.2	Pancreas	
Depending	on	their	genotype,	individuals	with	CF	may	develop	pancreatic	insufficiency.	In	
fact,	85%	patients	will	develop	exocrine	pancreatic	insufficiency	between	the	ages	of	1	-	2	
years	(34).	
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The	 mutated	 CFTR	 gives	 rise	 to	 impaired	 bicarbonate	 and	 chloride	 transport	 into	 the	
pancreatic	ducts,	leading	to	a	smaller	volume	of	a	more	acidic	fluid,	causing	precipitation	
of	the	secreted	enzymes.	This	results	in	obstruction	of	the	ducts	and	pancreatic	damage	
(35).	Indeed,	pancreatic	disease	was	also	demonstrated	in	the	CF	pig	model,	where	a	fatty	
pancreas	was	 found,	 as	well	 as	distended	pancreatic	ducts	 and	 fibrosis	 (23).	 Pancreatic	
insufficiency	 leads	 to	 poor	 digestion	 and	 subsequent	malabsorption	 of	 fat,	 protein	 and	
fat-soluble	vitamins,	resulting	in	malnutrition	(36).		
	
2.7	Diagnosis		
The	sweat	test	is	the	most	commonly	used	diagnostic	test;	newborn	genetic	screening	is	
also	available	in	many	countries.	In	addition,	there	is	an	investigation	available	for	
determining	pancreatic	sufficiency	status	once	the	patient	has	been	diagnosed	with	CF.	
Details	of	these	tests	(the	sweat	test,	newborn	screening	and	faecal	elastase)	are	
described	below:	
2.7.1	Sweat	Test	
The	 gold-standard	 diagnostic	 test	 for	 CF	 is	 the	 sweat	 test,	 in	 which	 the	 chloride	
concentration	 of	 the	 gland	 is	 measured.	 Pilocarpine	 is	 deposited	 onto	 the	 skin	 by	
iontophoresis	 in	 order	 to	 stimulate	 sweat	 gland	 secretion.	 Then,	 the	 sweat	 is	 collected	
with	gauze	or	filter	paper	and	analysed	(37).	
	
The	sweat	test	should	be	performed	after	a	positive	newborn	screening	result	when	the	
infant	is	at	least	2	weeks	of	age	and	weighs	at	least	2kg	(38).	However,	if	the	newborn	is	
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symptomatic,	 the	 test	 can	be	performed	48	hours	after	birth	–	 if	enough	sweat	 can	be	
collected.	This	can	often	be	difficult,	as	the	minimum	volume	of	sweat	required	for	a	valid	
result	should	exceed	1	g/m2	per	minute	(39).	
If	 the	 test	 reveals	 sweat	 chloride	 values	 of	≥60mmol/L,	 it	 is	 considered	 abnormal	 and	
indicative	 of	 CF.	 Values	 between	 40	 and	 59mmol/L	 are	 intermediate	 and	 values	 below	
39mmol/L	are	considered	normal.	However,	in	infants	under	6	months	of	age,	the	values	
are	 slightly	 different.	 Results	 ≥60mmol/l	 are	 still	 considered	 abnormal,	 but	 the	
intermediate	range	is	30-59	mmol/l	and	≤29mmol/l	means	CF	is	unlikely	(37).		
As	 with	 most	 diagnostic	 tests,	 there	 are	 some	 pitfalls	 when	 relying	 on	 the	 sweat	 test	
result.	 Many	 CF	 patients	 have	 elevated	 sweat	 chloride	 concentrations,	 but	 some	
mutations,	e.g.	R711H,	are	associated	with	borderline	or	even	normal	test	results	(40).	A	
CF	 diagnosis	may	 take	 several	 years	 in	 these	 patients,	 during	which	 time	 the	 child	 can	
develop	chest	symptoms	consistent	with	CF.		
Furthermore,	 the	 practicalities	 of	 performing	 a	 sweat	 test	 can	 be	 demanding,	 so	 user	
error	and	false	results	can	occur.	False	positives	may	also	occur	in	rare	conditions	such	as	
Addison’s	 disease,	 glycogen	 storage	 disorders	 and	 untreated	 hypothyroidism;	 however,	
these	should	be	easy	to	differentiate	clinically	from	CF	(3).	
	
2.7.2	Newborn	Screening	
Before	a	diagnostic	 test	 is	used,	all	newborns	 in	 the	UK	are	screened	using	 the	Guthrie	
heel	 prick,	 or	 blood	 spot	 test,	 in	 which	 a	 raised	 immune-reactive	 trypsinogen	 (IRT)	 is	
considered	to	be	abnormal.	The	screening	has	been	available	for	all	newborns	in	the	UK	
since	 2007	 (41).	 Newborn	 screening	 has	 some	 key	 advantages.	 Firstly,	 it	 will	 lead	 to	 a	
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prompt	 diagnosis,	 which	 means	 that	 the	 disease	 can	 be	 managed	 early	 on	 with	 the	
appropriate	medication.	This	can	prevent	the	child	from	developing	early	bronchiectasis,	
gastrointestinal	problems	(as	a	result	of	no	PERT)	and	nutritional	deficiencies,	which	may	
harm	their	growth	and	development.	Secondly,	newborn	screening	is	said	to	encourage	a	
proactive	 and	 preventative	 approach	 to	 the	 management	 of	 CF	 (42);	 indeed,	 recent	
evidence	shows	that	early	treatment	of	respiratory	infection	may	improve	the	prognosis	
of	CF	patients	(43).		
Disadvantages	of	newborn	screening	include	false-positive	results	or	inconclusive	results;	
both	of	these	can	cause	undue	stress	and	anxiety	for	families.	This	is	especially	true	when	
the	screening	test	produces	a	positive	result,	but	the	sweat	test	result	is	either	borderline	
or	 normal	 (in	 the	 presence	 of	 2	mutations,	 one	 if	 which	 is	 unclear).	 This	 is	 called	 “CF	
screen-	positive,	inconclusive	diagnosis”	or	“CFSPID”.	Infants	with	this	diagnosis	are	often	
asymptomatic	but	 can	develop	mild	CF-related	 symptoms	as	 they	 grow	up.	 “CFSPID”	 is	
given	as	a	diagnostic	 label	 to	provide	an	explanation	 for	 families	 regarding	 their	 child’s	
condition	and	to	activate	appropriate	support	in	healthcare	settings	(44).	
	
After	 a	 raised	 IRT,	 further	 screening	 in	 the	 form	 of	 DNA	 testing	 can	 be	 carried	 out	 to	
determine	 the	 genotype	of	 the	 individual.	DNA	 testing	 can	 also	be	used	 for	 individuals	
with	an	intermediate	chloride	value	to	help	ascertain	the	diagnosis	(37).	Once	a	diagnosis	
has	 been	 made,	 the	 individual’s	 relatives	 may	 be	 offered	 screening;	 the	 siblings	 are	
always	 screened	 to	 check	 for	 CF	 that	 has	 not	 been	 picked	 up	 and	 other	 adult	 family	
members	can	be	screened	to	check	for	carrier	status	(11).		
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2.7.3	Faecal	Elastase	
To	determine	pancreatic	sufficiency	status,	 the	faecal	elastase-1	enzyme	 is	measured	 in	
the	individual’s	stool.	This	test	is	non-invasive	and	easy	to	perform,	as	well	as	being	more	
sensitive	and	specific	than	direct	pancreatic	stimulation	tests	(45).	This	is	because	there	is	
significant	 correlation	 between	 faecal	 and	 duodenal	 elastase-1	 concentration	 and	 the	
concentration	of	duodenal	lipase,	amylase,	trypsin	and	bicarbonate	(46).	
2.8	System	Involvement	and	its	management	
In	this	section	I	will	discuss	the	clinical	consequences	and	management	of	the	systems	
most	affected	in	CF:	the	respiratory	system,	the	endocrine	system,	the	gastrointestinal	
and	hepato-biliary	system	and	the	reproductive	system.		
2.8.1	Overview	
There	 is	 a	 definite	 multi-disciplinary	 approach	 in	 the	 management	 of	 CF.	 The	 team	 is	
comprised	 of	 doctors,	 pharmacists,	 physiotherapists,	 dieticians,	 psychologists,	 social	
workers,	nurses	and	research	coordinators.	Such	a	large	team	is	required	because	CF	is	a	
multi-system	 and	 multifactorial	 condition,	 incorporating	 both	 the	 individual	 and	 their	
family	members.	Patients	become	rather	accustomed	to	the	clinical	setting.	They	attend	
frequent	appointments	(usually	every	2-3	months)	where	they	meet	with	members	of	the	
CF	team	to	track	their	progress.	Not	only	do	they	need	medication,	but	they	also	require	
dietary	input,	airway	clearance	techniques	and	psychological	and/or	social	support.			
Individuals	 are	 also	 closely	monitored	with	 investigations,	 either	 at	 each	 appointment,	
yearly,	or	when	they	become	unwell.		
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2.8.2	Respiratory	System	involvement	
The	respiratory	 tract	 is	 the	most	affected	system	 in	CF	and	respiratory	 failure	will	most	
likely	be	the	cause	of	death	(11).	The	clinical	presentation	of	CF	varies	according	to	age	
and	genotype	and,	as	mentioned	above,	individuals	are	not	born	with	lung	disease:	lung	
disease	usually	develops	during	early	childhood.	
	
Infants	 develop	 recurrent	 respiratory	 symptoms	 such	 as	 a	 cough,	 wheeze,	 dyspnoea,	
episodes	of	bronchiolitis	and	pneumonias.	Nose	polyps	and	sinusitis	may	also	occur	(11).	
The	 cough	 itself	may	 initially	 present	 as	 a	 recurrent,	 dry	 one	 that	will	 usually	 go	on	 to	
produce	 mucus	 and,	 eventually,	 purulent	 sputum	 (47).	 As	 the	 disease	 progresses,	 the	
build	up	of	 thick,	viscid	mucus	 in	 the	 lungs	 leads	 to	 recurrent	chest	 infections	 involving	
specific	bacteria	and	the	 individual	can	become	chronically	 infected.	The	most	common	
bacteria	 are	 Staphylococcus	 aureus,	 Haemophilus	 influenzae	 and,	 ultimately,	
Pseudomonas	 aeruginosa	 and	 Burkholderia	 species.	 Chronic	 infections	 with	 these	
bacteria	may	cause	bronchial	wall	damage,	bronchiectasis	and	abscess	formation	(16).		P.	
aeruginosa	 is	 often	 found	 in	 adults	with	 CF	 as	 it	 can	 be	 difficult	 to	 eradicate	 once	 the	
bacteria	is	deep	within	the	lung	tissue.		A	complication	that	can	occur	with	B.	Cepacia	 is	
“Cepacia	syndrome”,	which	is	a	combination	of	bacteraemia	and	necrotising	pneumonia.	
It	 produces	 bilateral	 nodular	 consolidation	 and	 cavitation	 and	 can	 result	 in	 respiratory	
failure	(48).	
In	well-established	disease,	there	are	certain	signs	to	observe	during	examination.	Finger	
clubbing	 may	 suggest	 advanced	 lung	 disease	 (although	 it	 not	 an	 accurate	 marker	 of	
disease	 severity)	 and	 the	 lungs	 can	 be	 hyper-inflated	 (as	 a	 result	 of	 air	 trapping)	 with	
coarse,	inspiratory	crepitations	and	an	expiratory	wheeze	(16).		
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Other	 complications	 of	 CF	 include	 pneumothorax,	 lobar	 collapse,	 pulmonary	
hypertension,	(due	to	chronic	hypoxia)	Aspergillus-	related	lung	disease	and	haemoptysis.		
Pneumothorax	 arises	 from	mucous	 plugging	 in	 the	 airways,	which	 leads	 to	 a	 relatively	
high	alveolar	pressure.	If	this	pressure	exceeds	the	interstitial	pressure,	air	can	leak	out	of	
the	alveoli	 into	the	pleural	space,	causing	a	pneumothorax.	Mucous	plugging	also	has	a	
role	to	play	in	lobar	collapse	(48).	
The	complications	described	above-	accompanied	by	thick	secretions	immersed	in	chronic	
bacterial	infection,	airway	inflammation	and	associated	oedema	(and	eventual	respiratory	
muscle	weakness)-	may	all	contribute	to	respiratory	failure	(49).	
	
2.8.3	Management	of	the	Respiratory	System	
a)	Monitoring	
Patients	 are	 separated	 according	 to	 their	 bacterial-colonisation;	 for	 example,	
Pseudomonas-infected	 patients	 are	 grouped	 together	 in	 one	 clinic	 to	 prevent	 the	
infection	of	non-colonised	patients.	At	every	appointment,	the	clinician	should	conduct	a	
history	 and	 respiratory	 examination	 to	 determine	 the	 patient’s	 respiratory	 signs	 and	
symptoms	 (or	 lack	 thereof).	 The	 physiotherapist	 should	 also	 assess	 the	 quality	 of	 the	
patient’s	 airway	 clearance	 techniques	 (see	 below)	 and	 ensure	 that	 they	 have	 a	 regular	
physiotherapy	routine.			
Pulmonary	 function	 tests	are	conducted	every	appointment	 to	monitor	 the	FEV1%.	The	
patient’s	oxyhaemoglobin	saturation	is	also	noted	and	a	sputum	sample	is	taken	(47).	On	
a	 yearly	 basis	 or	 when	 the	 patient	 develops	 respiratory	 symptoms,	 a	 chest	 x-ray	 is	
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performed.	Clinicians	may	also	request	a	CT-scan	of	the	chest	to	look	for	subtle	changes	
in	the	lungs	that	may	not	be	easily	identified	on	a	plain	radiograph.		
a)	Physiotherapy	
	
Airway	 clearance	 is	 a	 key	 component	 of	 CF	management,	 so	 various	 physical	 therapies	
are	utilised	in	the	treatment	of	CF.	These	are	comprised	of	the	different	airway	clearance	
regimens	 and	 physical	 training.	 Examples	 of	 airway	 clearance	 techniques	 include	
Conventional	Chest	Physiotherapy	(CCPT),	Positive	Expiratory	Pressure	(PEP),	Active	Cycle	
of	 Breathing	 Techniques	 (ACBT),	 Autogenic	 Drainage	 (AD),	 mechanical	 percussion	 and	
High-Frequency	 Chest	 Compression	 (HFCC).	 The	 general	 consensus	 among	 healthcare	
professionals	 is	 that	 airway	 clearance	 techniques	 encourage	 muco-ciliary	 clearance	 by	
altering	airflow	and	mucous	viscosity.	Furthermore,	short	 -term	trials	demonstrated	the	
benefit	 of	 airway	 clearance	 techniques	 compared	 no	 airway	 clearance	 techniques.	
However,	the	comparative	efficacy	of	individual	airway	clearance	techniques	seems	to	be	
a	subject	needing	further	research,	as	there	is	limited	evidence	on	this	at	present.	
Individuals	 with	 CF	 are	 also	 encouraged	 to	 maintain	 an	 active	 lifestyle;	 there	 is	 some	
evidence	to	suggest	that	physical	training	is	a	useful	addition	to	the	CF	care-plan	(50).	
b)	Antibiotics	
Antibiotics	are	a	 large	part	of	CF	management.	They	are	given	prophylactically	and	also	
for	 infective	 exacerbations.	 Individuals	 with	 CF	 are	 more	 susceptible	 to	 infection	 with	
organisms	 such	 as	 P.	 Aeruginosa,	 Aspergillus,	 B.	 Cepacia	 and	 Methicillin-resistant	
Staphylococcus	 aureus	 (MRSA).	 If	 chronically	 infected,	 these	 organisms	 can	 have	 a	
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detrimental	 effect	 on	 the	 patient’s	 lung	 function.	 Infected	 patients	 should	 therefore	
receive	a	prompt	eradication	regimen.		
Treatment	regimens	will	vary	according	to	the	CF	care	centre,	but	for	mild	infections	an	
oral	antibiotic	is	usually	given.		If	the	infection	becomes	more	severe,	the	exacerbation	is	
treated	 with	 intravenous	 antibiotics.	 The	 choice	 of	 antibiotic	 is	 dependent	 on	 the	
organism	 cultured,	 its	 sensitivities,	 the	 patient’s	 previous	 clinical	 response	 to	 certain	
antibiotics	and	previous	allergic	reactions.		
Oral	corticosteroids	are	sometimes	given	with	a	course	of	antibiotics	to	treat	an	infective	
exacerbation,	but	are	not	recommended	for	chronic	use	unless	the	patient	has	asthma	or	
allergic	bronchopulmonary	aspergillosis	(ABPA)	(51).	
	
In	 terms	 of	 prophylaxis,	 all	 patients	 who	 are	 chronically	 infected	 with	 P.	 aeruginosa	
should	be	given	long-term,	nebulised	anti-pseudomonal	therapy.	Furthermore,	for	infants	
under	 two	 years	 of	 age,	 anti-staphylococcal	 oral	 antibiotics	 should	 be	 given	 for	
prophylaxis	(51).			
c)	Anti-inflammatory	agents	
Based	on	a	2016	Cochrane	review,	there	is	evidence	to	suggest	that	the	use	of	ibuprofen	
twice	daily	 can	 slow	 the	progression	of	mild	 to	moderate	 lung	disease	 in	CF.	However,	
clinicians	 should	 be	 aware	 of	 its	 adverse	 effects	 on	 renal	 function,	 especially	 if	 used	
alongside	potentially	nephrotoxic	drugs,	such	as	aminoglycosides	(52).	
d)	Mucolytics	
One	of	the	main	features	of	CF	is	an	excess	of	thick,	sticky	mucus	produced	by	the	lungs	
and	 medications	 are	 required	 to	 shift	 these	 secretions.	 The	 most	 commonly	 used	
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mucolytics	 are	 Human	 recombinant	 DNase	 (Dornase	 alfa)	 and	 Hypertonic	 saline,	 both	
administered	via	a	nebuliser.	Dornase	alfa	works	by	degrading	the	DNA	within	CF	mucus,	
thereby	decreasing	 its	 viscosity.	Hypertonic	 Saline	works	by	osmosis,	 drawing	 fluid	 into	
the	 lumen	of	 the	airway,	 increasing	the	hydration	of	 the	airway	surface	 liquid	 (53).	 In	a	
controlled	 trial,	 hypertonic	 saline	 was	 shown	 to	 decrease	 the	 overall	 number	 of	
exacerbations	 and	 antibiotic	 use	 for	 exacerbations;	 although	 there	 was	 no	 significant	
effect	 on	 the	 rate	 of	 change	 in	 lung	 function,	 hypertonic	 saline	was	 associated	with	 a	
moderate,	sustained	improvement	in	the	level	of	lung	function	(54).	
Chronic	 use	 of	 Dornase	 alfa	 and	 Hypertonic	 Saline	 are	 therefore	 recommended	 for	 CF	
patients	who	are	6	years	and	older	 to	 improve	 lung	 function	and	 reduce	exacerbations	
(51).	
Other	 mucolytics	 are	 N-acetylcysteine	 (NAC)	 and	 mannitol.	 N-acetylcysteine	 works	 by	
breaking	 disulphide	 bonds	 in	 mucus,	 which	 decreases	 its	 viscosity.	 However,	 the	 CF	
foundation	does	not	recommend	NAC	for	chronic	use,	due	to	lack	of	sufficient	evidence	
on	 the	 subject.	On	 the	other	hand,	 inhaled,	 dry	powder	 (mannitol)	 has	been	 shown	 to	
improve	 lung	 function	 after	 prolonged	 periods	 of	 use	 (51).	 NICE	 has	 recommended	
mannitol	for	patients	who	are	not	suited	to	dornase	alfa	and	other	osmotic	agents,	and	
whose	lung	function	is	rapidly	worsening	(55).	
e)	Lung	Transplant	
Lung	 transplantation	 is	 reserved	 for	 end-stage	 CF	 for	 those	 patients	 who	 are	 not	
responding	to	medical	therapy,	to	the	extent	where	the	individual	is	hypercapnic	and/or	
needing	supplemental	oxygen.	As	with	all	 transplants,	 there	are	some	contraindications	
to	 lung	 transplantation.	 Sepsis,	 multi-organ	 dysfunction	 and	 colonisation	 with	
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Burkholderia	 Cepacia	 are	 among	 the	 absolute	 contraindications,	 but	 other	 factors	 are	
assessed	 For	 example,	 the	 patient’s	 nutritional	 status,	 how	 well	 their	 diabetes	 is	
controlled	and	overall	functional	ability	(56).	Post-lung	transplant	survival	is	improving	all	
the	time,	with	figures	at	around	68%	survival	at	5	years,	compared	to	33%	at	5	years	for	
no	transplantation	(57).	
2.8.4	Endocrine	System	involvement	
Due	to	the	destruction	of	pancreatic	tissue	in	CF,	many	patients	will	go	on	to	develop	CF-
related	diabetes	mellitus	(CFRD).	The	incidence	is	four	times	more	common	in	those	aged	
16	and	over,	 compared	 to	 those	between	 the	ages	of	10	and	16	 (8).	 This	 is	due	 to	 the	
progressive	 nature	 of	 the	 destruction	 of	 pancreatic	 tissue	 from	 exocrine	 pancreatic	
insufficiency.	 Over	 time,	 fibrosis	 and	 fatty	 infiltration	 destroys	 beta	 islet	 cell	 structure.	
There	 is	 also	 evidence	 from	 mouse	 models	 that	 CFTR	 dysfunction	 itself	 may	 also	
contribute	 to	 pancreatic	 inflammation.	 The	 pancreatic	 tissue	 of	 CF	mice	 revealed	 focal	
inflammatory	cell	infiltrates	without	specific	injury	to	the	pancreas,	suggesting	that	there	
is	a	certain	amount	of	intrinsic	pancreatic	disease	in	CF	(58).	
These	changes	to	the	pancreas	in	CF	result	in	poor	beta	cell	function	and	therefore	a	lack	
of	insulin.	As	well	as	a	lack	of	insulin,	resistance	to	insulin	(such	as	in	type	II	diabetes)	may	
also	have	an	important	part	to	play	in	the	pathophysiology	of	CFRD.	Insulin	resistance	in	
CFRD	 is	 thought	 to	 be	 due	 to	 factors	 such	 as	 anti-inflammatory	 therapy,	 (i.e.	
corticosteroid	 use	 and	 increased	 oxidative	 stress)	 which	 may	 lead	 to	 impaired	
translocation	of	important	glucose	transporters	at	the	cell	surface	(59,	58).	
CFRD	often	presents	 insidiously;	not	all	patients	will	experience	the	classic	symptoms	of	
hyperglycaemia	 (fatigue,	 polydipsia	 and	 polyuria)	 (58).	 Clinicians	 may	 suspect	 it	 in	 CF	
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patients	who	are	excessively	tired	and	fail	to	gain	weight,	despite	a	good	diet	and	correct	
Creon®	dosage.		
2.8.5	Management	of	the	Endocrine	System	
Patients	with	 pancreatic	 insufficiency	 are	more	 likely	 to	 develop	CFRD,	 so	 the	 CF	 team	
take	measures	to	screen,	monitor	and	manage	patients	who	are	at	risk.		
The	oral	glucose	tolerance	test	 (OGTT)	 is	 the	standard	 investigation	for	screening	CFRD,	
but	other,	perhaps	more	sensitive	tests	can	be	used	to	detect	pre-diabetic	patients.	These	
tests	include	continuous	glucose	monitors,	glucose	or	insulin	area	under	the	curve	(AUC)	
or	mid-OGTT	assessment	of	glucose	level	(60).		
CFRD	is	treated	with	insulin.	The	regimen	is	decided	upon	by	the	clinician,	based	on	what	
they	 believe	will	most	 suit	 the	 patient.	Mostly,	 patients	 are	 treated	with	 a	 basal-bolus	
regimen	(61).	A	team	of	professionals	specialising	 in	diabetes	guide	the	management	of	
CFRD.	Patients	attend	a	specialist	CF	diabetic	clinic	in	which	endocrinologists	and	diabetic	
nurses	review	their	glucose	control	and	can	adjust	the	dose	of	insulin	if	required.		
	
2.8.6	 Gastrointestinal	 and	 Hepato-biliary	 System	 involvement	
(excluding	constipation	and	DIOS)	
7-10%	neonates	will	present	with	meconium	ileus,	in	which	the	meconium	obstructs	the	
intestine	 and	 signs	 of	 bowel	 obstruction	 are	 observed,	 such	 as	 bilious	 vomiting	 and	
abdominal	 distension.	 If	 untreated,	 it	 can	 lead	 to	perforation	 and	peritonitis.	Neonates	
with	CF	are	also	more	likely	to	present	with	surgical	abdomen	pathologies,	for	example,	
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volvulus	and	gut	atresia.	Infants	and	young	children	may	also	present	with	rectal	prolapse	
(47).	
	
Over	 90%	 of	 individuals	 with	 CF	 have	 pancreatic	 exocrine	 insufficiency,	 in	 which	 the	
enzymes	(lipase,	amylase	and	proteases)	are	defective.	Pancreatic	ducts	become	blocked	
with	the	thick,	viscid	mucous,	leading	to	poor	digestion	of	fats,	proteins	and	fat-	soluble	
vitamins	(A,D,E	and	K):	this	can	lead	to	malabsorption	(16);	the	malabsorption	results	 in	
steatorrhoea	(malodorous,	greasy	stools,	difficult	to	flush),	increased	frequency	of	stools,	
abdominal	pain,	distension	and	nutritional	deficiencies.		
Individuals	 can	also	present	with	acute	pancreatitis.	Viscid	mucous	 in	 the	pancreas	 can	
cause	 the	 ducts	 to	 become	 obstructed,	 increasing	 the	 pancreatic	 ductal	 pressure	 and	
triggering	the	unregulated	activation	of	trypsin	within	acinar	cells	(62).	
Liver	and	biliary	tract	problems	can	also	be	a	complication	for	 individuals	with	CF.	They	
are	much	less	common	than	pulmonary	and	pancreatic	disease,	affecting	about	a	third	of	
patients	 in	 the	 first	 decade	 of	 life	 (63).	 Neonates	 may	 uncommonly	 present	 with	
obstructive	jaundice	(11)	and	older	children	can	develop	cirrhosis	(with	or	without	portal	
hypertension)	and	gallbladder	disease	(8).	
	
1.8.7	Gastrointestinal	and	Hepato-biliary	system	management	
a)	Nutritional	Interventions	
The	 dietician	 guides	 the	management	 of	 nutritional	 interventions	 in	 CF.	 At	 each	 clinic	
appointment,	 the	 patient’s	 height,	 weight	 and	 BMI	 are	 measured	 and	 the	 dietician	
reviews	the	patient’s	diet.	On	occasion,	they	may	ask	the	patient	to	fill	out	a	food	diary	to	
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ascertain	if	there	is	a	calorie	or	nutritional	deficit.	From	this,	the	dietician	can	advise	the	
patient	 (or	 parents	 of	 the	 patient)	 on	 foods	 to	 incorporate	 into	 the	 diet.	 Annually,	
patients	have	a	blood	test	to	measure	their	vitamin	A,	D	and	E	 levels	and	a	coagulation	
profile	 to	measure	 their	vitamin	K	 levels.	Due	 to	pancreatic	 insufficiency,	most	patients	
with	 CF	 do	 not	 effectively	 absorb	 fat-soluble	 vitamins	 A,	 D,	 E	 and	 K.	 Therefore,	 these	
vitamins	must	be	given	regularly	based	on	the	patient’s	blood	vitamin	levels	(prothrombin	
time	 is	 used	 to	 measure	 levels	 of	 vitamin	 K)	 and	 based	 on	 CF	 nutritional	
recommendations	(64).	
Pancreatic	 insufficient	 patients	 also	 require	 Pancreatic	 Enzyme	 Replacement	 Therapy	
(PERT).	These	are	given	as	oral	capsules	called	Creon®, made	up	of	 lipase,	amylase	and	
protease,	 which	 should	 be	 taken	 with	 every	 food	 intake.	 In	 babies,	 enzyme	 granules	
called	Creon	Micro®	are	used	instead.	These	are	usually	given	before	feeds	with	a	small	
spoonful	 of	 fruit	 puree.	 The	 fruit	 puree	 prevents	 the	 granules	 from	 degrading	 in	 the	
gastric	acid,	but	also	makes	it	easier	for	the	infant	to	swallow	(64).	
The	CF	dietician	decides	on	 the	dose	of	PERT,	based	on	 the	patient’s	 clinical	 symptoms	
(e.g.	degree	of	steatorrhoea)	and	fat	content	of	the	diet.	Proton	pump	inhibitors,	such	as	
omeprazole,	can	be	given	to	further	aid	the	action	of	PERT.		
	
Patients	with	CF	have	much	greater	energy	demands	 than	healthy	 individuals	 (65)	and,	
unfortunately,	 it	 can	 be	 difficult	 to	 always	meet	 those	 demands.	 In	 addition	 to	meals,	
high-energy	 supplements	 are	 given	 to	 those	 individuals	 failing	 to	 thrive,	 or	 whose	
appetite	may	be	declining.		If	oral	supplements	are	not	sufficient,	patients	may	need	tube	
feeding	to	complement	their	oral	 intake.	This	can	either	be	in	the	form	of	an	over-night	
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nasogastric	 tube	 or	 a	 gastrostomy	 tube.	 For	 long-term	 use,	 a	 gastrostomy	 tube	 is	
preferred,	as	the	process	of	feeding	is	usually	more	comfortable	for	the	patient	(64).	
	
b)	Liver	and	biliary	tract	problems	
As	well	as	examining	patients	for	signs	of	liver	disease	(such	as	an	enlarged	liver)	at	each	
clinic	visit,	clinicians	should	request	additional	tests	as	part	of	a	patient’s	annual	review.	
These	tests	usually	include	an	abdominal	ultrasound	scan	to	visualise	the	liver	and	biliary	
tree	and	liver	function	tests	for	measuring	levels	of	serum	liver	enzymes.		
For	established	hepato-biliary	pathology,	Ursodeoxycholic	acid	is	recommended.	It	works	
by	displacing	toxic	bile	acids	from	the	circulation	and	is	also	thought	to	have	a	protective	
effect	on	cell	membranes	that	are	exposed	to	bile	acids	(66).		
Constipation,	incomplete	DIOS	and	complete	DIOS	are	fully	described	in	section	2.14,	as	
these	are	the	mainstays	of	my	thesis.	 
2.8.8	Reproductive	system	involvement	
Although	 females	 are	 not	 technically	 infertile	 from	 CF,	 the	 cervical	mucus	 is	 often	 too	
viscid	to	allow	the	passage	of	sperm	through	the	cervical	canal.	Poor	nutrition	in	CF	may	
also	reduce	fertility,	as	amenorrhoea	is	more	common	in	women	with	a	lower	percentage	
of	body	fat	(67).	
	
Males	are	generally	more	affected	than	females,	with	over	98%	infertile	as	a	result	of	the	
congenital,	 bilateral	 absence	 of	 the	 vas	 deferens	 with	 azoospermia	 (CBAVD).	 The	
azoospermia	is	also	relatively	acidic,	due	to	the	defective	bicarbonate	ion	transport.	The	
bicarbonate	transport	is	essential	for	readying	the	sperm	for	fertilisation,	an	event	called	
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capacitation.	This,	 therefore,	 leads	 to	an	 impaired	 fertilising	capacity	of	 the	sperm	(68).	
Other	pathologies	include	absence	or	atrophy	of	the	epididymis	and	seminal	vesicles	(69).		
2.8.9	Bone	involvement	
CF	patients	are	more	likely	to	suffer	from	osteoporosis	than	healthy	individuals,	with	one	
third	of	adults	affected.	As	such,	they	will	have	regular	dual-energy	X-ray	absorptiometry	
(DEXA)	scans	 to	monitor	 their	bone	density.	Patients	are	already	recommended	to	 take	
vitamin	D,	but	may	also	be	given	calcium	and	bisphosphonates	 if	 the	clinician	deems	 it	
necessary	(70).	
	
2.9	Psychological	problems	associated	with	CF	
Psychological	 input	 from	 the	 multi-disciplinary	 team	 is	 an	 important	 factor	 in	 the	
management	of	CF	because	many	 individuals	 struggle	 (in	different	ways)	 in	growing	up	
with	 a	 chronic	 disease.	 The	 next	 sections	 will	 describe	 some	 of	 the	 psychological	
implications	of	having	CF	throughout	childhood,	adolescence	and	adulthood.		
	
2.9.1	Childhood	
During	early	childhood,	medical	procedures	and	treatments	can	cause	stress	for	children	
who	do	not	fully	understand	their	necessity.	The	child	may	perceive	these	procedures	as	
painful,	uncomfortable	or	intimidating,	resulting	in	an	intense	behavioural	reaction.	They	
then	 associate	 future	 similar	 experiences	 with	 heightened	 emotion	 and	 distress,	 thus	
approaching	further	encounters	with	greater	resistance.		
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A	limited	understanding	of	their	condition	also	means	that	many	young	children	do	not	
appreciate	 the	 importance	 of	 taking	 their	 regular	 medication,	 following	 their	
physiotherapy	routine	or	eating	a	high	calorie	meal.	This	can	be	stressful	for	families	and	
negatively	impact	parents’	mental	health	and	family	dynamic.	In	fact,	parents	who	have	a	
CF	child	are	two	to	three	times	more	likely	to	suffer	from	depression,	anxiety	-	or	both-	
compared	to	the	general	population	(71,	72).		
Furthermore,	 sibling	 relationships	may	 become	problematic	 in	 families	with	 a	 CF	 child.	
Due	 to	 the	 large	 amount	 of	 time	 that	 must	 be	 dedicated	 to	 activities	 such	 as	
physiotherapy,	appointments	and	medication	administration,	the	healthy	sibling	may	feel	
as	though	the	CF	child	is	getting	more	attention	from	the	parents	(72).	
	
2.9.2	Adolescence		
At	school	age	and	adolescence,	children	desperately	want	to	be	accepted	by	their	peers,	
yet	individuals	with	CF	may	feel	as	though	they	do	not	fit	in.	Various	factors	can	account	
for	this,	whether	those	are	specific	CF	behaviours	such	as	excessive	sputum	production,	
taking	Creon®	in	front	of	friends,	or	feeling	singled	out	by	teachers.		
It	can	be	especially	difficult	for	adolescents	whose	symptoms	are	often	worsening	just	as	
the	 point	when	 they	 feel	most	 insecure.	 Adolescents	may	 also	 begin	 to	wonder	 about	
what	their	future	holds	and	the	growing	complexity	of	peer	relationships	and	discovering	
their	sexuality	adds	to	these	feelings	of	angst	and	confusion	(72).		
Then	there	are	issues	surrounding	body	image.	In	an	era	where	social	media	plays	such	a	
prominent	role,	teenagers	of	today	probably	place	more	importance	on	their	appearance	
than	ever	before.	The	 fact	 that	a	high	calorie,	high	 fat	diet	 is	emphasised	 in	CF	may	be	
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conflicting	 for	 some	 adolescents	 who	 hear	 otherwise	 from	 peers	 or	 online.	 Not	 to	
mention	the	fact	that	their	weight	is	monitored	very	closely	with	measurements	at	every	
appointment.	Although	the	prevalence	of	eating	disorders	 is	no	different	to	the	general	
population,	 it	 is	 not	 surprising	 that	 there	 is	 a	 greater	degree	of	 eating	disturbance	and	
negative	eating	attitudes	in	CF:	53%	compared	to	40-47%	in	their	counterparts	(73,	72).	
	
2.9.3	Mental	health	in	CF	
With	regards	to	mental	health	issues,	anxiety	seems	to	be	the	condition	most	prevalent	in	
adolescents	 with	 CF	 (74).	 Some	 studies	 claim	 that	 symptoms	 of	 both	 depression	 and	
anxiety	are	elevated	in	patients	compared	to	the	general	population	(71),	but	others	find	
that	depression	does	not	significantly	affect	patients	with	CF	(72).		
	For	 adult	 patients,	 increasing	 age,	 unemployment	 due	 to	 their	 CF	 and	 worsening	
pulmonary	function	seem	to	be	connected	to	mental	health	issues	(75).	
	
2.10	Prognosis	
Currently,	 the	median	 life	 expectancy	 for	 someone	with	 CF	 is	 41	 years	 old,	 although	 a	
baby	born	today	could	be	projected	to	have	a	median	 life	expectancy	of	56	years	 if	 the	
mortality	rate	continues	to	decrease	at	the	rate	observed	between	2000	and	2010	(76).		
	The	next	sections	will	explain	the	different	factors	that	may	affect	prognosis,	such	as	the	
patient’s	 genotype,	 pulmonary	 function,	 nutritional	 status,	 treatment	 adherence	 and	
pancreatic	sufficiency	status.	
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2.10.1	Effects	of	genotype	on	prognosis	
A	2003	study	found	a	significant	difference	 in	standardised	mortality	between	mutation	
class	 II	 (higher	 mortality)	 and	 classes	 IV	 and	 V,	 with	 class	 IV	 possessing	 the	 lowest	
mortality	 rate.	 Researchers	 also	 found	 that	 patients	 with	 the	 most	 common	 class	 II	
mutation-	Phe508del-	presented	with	pancreatic	 insufficiency	and	had	worse	nutritional	
outcomes	than	other	mutations.		
However,	this	same	study	acknowledged	that	there	appear	to	be	significant	differences	in	
phenotype	and	mortality	between	several	Phe508del	heterozygous	genotypes,	as	well	as	
differences	 within	 the	 same	 class	 (77).	 These	 findings	 are	 similar	 to	 the	 differences	 in	
phenotype	 and	 class	 studied	 by	 Boeck	 (19).	 The	 non-Phe508del	 allele	 in	 heterozygotes	
can	also	play	a	part	in	the	relationship	between	mortality	and	phenotype;	as	mentioned	
in	 section	 2.5.3,	 there	may	 be	 non-CFTR	 genes	 that	 alter	 the	 disease	 progression	 and	
could	potentially	protect	against	certain	aspects	of	CF	(77).	
	
2.10.2	Effects	of	gender	on	prognosis	
Although	the	relationship	between	genotype	and	phenotype	 is	complex	and	sometimes	
difficult	 to	 ascertain,	 there	 are	many	 other	 aspects	 of	 the	 disease	 that	 can	 also	 affect	
prognosis.	A	study	on	“The	Gender	Gap	in	Cystic	Fibrosis	Mortality”	in	1997	found	poorer	
survival	in	females	compared	to	males	between	the	ages	of	1-20	years	(78).	Even	in	2014,	
an	observational	death	registration	study	found	that	the	median	age	at	death	for	males	
was	 greater	 than	 females,	 showing	 that	 this	 gender	 gap	 has	 not	 narrowed	 since	 1997	
(79).	
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This	is	most	likely	multifactorial	in	aetiology,	as	stated	in	both	papers.	One	logical	reason	
could	be	that	women	are	more	likely	to	be	underweight	than	their	male	counterparts	and	
poor	nutrition	is	associated	with	poor	outcome	(see	CF	complications	below).		
	Some	theories	claim	that	the	female	sex	hormone,	17-beta-	estradiol,	further	dehydrates	
the	 airway	 surface	 liquid	 and	 can	 heighten	 the	 Toll-Like	 Receptor	 responsiveness	 to	 a	
range	of	bacteria	(80).		
	
2.10.3	Effects	of	CF	complications	on	prognosis	
Morbidities	associated	with	CF	can	have	an	impact	on	the	overall	prognosis,	for	example	
respiratory	 microbiology	 and	 chronic	 infection,	 pancreatic	 insufficiency,	 CF	 related	
diabetes	(CFRD)	and	CF	related	liver	disease.		
	
Chronic	infection	with	organisms	such	as	P.Aeruginosa,	S.	Aureus	and	B.	Cepacia	complex	
has	the	biggest	influence	on	Forced	Expiratory	Volume	in	1	second	(%FEV1)	in	CF	(80).	
%FEV1	is	one	of	the	most	reliable	indicators	of	pulmonary	function	and	hence	prognosis	
in	 CF	 (81).	 A	 1992	 study	 established	 that	 patients	 with	 a	 %FEV1	 <	 30%	 had	 a	 2	 year	
mortality	 over	 50%	 (82).	 Although	 this	 finding	 is	 not	 fully	 reliable	 according	 to	 more	
recent	 studies	 (81),	 it	 still	 illustrates	 the	 significance	 of	 pulmonary	 function	 in	 CF	
prognosis.		
Pancreatic	 insufficiency	 is	 also	 associated	 with	 significant	 decreases	 in	 FEV1%	 and	
patients	with	pancreatic	 insufficiency	are	 twice	as	 likely	 to	develop	 severe	 lung	disease	
(%FEV1<40%	 predicted)	 (80,	 83).	 Pancreatic	 insufficiency	 is	 also	 related	 to	 fat	
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malabsorption	 and	 therefore	 poor	 nutrition,	which	 is	 a	 risk	 factor	 for	 poor	 outcome	 in	
itself.		
Another	 predicator	 or	 poor	 outcome	 is	 CFRD,	 which	 is	 associated	 with	 insufficient	
nutritional	outcomes	and	more	 severe	 lung	disease	 -	both	predictors	of	poor	prognosis	
(80).	Liver	disease	is	also	a	serious	morbidity	of	CF	as	it	is	the	third	highest	cause	of	death	
after	respiratory	failure	and	transplant	complications	(83).		
Overall	nutritional	 status	of	 the	 individual	affects	prognosis,	as	demonstrated	 in	a	2006	
study	looking	at	risk	factors	for	death	amongst	CF	patients	awaiting	lung	transplantation.	
They	 found	 that	 those	 requiring	 nutritional	 intervention	 had	 a	 higher	 risk	 of	 death	
compared	to	their	counterparts	(84).		
CF	 complications	are	 related	 to	one	another	and	 it	 is	 important	 to	appreciate	 that	one	
complication	 may	 lead	 to	 or	 worsen	 others.	 	 For	 example,	 respiratory	 complications,	
CFRD,	gastrointestinal	and	hepato-biliary	complications	all	affect	the	nutritional	status	of	
the	patient.	If	the	patient’s	nutritional	status	is	poor,	they	will	be	less	mobile,	have	lower	
energy	 levels	 and	mood,	 which	may	 affect	 their	 adherence	 to	 treatment.	 The	 cycle	 of	
poor	 health	 therefore	 continues	 and	 so	 it	 is	 essential	 that	 we	 appreciate	 the	 inter-
dependence	of	these	factors.		
	
2.12	The	Future	of	CF	
In	 the	previous	 section	 I	discussed	 the	current	MDT	management	of	CF.	There	has	also	
been	a	great	deal	of	 research	 looking	 into	new	 treatments	 for	 the	disease,	which	 I	will	
discuss	in	the	following	sections.	
	
	
32	
2.12.1	Genotype-specific	small-molecule	therapy		
In	recent	years	there	have	been	great	advances	in	the	field	of	CF,	namely	research	around	
small	 molecule	 therapies.	 One	 of	 the	 most	 successful	 of	 these	 is	 the	 drug,	 Ivacaftor.	
Unlike	 other	 CF	medications,	 Ivacaftor	 works	 by	 targeting	 CFTR	 itself,	 potentiating	 the	
action	of	channel	opening	so	that	chloride	ions	can	pass	through.	Ivacaftor	has	proven	to	
be	 very	 effective	 at	 targeting	 the	G551D	mutation.	 In	 a	 phase	 III,	 randomized,	 double-
blind,	placebo-controlled	trial	over	a	48-	week	period,	the	drug	maintained	a	significant	
treatment	effect	at	a	%FEV1	that	was	10.5	percentage	points	greater	 than	the	placebo.	
Furthermore,	after	adding	the	patients’	usual	treatments	to	Ivacaftor,	(dornase	alfa,	oral	
azithromycin	and	 inhaled	 tobramycin)	 the	change	 in	%FEV1	was	even	greater,	at	17.2%	
improvement	 compared	 to	 the	placebo.	This	was	also	 sustained	 for	48	weeks.	At	week	
48,	67%	patients	in	the	Ivacaftor	group	(compared	to	41%	in	the	placebo)	were	also	free	
from	pulmonary	exacerbations	(85).	This	treatment	is	currently	licensed	for	all	patients	(2	
years	 and	 above)	 with	 the	 G551D	 mutation	 (10).	 	 Unfortunately,	 Ivacaftor	 is	 a	 very	
expensive	treatment.	In	the	UK,	the	cost	stands	at	£182,000	per	patient	per	year.	This	had	
led	 to	more	 rigid	 testing	of	 the	 clinical	 benefit	 of	 Ivacaftor,	which	may	 limit	 its	 use	 for	
other	mutations	(86).	
	
Ivacaftor	was	 also	 tested	 for	 the	most	 common	mutation,	 homozygous	 Phe508del,	 but	
was	 shown	 to	have	very	 limited	efficacy	 (86).	The	overall	 adverse	effect	 frequency	was	
similar	 to	 the	 placebo	 group	 (87.5%	 in	 the	 ivacaftor	 group	 and	 89.3%	 in	 the	 placebo	
group)	and	 the	overall	difference	 in	 the	change	 in	FEV1%	between	 the	 two	groups	was	
just	1.7%	(87).	
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Following	 on	 from	 the	 research	 on	 Ivacaftor,	 another	 small	 molecule	 therapy	 was	
produced:	Lumacaftor.	Lumacaftor	was	originally	created	for	the	homozygous	Phe508del	
mutation	 but	 was	 shown	 to	 be	 unsuccessful	 in	 phase	 II	 clinical	 trials.	 However,	 the	
combination	of	both	Ivacaftor	and	Lumacaftor	brought	success	to	both	phase	II	trials	and	
phase	III	trials	with	significant	improvements	to	the	%FEV1	(86).	It	was	therefore	licensed	
for	use	in	2015	(88).	Unfortunately,	due	to	the	exceptionally	high	cost	of	this	drug,	NICE	
does	 not	 currently	 recommend	 it	 for	 CF.	 Although	 the	 improvement	 in	 %FEV1	 was	
significant,	 it	was	relatively	modest,	ranging	from	4.3	to	6.7%	compared	to	the	placebo.	
This	moderate	 improvement	at	 such	a	high	cost	 is	perhaps	why	NICE	has	not	approved	
the	combination	of	Lumacaftor	and	Ivacaftor	for	the	Phe508del	mutation	(89).	
	
2.12.2	Gene	therapy	
An	ongoing	area	of	research	in	CF	is	in	gene	replacement	or	editing	therapies	to	correct	
CF	mutations	before	the	disease	manifests	 itself.	The	UK	CF	gene	consortium	published	
results	of	a	randomized,	double	blinded,	placebo-controlled	phase	IIb	trial	done	in	2015,	
of	 which	 the	 results	 were	 encouraging,	 but	 not	 yet	 suitable	 for	 clinical	 care.	 It	 was	
encouraging	 that	 there	 was	 a	 small	 but	 statistically	 significant	 improvement	 in	 %FEV1	
with	the	pGM169/GL67A	gene	therapy	formulation.	However,	this	was	mainly	driven	by	a	
fall	 in	 the	%FEV1	 in	 the	 placebo	 group	 (90).	 The	 same	 organisation	 is	 also	 planning	 to	
conduct	a	clinical	trial	in	2017	using	a	Lentiviral	vector	gene	therapy.	So	far,	they	have	not	
experienced	 any	 problems	 in	 the	 preliminary	 safety	 studies	 and	 the	 data	 supports	 the	
progression	of	the	vector	into	a	first-in-man	CF	trial	in	2017.		
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2.14	Distal	Intestinal	Obstruction	Syndrome		
2.14.1	Overview	
DIOS	 is	 a	 gastrointestinal	 complication	 of	 CF.	 It	 is	 distinct	 from	 constipation	 (another	
complication	in	CF)	in	its	pathophysiology,	although	the	two	are	often	confused	with	one	
another	 in	 clinical	 practice.	 Constipation	 occurs	 when	 there	 is	 faecal	 accumulation	
throughout	the	colon	(91).	 Individuals	have	infrequent	bowel	movements	(<3	per	week)	
and	stools	become	hard	and	lumpy.	Patients	may	also	experience	straining	and	feelings	of	
incomplete	evacuation	and	anorectal	obstruction	(92).		
DIOS,	however,	occurs	when	thick,	 sticky	mucus	produced	 in	 the	CF	 intestine	combines	
with	viscid	faecal	material	 in	the	lumen	of	the	terminal	 ileum	and/or	caecum.	The	mass	
adheres	to	the	intestinal	crypts	and	villi,	making	it	very	difficult	to	pass	per	rectum	(91).	
This	can	block	the	lumen	either	partially	(incomplete	DIOS)	or	fully	(complete	DIOS).		
In	this	section,	I	will	firstly	review	the	literature	for	chronic	constipation,	as	it	is	a	common	
gastrointestinal	complication	in	CF	that	is	often	confused	with	DIOS.	I	will	then	go	on	to	
outline	 the	 epidemiology,	 risk	 factors,	 aetiology,	 pathophysiology,	 diagnosis,	 clinical	
features	and	treatment	of	DIOS.		
	
2.14.2	Constipation	
a)	Epidemiology	
There	are	very	few	reports	on	the	lifetime	prevalence	of	constipation	in	patients	with	CF.	
The	most	recent	annual	data	report	(8)	does	not	contain	any	information	on	constipation	
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in	CF,	but	available	figures	show	that	 it	 is	a	very	common	problem,	occurring	 in	26-47%	
paediatric	patients	and	42%	adult	patients	(93,	94).		
 
b)	Risk	factors		
The	correlation	between	pancreatic	insufficiency	and	constipation	is	generally	
acknowledged,	but	there	are	some	conflicts	in	the	literature	(95).	
However,	2010	study	by	Van	der	Doef	demonstrated	that	patients	with	constipation	had	
a	lower	mean	total	fat	absorption	to	patients	without	constipation	(86%	in	patients	with	
constipation	compared	to	90%	in	patients	without	constipation)	(96).	Indeed,	two	other	
studies	have	shown	that	high	doses	of	pancreatic	enzyme	supplements	correlate	with	
constipation	(97,	98).	
	
Although	the	constipation	management	guidelines	recommend	a	high	fibre	diet	and	good	
hydration,	(see	below)	research	has	found	that	there	is	no	correlation	between	these	
lifestyle	factors	and	CF	constipation	(96,	99).		
 
 
There	are	many	other	risk	factors	for	constipation,	although	it	is	important	to	note	that	
these	are	not	specific	to	CF.	In	children,	toilet	training	issues	and	psychological	issues	may	
play	a	part	in	aggravating	the	issue;	constipation	is	often	painful	and	may	lead	to	children	
suppressing	defecation.	The	lower	colon	becomes	distended	and	the	urge	to	defecate	
becomes	irregular	due	to	a	decrease	in	rectal	sensation	(100).	
 
In	both	children	and	adults,	physical	inactivity	is	a	risk	factor	for	constipation.	It	is	
important	to	be	aware	of	this	especially	during	the	later	stages	of	CF	when	the	patient’s	
overall	health	has	declined	and	their	activity	levels	may	be	very	low.		
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It	is	also	important	for	clinicians	to	be	aware	of	medications	that	may	cause	constipation;	
these	include	antidepressants,	calcium	supplements,	iron	supplements,	antiepileptics	and	
sedating	antihistamines	(101).		
 
	
c)	Diagnosis		
	
The	 Rome	 III	 criteria	 are	 generally	 used	 to	 diagnose	 constipation.	 A	 patient	must	 have	
experienced	 at	 least	 2	 of	 the	 following	 symptoms	 in	 the	 past	 3	months:	 fewer	 than	 3	
bowel	 movements	 per	 week,	 straining,	 lumpy	 or	 hard	 stools,	 sensation	 of	 anorectal	
obstruction,	 sensation	 of	 incomplete	 defection	 and	 manual	 manoeuvring	 required	 to	
defecate	(92).	
Sometimes	 it	 can	 be	 difficult	 to	 differentiate	 between	 incomplete	 DIOS	 and	 severe	
constipation	 in	 clinical	 practice	 and	 they	may	 both	 present	with	 abdominal	 pain	 and	 a	
mass	 felt	 on	 abdominal	 examination.	 Unlike	 DIOS,	 constipation	 runs	 a	 more	 gradual	
course,	whereas	DIOS	tends	to	present	more	acutely.	Constipation	is	also	more	likely	to	
present	with	a	left-iliac	fossa	mass	(rather	than	the	right-iliac	fossa	mass	in	DIOS)	as	it	is	
found	in	the	colon.		
To	further	clarify	the	differences	between	constipation,	incomplete	and	complete	DIOS	in	
CF,	 the	 European	 Society	 for	 Paediatric	 Gastroenterology,	 Hepatology	 and	 Nutrition	
(ESPGHAN)	CF	working	group	has	set	out	simple	clinical	criteria	for	each	condition	(102).	
This	was	done	in	a	cohort	of	patients	under	18	years	of	age	across	8	CF	centres	between	
2001	and	2005.	The	definitions	for	DIOS	can	be	found	later	in	this	section.	
The	ESPGHAN	group	defined	constipation	as	“gradual	faecal	impaction	of	the	total	colon”.	
Their	criteria	for	constipation	in	CF	is	shown	in	Table	1.1:	
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Table	1.1:	Criteria	for	diagnosing	constipation	(102)	
	
ESPGHAN	CF	Working	Group	definition	for	constipation	in	cystic	fibrosis.	
No.	1	Abdominal	pain	and/or	distension	
No.	2a	Reduced	frequency	of	bowel	movements	in	the	last	few	weeks	or	months	
No.	2b	Increased	consistency	of	stools	in	the	last	few	weeks	or	months	
No.	3	Symptoms	1	and	2	are	relieved	by	the	use	of	laxatives	
Constipation:	no.	1	or	no.	2a	or	no.	2b	and	no.	3	
	
Radiology	can	also	be	used	to	aid	diagnosis	in	constipation	if	there	is	doubt	in	the	clinical	
picture.	 A	 plain	 abdominal	 radiograph	 is	 typically	 used,	 which	 shows	 faecal	 loading	
throughout	 the	 colon	 (91).	 However,	 it	 is	 worth	 noting	 that	 in	 clinical	 practice,	
constipation	 can	 usually	 be	 diagnosed	 with	 a	 detailed	 history,	 abdominal	 and	 rectal	
examination.	 X-rays	 expose	 the	 patient	 to	 radiation	 and	 should	 therefore	 not	 be	 used	
routinely.			
The	figure	below	shows	a	plain	abdominal	radiograph	of	a	patient	with	constipation.	
Figure	2.1:	Plain	radiograph	of	constipation	
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This	figure	shows	a	paediatric	patient	with	stool	throughout	the	colon	(103).	
	
d)	Management	of	constipation	
Before	starting	medical	treatment,	it	is	recommended	that	clinicians	ensure	their	patients	
are	 adequately	 hydrated	 and	 on	 a	 balanced	 diet	 with	 good	 fibre	 intake.	 First-line	
treatment	for	constipation	is	commonly	an	osmotic	laxative,	such	as	polyethylene	glycol	
3350,	 under	 the	 brand	 name	 Movicol®;	 this	 should	 be	 given	 on	 an	 escalating	 dose	
regimen.	 Movicol®	 comes	 in	 sachets	 of	 oral	 powder	 and	 can	 be	 given	 in	 different	
strengths	and	forms,	depending	on	the	age	of	the	patient	and	the	indication.	For	chronic	
constipation,	the	national	guidelines	recommend	1	to	3	sachets	daily	in	divided	doses	for	
up	to	2	weeks	and	1	to	2	sachets	daily	for	a	maintenance	dose.	For	faecal	impaction,	the	
patient	may	be	given	up	 to	8	sachets	on	 the	 first	day,	after	which	 the	dose	 is	 reduced.	
There	is	also	Paediatric	Movicol®	which	is	administered	at	a	dose	of	1	sachet	per	day	for	
children	aged	2	to	5	years	and	2	sachets	per	day	for	children	aged	6	to	11	years.		Another	
commonly	used	osmotic	 laxative	 is	Lactulose.	Lactulose	 is	given	as	an	oral	 solution;	 the	
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doses	are	15ml	twice	per	day	for	adults,	5	to	20ml	twice	per	day	for	children	aged	5	to	17	
years	and	lower	doses	(2.5	to	10ml)	for	children	aged	1	to	4	years.	If	the	condition	fails	to	
resolve	 within	 2	 weeks,	 a	 stimulant	 laxative	 can	 also	 be	 added	 or	 substituted	 if	 the	
osmotic	 laxative	 is	 not	 tolerated;	 for	 example,	 senna,	 sodium	 picosulphate	 or	 sodium	
docusate	 (which	 also	 has	 stool	 softening	 properties).	 Senna	 is	 taken	 orally	 and	 can	 be	
given	as	a	tablet	or	as	syrup.	Younger	children	are	usually	given	syrup;	the	dose	is	3.75	to	
15mg	once	daily	for	patients	aged	between	1	and	3	years.	This	can	be	increased	to	30mg	
(as	a	tablet	or	syrup)	for	older	children	aged	up	to	17	years.	Adults	can	take	a	tablet	or	
syrup	at	doses	between	7.5	and	30mg	once	daily.	Adults	can	take	sodium	picosulphate	at	
a	dose	of	5	to	10mg	once	daily;	children	under	the	age	of	17	can	take	it	at	a	dose	of	2.5	to	
20mg	once	daily,	which	 is	adjusted	according	 to	 the	response.	Sodium	docusate	can	be	
given	 to	 patients	 aged	 over	 12	 years	 at	 a	 daily	 dose	 of	 up	 to	 500mg.	 Children	 aged	
between	2	and	11	years	can	take	between	12.5	and	25mg	3	times	per	day	in	the	form	of	
an	oral	solution.		If	the	response	to	oral	medication	is	not	sufficient,	a	stimulant	enema	or	
suppository	is	recommended	for	adults	(101,	104)	
	
2.14.3	Historical	background	of	DIOS	
DIOS	was	previously	known	as	Meconium	Ileus	Equivalent	(MIE),	first	described	in	1962	in	
the	case	of	a	15	year-	old	boy.	At	the	time,	he	was	apparently	treated	with	pancreatin	via	
an	 ileostomy	 to	 relieve	 the	obstruction	 (105).	 It	 is	 important	 to	note	 that	children	with	
bowel	obstruction	had	previously	been	described	 in	CF	 in	the	1950s,	but	they	were	not	
named	“MIE”(4).		
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A	very	popular	 treatment	of	MIE	 in	 the	1960s	and	70s	was	oral	n-acetylcysteine	 (NAC),	
also	used	to	treat	meconium	ileus	in	neonates.	The	first	documented	use	of	this	in	post-
neonatal	meconium	ileus	was	in	1967	(106).	Another	drug	used	to	successfully	treat	acute	
MIE,	 first	 described	 in	 a	 1986	 study,	 was	 diatrizoate	 maglumine	(Gastrografin®)	 (107).	
Both	NAC	and	diatrizoate	are	still	used	to	treat	DIOS	in	many	centres	today.	
The	use	of	pancreatic	enzymes	(e.g.	pancreatin),	mucolytics	(e.g.	NAC)	and	enemas	were	
deemed	unhelpful	 for	 the	treatment	of	MIE	 in	a	1986	Lancet	article,	 just	after	MIE	was	
given	 the	 name	DIOS.	 The	 article	 described	 them	as	 “neither	 predictably	 effective,	 nor	
rapid	in	action”	(108).	There	are	quite	a	few	contradictions	in	historical	literature	on	the	
subject	of	DIOS	 treatments.	A	proportion	 is	made	up	of	case	studies.	One	should	 judge	
these	 studies	with	 a	 critical	 eye,	 as	 they	 can	 be	 subjective	 and	may	 only	 apply	 to	 one	
patient	or	a	small	group	of	patients,	rather	than	the	general	condition.		
	
2.14.4	Epidemiology	of	DIOS	
DIOS	affects	10%	to	22%	of	individuals	with	CF	(109,	110).	One	study	found	that	children	
with	CF	had	complete	DIOS	at	a	rate	of	5	to	12	episodes	per	1000	patients	per	year,	with	
higher	 figures	 for	 incomplete	 DIOS	 (102).	 The	 CF	 annual	 report	 shows	 an	 increase	 in	
intestinal	obstruction	 for	adults	with	CF	 (7.4%)	compared	 to	 those	under	 the	age	of	16	
(3%)	(8).	However,	there	appear	to	be	disparities	in	the	literature	because	in	2016	Munck	
found	similar	 incidences	of	DIOS	between	children	and	adults	 (111).	The	reason	for	this	
difference	 is	 probably	 due	 to	 other	 factors	 that	 can	 increase	 likelihood	 of	 developing	
DIOS.	For	example,	once	an	individual	has	had	DIOS	the	recurrence	risk	can	be	as	high	as	
77%	(112).	It	also	occurs	in	more	individuals	who	have	pancreatic	enzyme	deficiency	and	
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is	 anecdotally	 more	 common	 in	 those	 who	 do	 not	 adhere	 to	 pancreatic	 enzyme	
replacement	 therapy	 (113).	 	 There	 are	 many	 risk	 factors	 to	 consider	 for	 DIOS,	 as	
illustrated	in	Table	1.1	(91).		
Table	1.2	Risk	factors	for	DIOS	(91)	
	
•	Severe	genotype	
•	Pancreatic	insufficiency	
•	Dehydration	
•	Poorly	controlled	fat	malabsorption	
•	History	of	meconium	ileus	
•	History	of	DIOS	
•	Post	organ	transplantation	
•	CF	related	diabetes	
	
	
2.14.5	Pathogenesis	of	DIOS		
In	the	gastrointestinal	tract	there	are	various	events	likely	to	predispose	an	individual	to	
bowel	obstruction.	This	 section	will	describe	 the	various	pathophysiological	and	cellular	
factors	contributing	to	the	development	of	DIOS.		
	
a)	The	ENaC	Theory	
Principally,	as	with	other	organs	in	the	body,	the	defective	CFTR	gives	rise	to	low	levels	of	
chloride	and	water	in	the	gut	lumen.	There	is	also	an	increase	in	the	number	of	epithelial	
sodium	channels	(ENaC)	in	the	CF	gut,	due	to	a	fault	in	normal	down-regulation	of	these	
channels	by	CFTR;	more	ENaC	results	 in	more	sodium	and	fluid	absorption	from	luminal	
mucus	 (114).	 These	 two	phenomena	create	a	dehydrated	environment	 in	 the	 intestinal	
lumen,	as	well	as	thick,	viscid	mucus,	predisposing	the	individual	to	faecal	impaction	(91).	
To	scrutinise	the	ENac	theory,	one	should	consider	that	we	are	yet	to	fully	comprehend	
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exactly	how	 its	 regulators	affect	human	physiology	after	 seeing	 these	promising	 results	
on	animal	and	cellular	models	(114).	
	
b)	Bile	acid	physiology	
There	 is	 also	 evidence	 of	 abnormalities	 in	 bile	 acid	 physiology	 in	 CF.	 Bile	 acids	 usually	
induce	 secretion	 via	 CFTR	 and	 are	 normally	 reabsorbed	 into	 the	 terminal	 ileum.	 In	 CF,	
these	mechanisms	are	affected	due	to	the	faulty	CFTR.	The	involvement	of	the	terminal	
ileum	in	DIOS	supports	this	theory	(115).	
	
c)	Bicarbonate	levels	
In	CF,	there	are	also	relatively	low	levels	of	bicarbonate	in	the	duodenum.	This	leads	to	a	
rather	acidic	environment	in	the	duodenum,	as	the	gastric	acid	from	the	stomach	cannot	
be	correctly	neutralized.	This	means	that	the	pH	of	the	duodenum	will	not	be	adequate	
for	 the	 digestive	 function	 of	 pancreatic	 enzymes	 and	 bile	 salts,	 contributing	 to	 the	
relatively	 poor	 digestive	 function	 of	 the	 small	 intestine	 in	 CF	 (116).	 Furthermore,	 the	
bicarbonate	is	said	to	help	maintain	the	normal	solubility	of	intestinal	mucus,	so	it	follows	
that	 there	will	 be	 an	 accumulation	 of	mucus	 if	 the	 bicarbonate	 levels	 are	 not	 suitable	
(117,	118).		
	
d)	Fat	Malabsorption	
Fat	 malabsorption	 as	 a	 result	 of	 pancreatic	 exocrine	 insufficiency	 has	 been	 associated	
with	the	development	of	more	viscid	faeces	in	the	intestine,	and	hence	the	development	
of	DIOS.	However,	this	theory	is	controversial	because	DIOS	can	also	occur	in	those	who	
are	pancreatic	sufficient	(119	,91)	
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e)	Inflammation	
Inflammatory	processes	may	also	have	a	part	to	play	in	the	pathogenesis	of	DIOS.	Recent	
studies	have	shown	that	submucosal	or	transmural	 inflammation	 is	common	in	patients	
with	 DIOS.	 This	 inflammation	 has	 been	 linked	 to	 enteric	 neuromuscular	 dysfunction,	
which	may	be	one	of	the	mechanisms	behind	faecal	impaction	(120).	
The	muscularis	mucosa	 is	often	thickened	 in	patients	with	DIOS	too,	which	may	be	as	a	
result	of	dysmotility,	or	due	to	the	dense	and	sticky	intestinal	contents	(121).	
	
In	 summary,	 there	are	various	mechanisms	 involved	 in	 the	pathogenesis	of	DIOS,	 some	
more	well	 recognised	 than	 others,	 as	 this	 section	 as	 highlighted.	 Currently,	 the	 overall	
significance	of	each	mechanism	in	the	full	picture	of	DIOS	is	not	completely	clear,	but	one	
can	deduce	that	the	faulty	CFTR	is	most	likely	at	the	core	of	the	whole	process,	especially	
since	those	with	a	severe	genotype	are	most	likely	to	develop	DIOS.	However,	there	are	
clearly	more	complex	factors	at	play	because	DIOS	is	also	seen	(albeit	rarely)	in	those	with	
mild	genotypes	(111).	
	
2.14.6	Clinical	features	of	DIOS	
Individuals	with	complete	DIOS	present	with	signs	and	symptoms	of	bowel	obstruction:	
abdominal	 pain,	 distension	 and	 vomiting	 (122).	 If	 the	 individual	 presents	 more	
intermittently	-	with	episodes	of	abdominal	pain,	nausea	or	anorexia	without	vomiting	-	
the	 diagnosis	 is	 more	 likely	 to	 be	 incomplete	 DIOS	 (91).	 To	 differentiate	 between	
constipation	 and	 incomplete	 DIOS	 can	 be	 tricky,	 but	 there	 are	 some	 important	
differences;	 a	 right	 iliac	 fossa	 mass	 should	 lead	 the	 clinician	 to	 consider	 DIOS	 over	
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constipation,	for	example.	 
	
2.14.7	Diagnosis	of	DIOS	
DIOS	is	usually	diagnosed	clinically.	Typically,	one	can	feel	a	right	lower	quadrant	mass	on	
abdominal	 palpation	 and	 the	 patient	may	 experience	 a	 colicky,	 progressive	 pain	 in	 the	
right	 lower	 quadrant	 or	 peri-umbilical	 area.	 If	 a	 known	 CF	 patient	 presents	 with	 this	
clinical	picture,	along	with	vomiting	and	abdominal	distension,	complete	DIOS	should	be	
suspected	(91).	
	
The	ESPGHAN	CF	Working	Group	defined	DIOS	as	“acute	complete	or	 incomplete	faecal	
obstruction	 in	 the	 ileocaecum”.	 They	 also	 set	 out	 clinical	 criteria	 for	 diagnosing	
incomplete	and	complete	DIOS,	as	shown	in	table	1.3	below:	
	
	
Table	1.3:	Criteria	for	diagnosing	DIOS	(102)	
	
ESPGHAN	CF	Working	Group	definition	for	DIOS	in	cystic	fibrosis	
No.	1	Complete	 intestinal	 obstruction	as	 evidenced	by	 vomiting	of	 bilious	material	 and/or	
fluid	levels	in	small	intestine	on	an	abdominal	radiography	
No.	2	Faecal	mass	in	ileo-caecum	
No.	3	Abdominal	pain	and/or	distension	
Complete	DIOS:	no.	1,	no.	2,	and	no.	3	
Incomplete/Impending	DIOS:	no.	2	and	no.	3,	without	no.	1	
	
	
a)	Differential	Diagnosis	of	DIOS	
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Surgical	pathologies	such	as	appendicitis,	intussuseption	and	volvulus,	are	also	important	
to	rule	out	as	they	can	also	present	acutely	in	similar	ways	to	DIOS	(91).		
	
b)	Radiological	evidence	for	DIOS	
If	 there	 is	any	doubt	 in	the	clinical	picture,	a	radiological	diagnosis	should	be	sought.	 In	
DIOS,	the	radiograph	will	show	a	bubbly,	granular	mass	in	the	right	lower	quadrant	(116).	
Air	levels	in	the	small	intestine	may	also	accompany	the	mass	(123);	a	CT	scan	can	also	be	
used	to	confirm	the	diagnosis	if	there	is	some	doubt	after	the	plain	radiograph.		
	
Examples	 of	 DIOS	 on	 a	 plain	 radiograph	 and	 a	 CT	 scan	 are	 shown	below	 in	 figures	 2.2	
(122)	and	2.3	(124).		
	
	
Figure	2.2:	Plain	radiograph	of	DIOS	with	dilated	loops	of	small	bowel	and	shadowing	in	
the	right	iliac	fossa	(122).	
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Figure	2.3:		CT	scan	of	a	37	year-	old	man	with	DIOS.	Dilated	small	bowel	loops	are	seen.	
White	arrowhead	shows	the	bubbly,	granular	intraluminal	contents	(124).	
	
2.14.8	Management	of	DIOS	
a)	Treatment	of	DIOS	
If	 a	 diagnosis	 of	 incomplete	DIOS	 is	made	 but	 the	 patient	 is	 clinically	 stable,	 they	may	
respond	to	one	of	the	laxative	regimens	described	in	section	2.14.2.	However,	if	there	is	
inadequate	 response,	 other	 drugs	 are	 used.	 One	 of	 these	 is	 another	 type	 of	 osmotic	
laxative,	Diatriozate	(Gastrografin®).	 It	 is	given	as	a	single	dose,	orally	or	via	nasogastric	
tube,	which	can	be	repeated	fully	or	as	half-doses	every	24	hours.	Adult	doses	range	from	
30	to	90ml,	children	aged	between	5	and	10	years	may	take	doses	of	60ml	and	children	
under	the	age	of	5	are	recommended	to	take	30ml	(104).	Another	osmotic	laxative	given	
is	polyethylene	glycol,	under	the	brand	name,	Klean-Prep®,	with	the	aim	to	cleanse	the	
bowel.	The	solution	is	given	until	clear	fluid	is	passed	per	rectum	and	there	is	resolution	
of	pain,	vomiting	and	abdominal	pain.	Children	aged	between	1	and	17	years	may	take	a	
dose	of	10ml	per	kg	per	hour	 for	30	minutes,	which	 can	be	 increased	up	 to	25ml.	This	
regime	is	usually	given	over	4	hours	and	can	be	repeated	in	necessary.	Adults	may	take	
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one	sachet	(69g)	dissolved	in	1	litre	of	water,	which	may	be	taken	twice	per	day.	A	single	
dose	of	oral	N-acetylcysteine	can	also	be	used	to	treat	DIOS.	As	a	mucolytic,	it	can	help	to	
degrade	 the	obstructing	 faecal	material	 (91).	 This	 is	 given	at	 a	dose	of	4	 to	6g	 in	older	
children	 (7	 to	 17	 years)	 and	 2	 to	 3g	 in	 younger	 children	 (2	 to	 6	 years).	 There	 are	 no	
guidelines	for	the	use	of	N-acetylcysteine	in	adults	with	DIOS,	as	it	is	only	recommended	
for	children	(104).	
Complete	DIOS	is	treated	in	a	similar	way	to	incomplete	DIOS,	but	is	usually	managed	in	
hospital.	Furthermore,	the	patient	may	be	commenced	on	conventional	“drip	and	suck”	
management	 for	 bowel	 obstruction:	 IV	 rehydration,	 nil	 by	 mouth	 and	 nasogastric	
aspiration.	 Diatriozate	 can	 be	 administered	 via	 enema,	 but	 should	 be	 done	 so	 with	
caution	as	fluid	shifts	in	the	bowel	can	lead	to	shock	and	perforation	(125,	91)	The	aim	of	
managing	 complete	DIOS	 is	 to	 avoid	 surgical	 intervention	as	much	as	possible,	 but	 this	
may	be	necessary	if	the	patient	is	not	responding	to	medical	treatment.	
b)	Prevention	of	DIOS	
For	 the	 prevention	 of	 DIOS,	 it	 is	 recommended	 that	 patients	 have	 adequate	 hydration	
and	 good	 adherence	 to	 pancreatic	 enzyme	 therapy.	 Furthermore,	 prophylactic	 laxative	
therapy	is	advised	if	the	patient	has	had	a	previous	episode	of	complete	DIOS	or	clinical	
evidence	of	 incomplete	DIOS.	 It	may	also	be	used	post-operatively	 for	CF	patients	who	
have	undergone	organ	transplantation.	Prophylaxis	can	also	be	given	to	patients	who	are	
pancreatic	 insufficient	 and	 have	 clinical	 or	 radiological	 evidence	 of	 constipation	 (e.g.	
palpable	faecal	masses	with	abdominal	pain)	(91).		
2.14.9	Summary	
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DIOS	 has	 been	 discussed	 in	 detail	 in	 this	 section.	 It	 occurs	 when	 thick,	 sticky	 mucus	
produced	 in	 the	 CF	 intestine	 combines	with	 viscid	 faecal	material	 in	 the	 lumen	 of	 the	
terminal	ileum	and/or	caecum.	It	is	distinct	from	constipation	in	its	pathophysiology,	but	
can	 sometimes	 be	 difficult	 to	 distinguish	 clinically.	 However,	 the	 ESPGHAN	CF	Working	
Group	 has	 provided	 clinical	 criteria	 to	 diagnose	 incomplete	 DIOS	 and	 complete	 DIOS.	
DIOS	is	surprisingly	common	and	affects	10-22%	individuals	with	CF.	Risk	factors	include	
previous	episodes	of	DIOS	or	meconium	ileus,	pancreatic	insufficiency	and	non-adherence	
to	PERT.		
Aside	 from	 measures	 such	 as	 good	 adherence	 to	 pancreatic	 enzyme	 therapy	 and	
adequate	hydration,	 there	 is	 little	 evidence	 for	 any	particular	 laxative	 regimen.	 For	 the	
prevention	 and	 treatment	 of	 DIOS,	 there	 are	many	 different	 types	 of	 laxatives	 used	 in	
various	combinations	across	the	CF	centres	in	the	UK.	This	subject	has	not	been	studied	in	
detail	 and	 as	 such,	 there	 are	 no	 recommendations	 on	 the	 prevention	 or	 treatment	 of	
DIOS.	 A	 systematic	 review	 of	 the	 literature	 is	 required	 to	 provide	 guidance	 for	 the	
management	of	DIOS.	The	review	may	discover	that	there	are	gaps	in	the	literature,	but	if	
this	is	the	case,	it	should	act	as	a	source	of	incitement	for	further	research	on	the	subject. 	
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Chapter	3.	The	Cochrane	Systematic	
Review:	An	Introduction.	
3.1	Defining	a	Cochrane	review	
Cochrane	reviews	are	systematic	reviews	of	research	on	a	particular	topic.	They	are	
considered	to	be	the	highest	standard	of	evidence-based	health	care	resources.	The	
Cochrane	Collaboration	is	named	after	the	late	Archibald	Cochrane,	a	Scottish	doctor	who	
was	famous	for	promoting	the	use	of	randomized	controlled	trials	to	improve	the	efficacy	
and	safety	of	clinical	practice.	His	1971	book,	“Effectiveness	and	Efficiency”	criticized	the	
lack	of	evidence-based	medicine.	His	work	was	extremely	influential	and	eventually	led	to	
the	creation	of	the	Cochrane	collaboration	in	1993	(126).	
Each	Cochrane	review	works	by	collating	and	analysing	the	data	and	results	of	relevant	
studies	relating	to	a	specific	objective.	Before	starting	a	review,	the	authors	must	produce	
a	set	of	strict	criteria	for	inclusion	and	exclusion	of	studies.	Authors	can	seek	advice	from	
the	Cochrane	Review	Group	(CRG)	in	their	particular	speciality.	The	relevant,	included	
studies	are	combined	and	put	through	a	detailed	process	of	data	extraction	and	statistical	
analysis	to	give	an	overall	result.	This	should	decide	whether	the	combined	study	results	
provide	statistically	significant,	good	quality	and	reliable	evidence	on	the	chosen	topic	
(127).	
3.2	Motivation	for	the	Cochrane	review	
Distal	intestinal	obstruction	syndrome	is	a	major	problem	in	CF,	as	discussed	in	Chapter	2.	
Incomplete	DIOS	 is	common	 (102)	and	 therefore	 it	 seems	rational	 that	 there	should	be	
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recognised	guidelines	for	its	management.	However,	anecdotally	and	as	demonstrated	by	
the	 results	 of	 the	 consultant	 survey	 (see	 chapter	 5),	 there	 is	much	 variation	 in	 clinical	
practice.		
There	are	some	general	guidelines	about	the	prevention	and	treatment	of	DIOS,	although	
they	 do	 not	 have	 a	 high	 quality	 evidence	 base.	 For	 preventative	 measures,	 adequate	
hydration	and	good	adherence	to	pancreatic	enzyme	supplementation	is	recommended,	
as	well	as	prophylactic	laxative	therapy	for	patients	who	have	had	a	previous	episode	of	
complete	 DIOS.	 Maintenance	 laxative	 therapy	 may	 also	 be	 given	 to	 patients	 with	
incomplete	DIOS	 or	 for	 those	with	 clinical	 or	 radiological	 evidence	 of	 constipation	 (see	
section	2.14.2)	 (91).	 For	 the	 treatment	of	DIOS,	 various	 laxative	 regimens	 can	be	used,	
but	 there	are	no	absolute	 recommendations.	 In	 some	cases,	medical	management	may	
fail	 and	 the	 patients	 will	 have	 to	 undergo	 surgery.	 This	 is	 seen	 as	 a	 last	 resort,	 as	 it	
dramatically	 increases	 the	 risk	 to	 the	patient	 (128).	By	 conducting	Cochrane	 reviews	 to	
investigate	the	current	management	strategies	for	DIOS,	I	aim	to	determine	the	aperients	
that	 are	 supported	 by	 the	 best	 evidence	 and	 secondly,	 identify	 important	 gaps	 in	 the	
research.	By	alerting	clinicians	to	gaps	in	the	literature,	it	may	encourage	further	research	
on	the	topic.		
It	 is	 also	 important	 to	 note	 that	 individuals	with	 CF	 experience	 a	 significant	 treatment	
burden.	 A	 review	 should	 address	 this	 by	 discussing	 the	 risks	 and	 benefits	 for	 various	
laxative	agents	and	give	information	on	their	potential	adverse	effects	and	tolerability.		
3.3	Starting	a	Cochrane	review	
3.3.1	The	Protocol	
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Before	starting	a	Cochrane	review,	one	must	first	publish	a	protocol.	The	protocol	acts	as	
a	 scaffold	 for	 the	 review	 and	 includes	 the	 essential	 information	 on	 which	 to	 base	 the	
review.	 Sections	 of	 the	 protocol	 include	 the	 background,	 objectives	 and	methods.	 The	
background	section	describes	the	condition	and	intervention,	how	the	intervention	might	
work	and	why	 it	 is	 important	 to	do	 the	 review.	The	objectives	 section	should	 include	a	
primary	 question	 or	 outcome.	 The	 methods	 section	 outlines	 the	 selection	 criteria	 for	
studies,	 search	 strategies	 and	 overview	of	 the	 process	 for	 data	 collection	 and	 analysis.	
The	 protocol	 should	 be	 set	 out	 clearly,	 according	 to	 the	 guidelines	 in	 the	 Cochrane	
handbook	 (129).	 It	 should	 also	 be	 relatively	 easy	 to	 read	 so	 that	 non-experts	 can	
understand	it.		
There	 are	 a	 few	 reasons	 why	 authors	 must	 produce	 a	 protocol.	 Firstly,	 discussing	
strategies	prior	 to	 the	 review	promotes	 transparency	and	 reduces	 risk	of	bias	 from	 the	
authors.	 For	 example,	 by	 setting	 the	 criteria	 for	 inclusion	 of	 studies	 in	 the	 protocol,	 it	
reduces	 the	risk	of	 inclusion	of	studies	 that	are	not	suitable	but	may	have	a	 favourable	
outcome	that	support	the	authors’	hypothesis.	A	protocol	also	ensures	that	peer	review	
of	 the	 methods	 is	 possible,	 which	 can	 help	 to	 improve	 the	 quality	 of	 the	 review.	
Furthermore,	publishing	a	protocol	reduces	risk	of	duplication	(130,	129).	
	
Publishing	a	Protocol	
Due	to	the	high	standard,	systematic	approach	of	Cochrane	reviews,	it	is	usual	for	
reviewers	to	receive	a	number	of	recommendations	from	the	CRG	before	a	protocol	is	
published.	The	CRG	must	ensure	that	the	reviewers’	protocol	is	relevant,	thorough	and	
transparent.		
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Initially,	the	CRG	reviews	a	protocol	and	if	there	are	improvements	to	be	made,	it	is	sent	
back	to	the	authors	with	recommendations.	Once	the	review	group	has	no	more	
recommendations	for	the	authors,	the	protocol	is	then	forwarded	to	the	contact	editor	
and	co-editor	for	approval	to	publish.		
	
3.3.2	Use	Of	Software		
The	software	program	used	by	authors	to	write	and	update	Cochrane	reviews	is	Review	
Manager	5.3®	(RevMan	5.3®)	(131).	It	is	also	used	to	help	prepare	the	protocol	and	comes	
with	a	set	of	headings	and	subheadings	to	prompt	the	user.	The	Methodological	
Expectations	for	Cochrane	Intervention	Reviews,	or	“MECIR”	guidelines	can	be	activated	
on	the	program	to	help	the	user	include	all	the	relevant	sections	in	the	protocol.	The	
Cochrane	Handbook	also	provides	useful	and	detailed	guidance.	When	it	comes	to	writing	
a	review,	RevMan®	facilitates	the	preparation	of	study	characteristics,	comparison	tables	
and	study	data.	Furthermore,	RevMan®	can	perform	meta-analysis	of	data	and	present	
the	results	in	graphs	(132).	
	
3.3.3	The	Review	Team	
The	process	of	writing	a	Cochrane	review	demands	teamwork.	At	least	two	authors	are	
required	for	the	process	of	screening	studies	and	data	extraction.	This	must	be	done	
independently	to	reduce	the	risk	of	bias	and	error.	To	give	an	example	of	how	our	team	
worked	for	the	review,	“Interventions	for	the	prevention	of	DIOS”,	WC	and	I	
independently	screened	studies	for	inclusion	or	exclusion.	Then	the	third	author,	FG,	
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acted	as	an	arbiter	to	review	any	disagreements	we	had.	This	process	and	the	process	of	
data	extraction	will	be	described	in	more	detail	in	Chapter	4.	
Ideally,	one	of	the	members	of	the	team	should	already	have	some	experience	in	
Cochrane	review	methodology.	We	were	fortunate	that	WC	had	attended	the	advanced	
training	courses	at	Cochrane	and	had	experience	in	statistics.	It	is	also	recommended	that	
one	member	of	the	team	should	be	an	expert	in	the	area	being	reviewed.	FG	had	a	great	
amount	of	clinical	experience	in	CF,	so	was	therefore	appointed	as	the	main	source	of	
clinical	knowledge.		
Our	team	also	extended	to	members	of	our	Cochrane	Review	Group	(CRG),	the	Cochrane	
Cystic	Fibrosis	and	Genetic	Disorders	Group.	CRGs	are	made	up	of	experts	in	Cochrane	
reviews	who	offer	support,	information	and	guidance	for	authors.	Two	members	of	our	
CRG	who	particularly	assisted	us	in	creating	the	protocol	and	review	were	NH,	an	
information	specialist	and	NJ,	the	managing	editor.		
	
3.3.4	Cochrane	Review	Training	
Although	the	Cochrane	Handbook	and	CRG	provide	very	useful	information,	first-time	
reviewers	are	encouraged	to	complete	training	courses.	To	improve	my	understanding,	I	
attended	the	four-part	training	course	at	the	UK	Cochrane	Centre	in	Oxford.		
The	Review	Author	(RA)	training	courses	are	grouped	into	two	main	parts.	RA1	and	RA2				
(attended	18-19th	October,	2016)	are	designed	to	help	authors	construct	their	protocol	
and	RA3	and	RA4	(attended	15-16th	February,	2017)	address	the	methodology,	analysis	
and	reporting	of	systematic	reviews.	The	courses	greatly	improved	my	understanding	of	
how	to	write	a	protocol	and	the	main	steps	involved	in	generating	a	Cochrane	review.	The	
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certificates	of	attendance	from	the	Cochrane	Review	Author	training	courses	can	be	
found	in	Appendix	6	of	this	thesis.	
	
3.3.5	Types	of	Interventions	for	DIOS	
The	management	of	DIOS	is	divided	into	the	treatment	of	DIOS	and	the	prevention	of	
DIOS,	so	I	undertook	two	separate	Cochrane	reviews	to	investigate	the	evidence	base	for	
these	two	areas	of	management.	The	indications	and	main	outcomes	for	prevention	and	
treatment	are	different;	therefore	separate	reviews	were	required.	Furthermore,	
although	laxatives	are	used	for	both	treatment	and	prevention	of	DIOS,	there	would	most	
likely	be	differences	in	the	type	of	laxative	used,	as	well	as	the	dose	and	the	route	of	
administration.	In	the	next	chapter,	I	will	discuss	the	Cochrane	review	on	the	
Interventions	for	the	prevention	of	DIOS.	In	chapter	5,	I	will	discuss	the	Cochrane	review	
on	the	Interventions	for	the	treatment	DIOS.	I	will	aim	to	meet	the	first	objective	of	this	
thesis	by	describing	and	explaining	the	methods	used	to	conduct	these	systematic	
reviews.	I	will	explain	the	criteria	for	inclusion	of	studies,	descriptions	of	the	medical	
databases	used,	the	search	strategy	and	search	terminology	used.		I	will	also	describe	the	
process	of	data	extraction	and	the	methods	used	to	analyse	the	data.			
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Chapter	4:	Cochrane	Systematic	Review	on	
the	Interventions	for	Preventing	DIOS	in	CF.	
4.1	Objective	
• To	assess	the	effectiveness	and	safety	of	different	groups	of	laxative	agents	for	
preventing	distal	intestinal	obstruction	syndrome	(incomplete	and	complete)	in	
children	and	adults	with	CF.		
4.2	The	Protocol		
The	protocol	had	to	be	designed	before	the	academic	year	started	so	there	would	be	
enough	time	to	complete	the	review.	Therefore,	WC	initially	drafted	the	protocol.	The	
CRG	then	sent	the	protocol	back	with	advice	for	improvement.		After	I	completed	the	first	
part	of	the	Cochrane	training	course,	I	contributed	content	and	references	to	sections	
describing	the	condition	and	intervention.	I	then	assisted	WC	in	editing	parts	of	the	
methods	section	(e.g.	the	outcomes	measures,	search	methods	and	measures	of	
treatment	effect).		
	
Our	final	submission	of	the	protocol	took	place	on	27/02/2017	and	it	was	published	on	
11/04/2017.	It	can	be	found	in	Appendix	2	of	this	thesis.		
4.2.1	Writing	the	protocol	
	
57	
It	is	recommended	that	authors	should	write	the	protocol	for	a	review	using	the	PICOS	
criteria,	an	abbreviation	for,	“Participants,	Intervention,	Comparison,	Outcomes	and	
Study	design”	(129).	These	criteria	should	be	set	out	in	every	protocol	and	are	expanded	
to	establish	clear	guidelines	for	the	inclusion	or	exclusion	of	studies	in	the	review.	This	
facilitates	the	process	of	study	screening	and	data	extraction.		
In	the	sections	below,	I	detail	these	criteria:	
a)	Participants	
Distal	intestinal	obstruction	syndrome	is	specific	to	patients	with	CF,	so	I	required	the	
participants	to	have	CF,	diagnosed	by	either	sweat	test	or	genetic	testing.	Although	it	is	
usually	more	common	in	adults	(8),	children	can	suffer	from	DIOS	too.	Therefore,	I	
searched	for	studies	including	children	and	adults	with	CF	(with	all	stages	and	severity	of	
lung	disease	and	with	or	without	pancreatic	sufficiency).		
b)	Intervention	and	Comparison	
i)	Types	of	interventions	
Laxatives	form	the	basis	for	the	prevention	of	DIOS.		We	(WC,	FG	and	I)	agreed	that	I	
should	investigate	laxatives	as	the	main	intervention	for	this	Cochrane	review.		
ii)	Categorising	the	difference	types	of	laxative	
I	decided	to	group	the	laxatives	according	to	their	main	mode	of	action.	I	ultimately	
arrived	at	3	main	categories	of	laxative:	osmotic	agents,	stimulants	and	mucolytics.		
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Osmotic	laxatives	act	as	stool	softeners.	They	exert	an	osmotic	effect	in	the	lumen	of	the	
large	intestine	and	either	cause	a	fluid	shift	from	the	body	to	the	bowel,	or	prevent	fluid	
from	leaving	the	bowel	(104.).	In	DIOS,	osmotic	laxatives	may	soften	the	viscid	stool	
(caused	by	the	combination	of	mucus	and	faeces)	that	has	accumulated	in	the	bowel.		
Stimulant	laxatives	are	effective	are	stimulating	peristalsis	(104)	so	could	reduce	gut	
transit	time	and	prevent	mucofaeculant	material	from	adhering	to	the	bowel	wall.		As	
depicted	in	the	name,	Mucolytics	work	by	disintegrating	the	mucus	produced	in	CF.	They	
could	therefore	prevent	the	combination	of	faeces	and	mucus	or	breakdown	existing	
mucofaeculant	material.	
There	are	various	medications	that	fall	into	the	3	categories	of	laxative.	These	are	
described	in	Appendix	2.		
During	the	process	of	categorising	the	laxatives,	it	became	evident	that	some	drugs	have	
more	than	one	mechanism	of	action	(e.g.	Macrogrol	3350	is	an	osmotic	agent	with	
stimulatory	effects).	To	avoid	confusion,	I	would	primarily	compare	any	laxative	therapy	
to	a	control	or	no	treatment.	Thereafter,	I	would	assess	the	relative	effectiveness	of	
laxative	agents	in	a	subgroup	analysis.	For	the	purpose	of	the	protocols,	I	categorised	
agents	with	more	than	one	mode	of	action	according	to	their	main	mechanism	e.g.	I	listed	
sodium	docusate	as	a	stimulant,	but	it	also	has	stool	softening	properties.	
iii)	Types	of	comparisons	
I	decided	to	compare	various	laxative	therapies	at	any	dose	to	placebo,	no	treatment	or	
alternative	laxatives	for	the	prevention	of	DIOS.	I	would	evaluate	the	effectiveness	of	
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laxatives	at	any	dose	in	order	to	comprehensively	assess	the	therapeutic	range	of	
different	aperients.	For	example,	high	doses	may	cause	adverse	effects	such	as	flatulence,	
abdominal	pain,	diarrhoea	or	soiling.	Knowing	the	risk	of	these	effects	would	be	useful	in	
future	clinical	practice	for	titrating	patient	doses.		
c)	Outcomes	
Reviewers	must	compile	a	list	of	main	outcomes	they	deem	to	be	most	relevant	to	the	
review’s	objective.	There	should	be	a	maximum	of	7	outcomes,	each	one	reflecting	an	
important	part	of	the	decision-making	process	for	patients.	Because	of	this,	many	
intervention	reviews	share	similar	outcomes.	Common	outcomes	include	adverse	effects,	
survival,	clinical	events	(e.g.	complete	bowel	obstruction)	and	quality	of	life.		Outcomes	
are	central	to	the	review,	not	only	because	they	are	used	to	judge	the	effectiveness	of	the	
intervention,	but	also	because	they	are	used	to	construct	the	“Summary	of	Findings”	
table	at	the	end	of	the	review.	This	table	presents	the	main	conclusions	of	the	review	in	a	
clear	and	concise	manner.		
When	it	comes	to	the	process	of	screening	studies,	outcomes	are	not	usually	part	of	the	
eligibility	criteria	for	including	studies.	As	mentioned,	they	are	used	to	judge	the	
effectiveness	of	the	intervention	in	question.	Instead,	the	reviewers	should	include	
studies	that	match	the	rest	of	the	eligibility	criteria	i.e.	participants,	intervention,	
comparison	and	study	design	(129).		
i)	Primary	outcomes			
Primary	outcomes	are	chosen	from	the	list	of	main	outcomes.	There	should	be	a	
maximum	of	3	and	as	suggested	in	the	title,	they	are	the	most	important	outcomes	for	
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assessing	the	intervention	of	a	review.	It	is	strongly	advised	that	reviewers	include	at	least	
one	“undesirable”	outcome	in	their	list	of	primary	outcomes	(129).		
I	aimed	to	assess	the	following	primary	outcomes	for	the	review,	“Interventions	for	the	
prevention	of	DIOS”:	
1. Complete	or	incomplete	DIOS	diagnosed	either	clinically	(e.g.	abdominal	masses,	
or	distension	or	pain)	or	radiologically	(e.g.	dilated	bowel	or	faecal	mass).	
2. Adverse	effects	from	treatments	
i)	Serious	adverse	effects	of	treatment	regimens	(including,	but	not	limited	to,	
rectal	bleeding,	intestinal	perforation,	mucosal	erosions,	anaphylactic	
reaction,	vomiting	with	electrolyte	disturbance)	
ii)	Other	adverse	effects	of	treatment	(e.g.	diarrhoea	or	soiling,	abdominal	
distension,	loss	of	continence	or	pain)	
1.	Clearly,	the	diagnosis	of	DIOS	is	a	significant	clinical	event	for	this	review,	as	its	main	
objective	is	to	assess	laxatives	for	their	effectiveness	in	preventing	DIOS.		
2.	As	previously	mentioned,	adverse	effects	are	commonly	used	as	outcomes	for	
intervention	reviews.	They	are	important	in	evaluating	the	safety	of	an	intervention.	
Assessing	the	safety	of	different	aperients	was	stated	in	the	review’s	objective	and	so	it	is	
fitting	that,	“adverse	effects	from	treatments”	is	listed	as	a	primary	outcome.	
Information	on	adverse	effects	can	be	gathered	in	different	ways.	One	may	either	
consider	the	range	of	adverse	effects	per	person,	or	the	range	of	adverse	effects	for	all	
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the	participants	in	the	study.	For	our	reviews,	I	would	assess	the	adverse	effects	across	
the	whole	study.	Reviewers	should	also	state	whether	they	are	assessing	the	severity	or	
seriousness	of	adverse	effects.	Severity	of	adverse	effects	is	similar	to	intensity.	The	
severity	may	be	mild,	moderate	or	severe.	An	example	of	an	adverse	effect	measured	in	
severity	would	be	abdominal	pain.		
On	the	other	hand,	serious	adverse	effects	include	those	that	could	be	dangerous	or	even	
fatal.	I	would	assess	these	in	our	review.	Examples	of	serious	adverse	effects	from	
laxatives	are	listed	above	i.e.	rectal	bleeding,	intestinal	perforation.	
ii)	Secondary	outcomes			
Secondary	outcomes	are	also	taken	from	the	list	of	main	outcomes.	They	are	not	as	
significant	for	clinical	decisions	as	primary	outcomes	are,	but	help	to	make	the	review	
more	comprehensive	in	assessing	the	effectiveness	of	an	intervention.		
I	aimed	to	assess	the	following	secondary	outcomes	for	the	review,	“Interventions	for	the	
prevention	of	DIOS”:	
1. Time	to	hospital	admission	
i)	All	causes	
ii)	Due	to	DIOS	
2. Patient-reported	quality	of	life	(QoL)	scores	
3. Patient-reported	symptom	scores	
4. Tolerability	(participant-	or	investigator-reported	rates	of	concordance)	
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The	first	secondary	outcome	for	this	review	is	a	time-to-event	outcome	(133).	Patients	
with	complete	DIOS	are	acutely	unwell,	so	they	are	usually	admitted	to	hospital	in	this	
situation.	This	outcome	may	therefore	be	useful	for	determining	the	effectiveness	of	a	
laxative	regimen	in	preventing	complete	DIOS.	I	separated	the	outcome	into	two	points,	
because	patients	with	CF	may	be	admitted	to	hospital	for	various	reasons	other	than	DIOS	
e.g.	respiratory	tract	infections.		
	The	next	three	secondary	outcomes	are	related	to	patient	experiences.	Patient	reported	
outcomes	measures	(PROMs)	are	often	useful	when	objective	outcomes	are	not	available,	
or	for	complementing	more	objective	outcomes	(e.g.	diagnosis	of	DIOS)	as	they	come	
directly	from	the	patient	without	influence	from	clinicians	or	study	investigators.	PROMs	
offer	the	patient’s	perspective	on	the	treatment	and	may	alert	investigators	to	flaws	in	
the	treatment	that	cannot	be	picked	up	by	objective	markers.	For	example,	a	treatment	
may	demonstrate	great	efficacy	and	have	a	low	adverse	effect	profile,	but	the	patient	
may	feel	as	though	the	treatment	burden	has	an	impact	on	their	quality	of	life.	PROMs	
are	key	for	delivering	the	patient-centred	care	that	is	practiced	in	medicine	today.	They	
may	be	collected	in	different	ways,	though	diaries,	questionnaires	and	interviews	are	
commonly	used	(129).	
d)	Study	Design	
As	these	were	intervention	reviews,	the	most	suitable	studies	to	use	were	comparative	
studies,	as	they	would	evaluate	the	differences	between	a	control	and	intervention.	The	
highest	quality	comparative	studies	are	randomised-controlled	trials	(RCTs).	RCTs	are	the	
best	studies	to	judge	the	effectiveness	of	an	intervention	because	they	randomly	allocate	
participants	(e.g.	by	a	computer	generated	random	sequence)	to	a	group.	This	means	that	
	
63	
the	demographics	and	characteristics	of	participants	are	not	taken	into	account.	Each	
participant	has	an	equal	chance	of	being	chosen	for	the	intervention.	RCTs	therefore	
minimise	the	risk	of	selection	bias	and	generally	provide	more	reliable	evidence	for	
interventions	than	other	types	of	studies.		
After	discussion	with	my	supervisors,	I	also	chose	to	include	quasi-RCTs.	These	are	
comparative	studies,	but	allocate	participants	based	on	known	criteria,	such	as	date	of	
birth	or	alternation	(e.g.	Monday’s	patients	receive	intervention,	Tuesday’s	patients	
receive	control).	Unlike	RCTs,	participants	are	not	assigned	to	groups	through	concealed	
randomisation.	This	may	pose	a	problem	if	clinicians	are	aware	of	the	sorting	process.	For	
example,	they	could	potentially	ask	the	sickest	patients	to	come	in	for	clinic	on	the	day	
that	participants	are	receiving	the	intervention.		Quasi-	randomisation	runs	the	risk	of	
manipulation	of	the	selection	process,	which	can	imbalance	the	baseline	characteristics	of	
participants,	leading	to	unreliable	results.	Therefore,	I	planned	to	assess	quasi-RCTs	on	
their	merit	using	the	Cochrane	risk	of	bias	tool.	I	would	only	include	a	quasi-RCT	if	the	
second	reviewer	and	myself	were	satisfied	that	the	intervention	and	control	group	were	
similar	at	baseline	(134).	
After	discussion	with	WC	and	FG,	I	also	decided	to	assess	crossover	trials	for	inclusion	in	
the	review.	In	crossover	trials,	all	participants	follow	a	succession	of	interventions,	rather	
than	being	allocated	to	parallel	groups	(such	as	in	an	RCT).	For	example,	participants	
could	be	sorted	into	two	groups.	Group	A	takes	the	intervention	and	Group	B	takes	the	
control.	After	a	period	of	time,	the	groups	switch	so	that	the	intervention	group	now	
takes	the	control	and	vice	versa.		This	means	that	all	participants	experience	the	control	
and	intervention.	Crossover	trials	can	therefore	be	useful	in	determining	individual	
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comparisons,	which	removes	baseline	variations	that	are	in	parallel	group	trials.	However,	
there	are	also	weaknesses	in	this	model.	The	main	downside	is	that	the	effects	of	the	
intervention	could	be	carried	over	to	the	control	group.	This	could	influence	the	
treatment	effect	and	increase	the	risk	of	bias.	(134).	
4.3	Search	methods		
NH,	a	Cochrane	information	specialist,	designed	the	search	strategy	for	the	review.	
During	the	screening	process	I	decided	to	accept	titles	and	abstracts	that	matched	the	
eligibility	criteria	for	the	review.	In	this	section,	I	will	describe	the	medical	databases	and	
online	registries	used	to	search	for	studies,	as	well	as	the	search	terminology	and	syntax	
used	in	the	search	strategy.	I	will	also	describe	the	screening	process	and	include	details	
about	the	software	used	to	screen	the	studies.	
	
4.3.1	Medical	databases	
I	searched	the	following	online	databases	for	relevant	studies	to	be	included	in	the	
Cochrane	systematic	review:	
• Cochrane	Central	Register	of	Controlled	Trials	(CENTRAL)	(135):	This	database	is	
part	of	the	Cochrane	Library	and	is	updated	quarterly.	It	is	frequently	used	to	run	
searches	for	trials	and	studies	to	be	included	in	Cochrane	reviews.	It	contains	the	
highest	number	of	reports	of	controlled	trials.	As	of	January	2008,	CENTRAL	
contained	nearly	530,000	citations	suitable	for	Cochrane	reviews.	310,000	trials	
reports	are	from	MEDLINE,	50,000	are	from	EMBASE	and	170,000	are	derived	
from	other	databases	and	handsearching (129). 
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• MEDLINE:		This	bibliographic	database	has	very	broad	subject	coverage,	
containing	citations	from	over	5,600	journals	worldwide.	It	is	the	main	database	
used	by	the	US	National	Library	of	Medicine	®	(NLM)	and	is	all-encompassing	in	
the	subjects	of	biomedicine	and	health.	It	includes	literature	outside	the	reaches	
of	clinical	medicine,	for	example:	life	sciences	(such	as	plant,	marine	and	animal	
biology),	behavioural	and	chemical	sciences	and	bioengineering.	The	NLM	indexes	
the	records	in	MEDLINE	with	Medical	Subject	Headings	(MeSH),	which	is	a	unique	
feature	of	the	database.	MEDLINE	was	searched	from	1946	to	present,	using	Ovid	
as	a	search	engine (136,	129).	
• EMBASE	(Excerpta	Medica	Database):	This	database	contains	a	wide	array	of	
pharmaceutical	and	biomedical	information,	with	over	2,900	journals	that	cannot	be	
found	at	MEDLINE.	EMBASE	is	particularly	useful	when	looking	at	drug	efficacy,	drug-
disease	relationships,	drug-drug	interactions	and	adverse	events.	It	also	uses	its	own	
thesaurus	called	EMTREE,	which	indexes	all	of	the	EMBASE	content.	It	contains	a	
much	higher	number	of	synonyms	and	terms	than	MeSH	(from	MEDLINE)	and	a	more	
extensive	drugs	facet	(137,	129).	EMBASE	was	searched	from	1974	to	present,	using	
the	Healthcare	Databases	Advanced	Search	(HDAS)	tool.		
	
4.3.2	Electronic	searches	
I	also	searched	the	following	online	registers	and	resources	for	relevant	studies:	
	
• Cochrane	Review	Group	Specialist	Register:	The	relevant	studies	were	searched	
for	from	the	Group's	Cystic	Fibrosis	Trials	Register	using	the	term:	distal	intestinal	
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obstruction	syndrome	(DIOS).	The	Cystic	Fibrosis	Trials	Register	is	compiled	from	
electronic	searches	of	the	Cochrane	Central	Register	of	Controlled	Trials	
(CENTRAL)	(updated	each	new	issue	of	The	Cochrane	Library),	weekly	searches	of	
MEDLINE,	a	search	of	Embase	to	1995	and	the	prospective	hand-searching	of	two	
journals	-	Pediatric	Pulmonology	and	the	Journal	of	Cystic	Fibrosis.	Unpublished	
work	is	identified	by	searching	the	abstract	books	of	three	major	cystic	fibrosis	
conferences:	the	International	Cystic	Fibrosis	Conference;	the	European	Cystic	
Fibrosis	Conference	and	the	North	American	Cystic	Fibrosis	Conference	(138,	129).	
• US	National	Institutes	of	Health	Ongoing	Trials	Register-	Clinicaltrials.gov.	This	is	a	
registry	and	results	database	containing	details	about	clinical	trials	involving	humans	
around	the	world.	One	can	search	for	proposed,	ongoing	and	completed	studies.	
According	to	the	most	recent	website	figures	(17/04/2017),	the	registry	lists	241,812	
studies	(139).	
• International	Standard	Randomised	Controlled	Trial	Number	(ISRCTN)	Registry:	This	is	
a	clinical	trials	registry	that	provides	each	trial	with	a	unique	identifying	number.	The	
number	is	used	to	keep	track	of	reports	and	publications	related	to	the	trial.	ISRCTN	
features	trials	that	assess	the	efficacy	of	a	health	intervention	in	a	human	population,	
incorporating	both	observational	and	interventional	trials	(140).	
• World	Health	Organization	International	Clinical	Trials	Registry	Platform	(WHO	ICTRP):	
The	main	aim	of	the	WHO	ICTRP	is	to	facilitate	the	registration	of	clinical	trials	to	
make	them	accessible	to	the	public.	The	search	portal	provides	a	single	point	of	access	
to	these	ongoing	and	completed	trials	that	adhere	to	WHO	standards	(World	Health	
Organisation	(141).	
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• Open	Grey:	This	is	a	resource	containing	700,000	bibliographic	references	of	grey	
literature	(paper	records)	produced	in	Europe.	It	is	an	open	access	website,	so	the	
records	can	be	easily	located	and	exported.	Grey	literature	includes	sources	such	as	
research	reports,	doctoral	dissertations	and	conference	papers,	among	others	(142).	
I	searched	these	main	medical	databases	and	registries	on	the	recommendation	from	NH	
in	order	to	obtain	extensive	information	on	the	current	practices	for	the	prophylaxis	of	
DIOS.	As	a	minimum,	it	is	recommended	that	CENTRAL	and	MEDLINE	are	both	used	to	run	
searches	for	Cochrane	Systematic	Reviews.	EMBASE	is	also	recommended,	if	available	to	
the	Cochrane	Review	Group	(CRG)	or	review	author	(JG)	(129).	As	per	the	Methodological	
Expectations	of	Cochrane	Intervention	Reviews	(MECIR)	guideline	(143),	NH	advised	that	
clinicaltrials.gov	and	WHO	ICTRP	were	searched	too.	Ongoing	trials	are	important	to	
identify,	so	that	they	can	be	later	assessed	for	inclusion	in	the	updates	of	the	review.			
4.3.3	Search	strategy	
a)	Search	methods	for	identification	of	studies	
I	searched	all	relevant	published	and	unpublished	trials	using	the	search	strategy	devised	
by	 NH,	 without	 restrictions	 on	 language	 or	 publication	 status.	 Details	 of	 the	 search	
strategies	used	can	be	found	in	Appendix	1.		
	
b)	Search	terminology:	
I	 identified	 search	 terms	with	 the	aid	of	NH.	The	 search	 terminology	was	based	on	 the	
eligibility	criteria	for	the	review	as	outlined	in	the	protocol.	
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i)	 Condition	 of	 interest:	 The	 condition	 was	 CF.	 I	 also	 searched	 other	 terms	 for	 cystic	
fibrosis	in	order	to	retrieve	a	higher	number	of	studies.	I	also	included	the	abbreviation	of	
cystic	 fibrosis,	 “CF”,	 as	 well	 as	 “mucoviscidosis”	 and	 “fibrocystic”.	 The	 latter	 refers	 to	
fibrocystic	disease	of	the	pancreas.	Both	terms	were	used	to	describe	CF	in	the	mid	20th	
century	(7).	
ii.)	 Outcome	 of	 interest:	 The	 main	 outcome	 for	 the	 reviews	 was	 distal	 intestinal	
obstruction	 syndrome.	 I	 also	 searched	 the	 abbreviation,	 “DIOS”,	 as	 well	 as	 descriptive	
terms	for	the	condition,	such	as	“faecal	obstruction”	and	“faecal	 impaction”.	 I	searched	
the	 subject	 headings,	 “intestinal	 obstruction”	 and	 “constipation”	 and	 then	 “exploded”	
these	to	include	more	specialised	terms	in	the	search.	I	also	included	the	historical	name	
for	DIOS,	“Meconium	ileus	equivalent”	or	“MIE”	(105)	
iii.)	 Interventions	 of	 interest:	 The	 potential	 interventions	 for	 this	 review	were	 osmotic	
laxatives,	 stimulant	 laxatives,	 mucolytics	 and	 laxatives	 with	 more	 than	 one	 mode	 of	
action.	I	searched	the	index	term,	“Laxatives”	and	exploded	it	to	retrieve	more	definitive	
terms.	 I	 also	 searched	 individual	 names	 of	 laxatives.	 In	 order	 to	 obtain	more	 results,	 I	
used	both	generic	and	brand	names	of	drugs	e.g.	“polyethylene	glycol”	and	“Movicol®”.		
	
c)	Search	Syntax	
I	 searched	 thesaurus	 terms	 in	 the	 databases	 that	 had	 an	 indexing	 system	 (CENTRAL,	
MEDLINE	 and	 EMBASE)	 to	 identify	 relevant	 results	 that	 could	 be	 labelled	 as	 different	
terms.	 I	 did	 this	 by	 writing	 “MeSH	 descriptor”	 after	 a	 word	 or	 term	 in	 the	 CENTRAL	
system,	e.g.	“Laxatives	[Mesh	descriptor]”,	or	by	adding	a	forward	slash	(/)	after	the	term	
e.g.	“Laxatives/”	in	MEDLINE	and	EMBASE.		
	
69	
I	 also	used	extensive	 truncation	 in	 the	medical	 database	 strategies.	 This	 is	 a	 technique	
used	to	obtain	all	possible	suffix	variations	of	the	word	in	question,	e.g.	“constipate$”	or	
“constipate*”	could	retrieve	terms	such	as	constipated,	constipation	or	constipating.		
	I	 used	 the	 Boolean	 operators	 (144)	 “AND”	 and	 “OR”	 to	 improve	 the	 search	 strategy.	
Combining	terms	using	“OR”	resulted	 in	a	broader	set	of	results.	This	was	 implemented	
for	each	component	to	ensure	that	all	synonyms	of	a	term	e.g.	“cystic	fibrosis”	or	“distal	
intestinal	obstruction	syndrome”	were	accounted	for.	The	operator,	“AND”,	was	used	to	
narrow	the	results	 in	 the	search	strategy.	This	was	used	at	 the	end	of	each	search.	The	
terms	 for	 the	 outcome	 and	 intervention	were	 combined	 to	 retrieve	more	 specific	 and	
therefore,	more	relevant	results.		
	
To	include	results	in	which	two	desired	words	would	appear	next	to	one	another,	I	used	
the	 command,	 “adj”,	 e.g.	 “(faecal	 adj	 (obstruction	 or	 impact*)).	 This	means	 the	 word,	
“faecal”	 should	 appear	 next	 to	 either	 “obstruction”	 or	 “impact*”	 in	 a	 phrase.	 This	
command	 can	 be	 expanded	 to	 include	 words	 that	 appear	 near	 each	 other	 but	 not	
necessarily	 next	 to	 one	 another.	 For	 example,	 “(faecal	 adj3	 (obstruction	 or	 impact*))”	
means	two	additional	words	are	permitted	between	“faecal”	and	either	“obstruction”	or	
“impact*”.		
	
d)	Issues	with	syntax	
I	 planned	 to	 search	 EMBASE	 using	Ovid	 as	 a	 search	 engine,	 but	 due	 to	 problems	with	
access	to	the	system,	I	had	to	use	Healthcare	Databases	Advanced	Search	(HDAS)	instead.	
On	 the	 advice	 of	 NH,	 I	 altered	 the	 search	 syntax	 to	 accommodate	 this	 change.	 For	
	
70	
example,	“tw”,	meaning	title	or	abstract	in	Ovid,	was	changed	to	“af”,	meaning	“all	fields”	
in	HDAS.	The	truncation	symbol,	shown	as	the	dollar	sign	($)	in	EMBASE	Ovid,	had	to	be	
changed	to	an	asterisk	(*)	for	EMBASE	HDAS.		
	 	
4.4	Data	collection	and	extraction	
4.4.1	Selection	of	studies	
a)	Use	of	software	
After	entering	each	search	strategy	into	the	relevant	database,	I	then	exported	the	search	
results	(titles	and	abstracts	of	the	studies)	onto	an	online	software	program	called	
Covidence©	(145).	Reviewers	use	Covidence©	for	organising	and	screening	studies.	It	also	
facilitates	the	process	of	data	extraction,	the	risk	of	bias	assessment	and	exports	data	and	
references	into	RevMan®.	
	
I	imported	citations	from	CENTRAL,	MEDLINE,	Embase,	ISRCTN	and	Open	Grey	onto	
Covidence©.	Citations	from	WHO	ICTRP	and	clinicaltrials.gov	could	not	be	imported	onto	
Covidence©,	so	I	uploaded	the	citations	manually	and	created	a	hyperlink	for	each	one	so	
that	the	other	reviewers	could	view	the	clinical	trial	online.		
	
b)	De-duplication	of	studies	
When	I	exported	the	citations	to	Covidence©,	it	automatically	removed	a	588	duplicates.	
However,	Covidence©	can	only	remove	very	precise,	identical	citations,	so	some	
duplicates	remained	and	were	included	in	the	screening	of	titles	and	abstracts.	
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c)	Screening	studies	
The	first	stage	of	the	screening	process	is	to	select	relevant	titles	and	abstracts	that	can	
be	included	in	full-text	screening.		
WC	and	myself	screened	the	titles	and	abstracts	independently.	Covidence©	is	set	up	so	
that	each	reviewer	simply	votes,	“yes”,	“no”	or	“maybe”	for	each.	If	both	reviewers	vote	
“yes”	or	“maybe”	for	a	study,	it	is	then	taken	to	full-text	screening.	
If	both	reviewers	vote	“no”	for	a	study,	it	is	simply	listed	as	“irrelevant”	and	excluded	
from	the	review.		When	WC	and	I	voted	differently	for	a	study,	it	was	flagged	up	as	a	
“conflict”	on	Covidence©.	In	these	situations,	FG	acted	as	an	external	arbiter	to	have	a	
final	say	on	whether	the	study	should	go	through	to	full-text	screening.	
	
Most	imported	citations	included	titles	and	abstracts	of	the	studies,	but	some	only	
included	the	title.	It	was	usually	clear	from	the	title	whether	or	not	the	study	was	relevant	
to	either	review	(e.g.	respiratory	intervention	studies	were	excluded).	If	it	was	not	clear,	I	
could	hand-search	for	the	abstract	online.	In	some	circumstances,	the	title	was	very	
vague	and	no	more	information	could	be	found	elsewhere.	In	5	cases	where	we	could	not	
rule	out	the	study,	it	had	to	be	included	in	the	full-text	screening	process.		
	
d)	Examination	of	full	text	reports	
After	FG	resolved	the	conflicts	from	the	title	and	abstract	screening,	we	initially	had	9	
citations	to	go	to	full	text	screening.	However,	one	study	was	duplicated	on	Covidence©,	
so	there	were	actually	8	different	studies	to	assess	for	inclusion	or	exclusion.		
	
72	
More	details	about	the	results	of	the	searches	can	be	found	in	the	Results	section	later	in	
this	chapter.	
	
e)	Reference	Lists	
I	checked	the	bibliographies	of	relevant	studies	to	identify	further	references	to	
appropriate	trials.	I	screened	these	studies	according	to	the	eligibility	criteria	applied	to	
the	other	titles/abstracts. 
	
4.4.2	Data	extraction		
Data	extraction	is	very	important	in	a	Cochrane	review.	Essentially,	the	reviewers	
carefully	examine	full-text	versions	of	studies	(usually	in	the	form	of	reports	or	articles	
from	journals)	(129)	to	determine	their	eligibility	for	inclusion	in	the	review.		
	
Paper	data	extraction	forms	were	provided	to	us	by	our	CRG.	Covidence©	also	provides	an	
electronic	tool	for	data	extraction.	I	used	the	paper	form	to	obtain	the	basic	information	
for	each	study,	and	then	entered	the	data	onto	the	more	detailed	form	online.		
Data	collection	and	extraction	offers	a	useful	summary	of	all	the	important	criteria	that	is	
relevant	to	the	review.	On	the	paper	form	and	electronic	form,	there	are	prompts	to	
ensure	that	reviewers	are	aware	of	the	information	that	needs	to	be	extracted.	Secondly,	
they	provide	a	record	of	the	thought	process	and	decisions	made	during	data	extraction,	
which	can	be	useful	to	refer	back	to	during	the	write-up	of	a	review.	But	perhaps	most	
importantly,	data	collection	forms	provide	data	that	will	be	analysed	in	the	Cochrane	
review	(146).	
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If	we	decided	that	a	study	did	not	have	a	relevant	design,	participants	or	intervention(s),	
it	would	be	excluded	from	the	review.	For	studies	with	unclear	outcomes,	we	would	try	to	
contact	the	trial	authors	for	more	information.	During	this	time,	it	would	be	listed	as	
“awaiting	assessment”.	If	there	were	no	clarification	regarding	the	outcomes	after	3	
attempts	at	contact,	the	study	would	be	excluded.	 
	
It	is	recommended	that	more	than	one	reviewer	should	be	involved	in	the	data	extraction	
process.	WC	and	I	independently	used	the	data	extraction	tool	on	Covidence©	for	each	
study.	Then	we	compared	our	forms	for	discrepancies	and	discussed	these	in	order	to	
arrive	at	a	final	decision.	FG	also	acted	as	an	external	arbiter	for	any	disagreements	we	
could	not	resolve	with	discussion.	
After	extracting	data	from	studies,	I	entered	it	into	RevMan®	for	analysis.		
The	figures	below	are	screenshots	demonstrating	the	data	extraction	forms	on	
Covidence©:	
Figure	4.1:	Screenshot	1	of	the	outcomes	section	on	a	Covidence©	data	extraction	form.	
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The	bar	on	the	left	hand	side	(Identification,	Methods,	Population)	shows	the	other	main	
areas	covered	in	data	extraction.	Covidence©	prompts	the	user	to	select	an	outcome	type	
for	each	outcome	so	that	the	measure	used	is	correct.	
	
Figure	4.2:	Screenshot	2	of	the	outcomes	section	on	a	Covidence©	data	extraction	form.	
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This	figure	illustrates	the	various	ways	to	classify	and	detail	each	outcome.	
	
4.5	Data	analysis	
In	the	next	sections,	I	will	describe	the	tools	and	methods	used	for	analysing	the	study	
data.	Each	section	directly	relates	to	a	step	briefly	described	the	protocol	(Appendix	2).	
However,	I	also	aim	to	include	definitions	and	explanations	of	the	methods	in	each	
section,	using	my	knowledge	from	the	Cochrane	training	courses	and	guidance	from	the	
Cochrane	Handbook	(129).	The	different	methods	include	assessing	the	risk	of	bias,	
measuring	the	effects	of	treatments,	unit	of	analysis	issues,	dealing	with	missing	data,	
assessing	heterogeneity,	subgroup	analysis	and	sensitivity	analysis.		
	
4.5.1	Assessment	of	risk	of	bias	in	included	studies	
a)	Types	of	bias	
There	are	main	6	categories	of	bias	that	can	be	found	in	studies:	selection	bias,	
performance	bias,	detection	bias,	attrition	bias,	reporting	bias	and	other	types	of	bias	
(147).	It	is	essential	for	authors	to	carefully	assess	the	risk	of	bias	for	each	study,	so	that	
the	review	provides	reliable	information.		
Selection	bias	is	assessed	by	the	how	the	participants	were	allocated	to	either	the	
placebo	or	intervention.		For	a	low	risk	of	bias	in	this	category,	the	study	should	describe	
random	sequence	generation	(e.g.	by	computer	generated	randomisation)	and	concealed	
allocation	(e.g.	giving	participants	opaque,	sealed	envelopes)	so	that	the	investigators	do	
not	know	what	the	allocation	will	be.	
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Performance	bias	is	related	to	the	blinding	of	those	involved	in	the	study	(the	participants	
and	personnel).	Low	risk	of	performance	bias	may	be	described	in	studies	as	“double-
blinding”,	meaning	that	both	personnel	and	participants	had	no	knowledge	of	the	
intervention	administered	or	received.		
Detection	bias	is	related	to	the	blinding	of	outcome	assessors	for	an	intervention.	This	is	
low	risk	if	the	study	described	“blinding”	or	“masking”	of	the	outcome	assessors	to	the	
type	of	intervention	each	participant	received.	
Attrition	bias	occurs	when	there	is	incomplete	outcome	data	resulting	from	withdrawals	
in	a	study	(e.g.	due	to	adverse	effects	or	loss	of	follow-up).	If	the	study	has	described	
reasons	for	these	missing	data	and	included	an	intention-to-treat	(ITT)	analysis,	the	risk	of	
bias	may	be	low	in	this	category.	ITT	analysis	simply	means	that	all	participants	were	
analysed	as	per	their	randomised	groups,	even	if	some	had	dropped	out	or	been	excluded	
before	the	end	of	the	study.		
Reporting	bias	means	that	the	study	has	selectively	reported	outcomes,	rather	than	
reporting	all	the	outcomes	that	were	measured.	It	is	useful	to	have	access	to	the	study	
protocol	in	order	to	judge	this,	as	we	can	directly	compare	the	outcomes	listed	in	the	
protocol	to	those	reported	in	the	study.	
	
b)	Assessing	Bias	for	each	study	
I	used	the	Cochrane	Risk	of	Bias	Tool	to	assess	the	risk	of	bias	in	the	six	domains	
described	above.	Covidence©	provided	accessible	and	simple	software	to	facilitate	this.	
Independently,	WC	and	I	ranked	each	of	the	domains,	“high”,	“low”	or	“unclear”,	
depending	on	the	description	in	the	study.	For	each	ranking,	we	added	comments	to	
justify	our	decision.	After	we	had	completed	the	assessment,	we	compared	our	
	
77	
judgements,	resolved	our	disagreements	with	discussion	and	came	to	a	consensus.	We	
initially	had	conflicting	views	on	the	risk	for	the	domain	of	selection	bias	and	detection	
bias;	WC	ranked	these	domains	as	having	a	low	risk	of	bias,	but	I	ranked	them	as	having	
an	unclear	risk	of	bias.	We	came	to	an	agreement	after	discussion	amongst	ourselves	and	
with	FG’s	opinion.	I	will	explain	our	final	decision	and	how	we	arrived	at	this	conclusion	in	
the	Results	section	later	in	this	chapter.	
	
4.5.2	Measures	of	treatment	effect	
a)	Types	of	outcome	measures	
There	are	two	main	types	of	standardised	outcome	data	described	in	the	Cochrane	
handbook:	dichotomous	and	continuous	(148).	
	
i)	Dichotomous	data	
Dichotomous	data	can	have	one	of	two	outcomes.	For	example,	a	patient	either	has	
complete	DIOS	or	does	not	have	complete	DIOS.	The	dichotomous	treatment	measures	
are	described	in	the	protocol,	Appendix	2.	
Dichotomous	data	are	expressed	as	the	chance	of	an	outcome	occurring	and	is	measured	
in	risk	or	odds.	Risk	is	commonly	used	in	healthcare	because	it	can	describe	the	chance	of	
adverse	outcomes.	It	can	be	expressed	as	a	decimal	between	0	and	1	or	a	number	per	
1000	people.	For	example,	the	risk	of	a	patient	developing	complete	DIOS	may	be	0.2,	or	
200	per	1000	patients.	
For	measuring	the	difference	in	risk	between	two	groups	of	patients	(risk	of	outcome	with	
intervention	versus	risk	of	outcome	with	control),	risk	ratio	(RR)	is	used.	This	is	purely	
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written	as	a	decimal	between	0	and	1,	but	may	be	converted	into	a	percentage.	For	
example,	the	RR	of	complete	DIOS	in	the	control	group	may	be	0.6	(60%	risk	of	patient	
having	complete	DIOS).	
In	the	review,	I	measured	dichotomous	outcomes	using	the	RR	with	95%	confidence	
interval	(CI),	or	99%	CI	for	individual	adverse	effects.	A	99%	confidence	interval	was	used	
for	this	outcome	because	I	wanted	to	increase	the	certainty	of	the	effect	estimate.	Having	
a	99%	CI	means	that	if	the	study	were	repeated	any	number	of	times,	the	CI	containing	
the	true	effect	would	appear	in	99%	of	those	times.	In	clinical	terms,	a	healthcare	
provider	would	rather	be	99%	sure	than	95%	sure	that	an	intervention	would	not	cause	
an	adverse	effect	that	could	harm	the	patient.	Healthcare	providers	and	patients	
rightfully	regard	adverse	effects	as	very	important	aspects	of	medications	because	they	
have	the	potential	to	negatively	impact	the	patient’s	quality	of	life,	adherence	to	
treatment	and	in	serious	cases,	can	compromise	the	patient’s	safety.				
	
ii)	Continuous	data	
Continuous	data	can	take	any	value	in	a	specified	range,	for	example,	height	and	weight.	
We	decided	to	record	quality	of	life	and	symptom	scores	as	continuous	data.	When	
expressing	continuous	outcomes,	the	best	measures	to	use	are	mean	value	and	standard	
deviation.	However,	if	comparing	two	groups	in	a	study	(the	control	group	versus	the	
intervention	group),	mean	difference	(MD)	and	standardised	mean	difference	(SMD)	are	
often	used.		
MD	measures	the	absolute	difference	between	the	mean	values	of	two	groups,	where	0=	
no	change.	Here	is	an	example:	If	the	mean	change	in	quality	of	life	score	for	the	
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intervention	is	+0.3	and	+0.1	for	the	control,	the	MD	will	be		+0.2.	It	is	important	to	be	
aware	of	the	direction	of	the	scale	in	MD.	A	higher	score	is	better	for	quality	of	life,	but	
for	a	negative	outcome	like	pain,	it	is	not.	In	this	instance,	a	MD	of	+0.2	would	indicate	
that	patients	taking	the	intervention	scored	0.2	points	higher	on	the	pain	scale.		
I	aimed	to	use	MD	with	95%	CI	to	measure	the	effect	of	treatments.	However,	if	the	study	
used	different	scales	to	measure	the	same	outcome	and	there	was	no	way	to	change	the	
unit	of	measurement,	I	would	use	SMD.	The	SMD	is	used	as	a	summary	statistic	in	a	meta-
analysis	when	the	same	outcome	is	measured	in	the	included	studies	but	done	so	in	
different	ways.	For	example,	quality	of	life	could	be	measured	using	different	scoring	
systems.	SMD	takes	the	difference	in	mean	outcome	in	the	groups	and	divides	it	by	the	
standard	deviation	of	the	outcome	among	participants.	This	means	that	it	uses	the	
variability	seen	in	each	study	to	express	the	size	of	the	intervention	effect.		
iii)	Time-to-event	data	
I	aimed	to	use	time-to-event	data	for	time	to	hospitalisation.	This	is	expressed	differently	
to	standardised	data.	Hazard	ratios	(HR)	are	often	used	to	measure	survival	data	or	time-
to-event	data.	This	is	because	they	describe	how	fast	or	slow	a	particular	group	will	
progress	to	the	event.	In	a	HR,	a	score	of	1	means	that	there	is	no	difference	between	the	
control	and	intervention,	>1	favours	the	intervention	and	<1	favours	the	control.	If	there	
is	a	HR	of	2,	it	means	that	twice	the	number	of	patients	in	the	intervention	group	will	
progress	to	the	event	than	the	control	group	in	an	allocated	period	of	time.		
For	time-to-event	data	I	planned	to	calculate	the	hazard	ratio	(HR)	with	95%	CIs	using	the	
generic	inverse	variance	method	(GIV)	on	RevMan®.	GIV	can	be	used	for	any	summary	
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statistic	and	as	suggested	in	the	name,	it	uses	the	inverse	of	the	variance	(with	“variance”	
implying	how	far	the	data	varies	from	the	mean)	to	combine	the	studies	together.	Each	
study	is	represented	according	to	the	inverse	of	their	variance.	This	means	that	larger	
studies	are	given	more	weight	than	smaller	studies,	as	the	larger	the	study,	the	smaller	
the	standard	error.	The	objective	of	this	method	is	to	increase	the	precision	of	the	
presented	data	in	the	review	(148,	149,	150).	
b)	Collecting	data	for	outcome	measures	
Using	the	data	extraction	tool	on	Covidence©,	I	collected	the	data	on	outcomes	from	the	
studies.	For	each,	I	specified	whether	it	was	measured	as	a	continuous	or	dichotomous	
outcome,	then	stated	how	it	was	reported	e.g.	standard	deviation,	standard	error	or	with	
a	confidence	interval	for	continuous	outcomes.	For	each	outcome,	Covidence©	also	
prompted	me	to	state	the	unit	of	measurement	(e.g.	kilograms)	and	range	(e.g.	1-100)	if	
the	information	in	the	study	was	available.	Outcomes	that	were	not	reported	as	
continuous	(mean	with	SE,	SD	or	CI),	dichotomous	(number	of	events,	percentage	of	
events,	ratios	with	CI)	or	adverse	events	(number	of	events,	percentage	of	events,	ratios	
with	CI)	could	be	customised.	For	example,	if	a	p-value	was	the	only	result	available	in	the	
report,	I	could	create	a	tailored	table	to	input	the	values.	However	with	the	current	
Covidence©	software,	custom	measures	can	only	be	directly	exported	to	Excel,	not	
RevMan®.		
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4.5.3	Unit	of	analysis	issues	
Unit	of	analysis	issues	are	relevant	when	the	included	studies	do	not	follow	the	simple,	
parallel	trial	pattern	(where	participants	are	individually	randomised	into	two	groups	and	
outcomes	are	measured	from	each	participant	as	single	measurements)	(149).	
Crossover	trials	may	present	unit	of	analysis	issues	if	the	investigators	have	not	accounted	
for	the	carry-over	effect	of	treatment	from	one	phase	to	another,	or	if	the	participants	
have	not	been	sufficiently	randomised.		
If	there	were	evidence	of	a	carry-over	effect	so	the	participants	differed	from	their	initial	
state,	I	would	exclude	the	trial	unless	the	data	from	the	first	phase	was	available.	In	these	
cases,	I	may	have	to	ask	for	additional	information	from	the	authors.	However,	it	should	
be	noted	that	using	first-phase	data	only	not	always	recommended,	as	it	takes	away	the	
benefit	of	using	a	participants	as	their	own	controls	(151).	
There	may	also	be	unit	of	analysis	issues	in	studies	where	there	are	multiple	treatments	
compared	to	placebo	and	compared	to	one	another.	In	these	cases,	I	planned	to	compare	
each	treatment	to	placebo	first	and	then	undertake	a	subgroup	analysis	to	compare	the	
relative	efficacies	of	each	treatment.	This	is	also	described	in	section	4.5.8	below.	
4.5.4	Missing	data	
a)	Types	of	missing	data	
For	missing	data,	it	is	important	ascertain	the	reason(s)	for	their	omission.	The	data	may	
be	“missing	at	random”	for	reasons	completely	unrelated	to	the	assessment	of	that	data.	
For	example,	if	a	participant	insufficiently	completes	a	symptom	score	questionnaire	
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simply	because	of	busy	work	schedule,	it	is	probably	not	related	to	the	data	being	
measured.	
However,	if	that	participant	does	not	complete	the	symptom	score	questionnaire	due	to	
adverse	effects	from	the	treatment,	the	missing	data	may	be	related	to	the	assessment	or	
data	measured.		In	these	cases,	the	data	is	referred	to	as	“not	missing	at	random”.	
If	data	is	“not	missing	at	random”	it	may	be	related	to	selective	reporting	bias,	attrition	
bias	or	publication	bias.	Publication	bias	occurs	when	the	publication	of	studies	depends	
on	the	outcome	or	the	overall	treatment	effect	shown	in	the	results.	In	these	situations,	
the	data	from	published	studies	is	very	different	to	data	from	unpublished	studies	(152).	
	
b)	Dealing	with	missing	data	
To	avoid	the	issues	that	can	occur	from	missing	data,	reviewers	must	take	steps	to	ensure	
that	any	existing	published	results	are	found.	We	would	try	to	contact	the	investigators	(3	
times	at	the	most)	if	there	were	missing	data	in	the	study	or	if	it	was	unclear	how	the	
data	were	analysed.		
	
Missing	participants	may	be	accounted	for	by	an	ITT	analysis,	which	should	preferably	be	
done	by	the	study	authors.	In	cases	where	there	is	no	ITT	analysis	but	there	are	clear	
records	of	participants	throughout	the	study,	I	planned	to	undertake	an	ITT	analysis	
myself.		
I	also	planned	to	undertake	a	sensitivity	analysis	(described	in	below	section	4.5.8)	to	help	
to	pinpoint	the	studies	that	unfairly	influence	the	overall	estimate	of	treatment	effect.			
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Any	missing	data	should	be	described	in	the	Discussion	at	the	end	of	the	review.	This	
demonstrates	that	the	reviewers	have	considered	the	influence	of	the	missing	data	on	
the	results	(149).		
	
4.5.5	Assessment	of	heterogeneity	
a)	Definition	of	heterogeneity	
In	a	meta-analysis,	heterogeneity	refers	to	the	effects	of	the	intervention	displaying	more	
variation	than	random	effects	(chance)	would	alone.	It	can	be	caused	by	many	different	
factors,	such	as	variation	in	participant	characteristics,	blinding	or	concealment	of	
allocation	methodology	(which	may	also	bring	about	a	higher	risk	of	bias),	differences	in	
how	outcomes	are	measured	or	where	there	are	many	different	interventions	for	the	
same	condition	of	interest	(148).	
	
b)	Determining	levels	of	heterogeneity	
For	assessing	the	level	of	heterogeneity,	I	would	look	at	the	trials	reporting	the	same	
outcomes	that	I	could	include	in	a	meta-analysis.		
Heterogeneity	can	be	crudely	evaluated	by	inspecting	a	forest	plot	for	overlap	of	the	CIs.	
If	they	have	poor	overlap,	it	suggests	that	there	is	heterogeneity.	The	chi-squared	test	is	
automatically	shown	on	forest	plots	and	provides	more	information	about	whether	the	
heterogeneity	is	simply	due	to	chance.	This	is	coupled	with	a	p-value.	A	low	p-value	and	
large	chi-squared	test	implies	variation	of	treatment	effects	beyond	the	realms	of	chance.	
It	is	important	to	note,	however,	that	the	chi-squared	test	has	low	power	for	a	small	
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number	of	studies.	In	these	cases,	I	would	consider	the	p-value	and	appearance	of	CIs	on	
the	forest	plot.		
I	also	planned	to	use	the	I2	statistic,	which	describes	the	percentage	of	variability	due	to	
heterogeneity	rather	than	chance.	A	low	percentage	(up	to	40%)	implies	low	
heterogeneity	and	a	higher	percentage	(the	levels	are	shown	in	the	protocol,	Appendix	2)	
suggests	more	substantial	heterogeneity.	However,	the	I2	statistic	should	also	be	
interpreted	with	caution.	Again,	I	would	judge	this	alongside	the	P	value	and	the	overall	
appearance	of	the	CIs	on	the	forest	plot	(148).	
	
4.5.6	Assessment	of	reporting	bias	
To	assess	reporting	bias,	I	would	firstly	compare	the	outcomes	in	the	protocol	of	a	study	
(where	available)	with	the	outcomes	in	the	report.	Otherwise,	the	methods	section	of	a	
report	could	be	compared	with	the	results.	These	processes	would	highlight	any	areas	
that	were	selectively	reported	in	the	results	in	order	to	reflect	a	particular	treatment	
effect.	
Additional	information	could	be	requested	from	the	study	authors,	although	this	is	not	
always	possible.	I	would	search	clinical	trials	registries	for	any	unpublished	data	on	a	
study	and	deal	with	missing	data	transparently,	as	described	in	section	4.5.4.	I	planned	to	
examine	the	missing	data	very	closely	to	determine	whether	certain	results	were	
deliberately	left	out,	for	example,	if	investigators	only	reported	positive	results	of	an	
intervention.		
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I	also	planned	to	consider	sources	of	funding	and	conflicts	of	interests	within	the	group	of	
study	investigators.	These	may	influence	the	reporting	of	results	and	introduce	
publication	bias	(153).	
	
a)	Funnel	plots	
A	funnel	plot	is	a	scatter	plot	that	measures	the	effect	estimate	against	the	size	of	the	
study.	There	should	be	a	positive	correlation	between	the	estimated	intervention	effect	
and	the	size	of	the	study.	Results	from	the	smaller	studies	should	scatter	more	widely	at	
the	bottom	of	the	graph,	giving	the	appearance	of	a	funnel.	If	there	is	publication	bias,	
the	funnel	plot	will	lose	the	symmetry	of	the	inverted	triangle	shape	(153).	
If	more	than	10	studies	were	included	in	the	review,	I	would	construct	a	funnel	plot	to	
assess	the	risk	of	publication	bias.		
	
4.5.7	Data	synthesis	
I	planned	to	use	forest	plots	to	display	results	graphically	and	assess	heterogeneity.		
a)	Fixed	effects	and	Random	effects	models	
There	are	also	two	statistical	models	that	are	used	for	meta-analysis	in	the	RevMan®	
software:	the	fixed	effects	model	and	random	effect	model.	The	fixed	effects	model	
assumes	that	all	studies	are	measuring	the	one	true	treatment	effect	and	that	any	
differences	between	studies	are	simply	due	to	random	error	(chance).	The	studies	are	
assumed	to	have	the	same	conditions	and	characteristics.	If	there	were	no	random	error,	
the	results	would	be	the	same.	In	a	fixed	effects	model,	the	CI	is	smaller	than	in	a	random	
effects	model.	
	
86	
A	random	effects	model	assumes	that	the	treatment	effect	varies	between	studies	and	
allows	for	heterogeneity.	The	variance	within	studies	and	between	studies	is	
incorporated.	Because	of	this,	the	CI	is	usually	wider	in	a	random	effect	model.		
It	is	important	to	consider	using	each	model,	depending	on	the	levels	of	heterogeneity	
(153).	
	
b)	Using	the	Fixed	Effects	and	Random	Effects	models	
I	aimed	to	use	the	fixed	effect	model	for	low	levels	of	heterogeneity	(up	to	40%).	(As	it	
assumes	no	heterogeneity,	it	is	unrealistic	to	use	for	an	I2	of	greater	than	40%).	I	aimed	to	
use	a	random	effects	model	for	heterogeneity	greater	than	40%.	However,	a	summary	
from	this	model	may	not	be	accurate	if	there	is	high	risk	of	bias,	due	to	the	relatively	wide	
CI.	Furthermore,	a	random	effects	model	gives	smaller	studies	greater	weighting	than	a	
fixed	effects	model,	which	may	influence	the	estimate	of	treatment	effect.	I	would	
therefore	compare	both	models	to	assess	the	influence	of	these	studies	on	the	overall	
effect	of	the	intervention	(153).	
	
4.5.8	Subgroup	analysis	and	investigation	of	heterogeneity	
I	planned	to	undertake	a	subgroup	analysis	if	studies	showed	heterogeneity	greater	than	
40%	(154).	Areas	of	subgroup	analysis	are	described	in	the	protocol	in	Appendix	2.	
	
a)	Sensitivity	analysis		
In	the	previous	sections,	I	have	described	methods	and	tools	that	help	reviewers	come	to	
decisions	and	overall	findings	based	on	these	data.	Sometimes,	the	results	of	a	meta-
	
87	
analysis	can	be	based	on	findings	that	are	not	very	accurate	or	reliable.	Unit	of	analysis	
issues	(e.g.	using	crossover	trials),	missing	data,	high	risk	of	bias	and	inappropriate	
analysis	methods	can	contribute	to	this.	Therefore,	it	is	recommended	that	reviewers	
undertake	a	sensitivity	analysis	at	the	end	of	a	review	to	evaluate	the	robustness	of	their	
findings.		
I	planned	to	do	this	by	excluding	trials	that	have	a	high	risk	of	bias	or	those	with	a	
crossover	design	in	a	second	meta-analysis,	to	look	for	any	change	in	the	estimate	of	
treatment	effect	(148).	
	
4.5.9	Summary	of	Findings	table	
At	the	conclusion	of	a	Cochrane	review,	it	is	recommended	that	reviewers	summarise	the	
findings	for	the	outcomes	outlined	in	their	protocol.		Systematic	reviews	of	interventions	
are	usually	long	and	complex,	with	discussion	about	the	many	different	factors	affecting	
results.	It	can	therefore	be	confusing	for	the	reader	to	understand	clinically	significant	
risks	and	benefits	of	the	intervention.	The	Summary	of	Findings	(SoF)	table	is	designed	to	
present	this	information	clearly	(129).	
I	aimed	to	include	the	measures	for	each	of	our	outcomes	(see	protocol,	Appendix	2)	for	
the	interventions	described	the	studies	e.g.	laxative	agents,	control	or	other	therapies.	If	
an	outcome	is	not	reported,	I	would	specify	this	in	the	table	with	the	description,	“data	
not	reported”.	For	each	outcome,	I	would	state	the	number	of	participants	and	studies,	
the	comparative	risk	of	the	intervention	and	control	and	the	relative	effect	(RR	or	MD).	
For	each	outcome	I	aimed	to	use	to	the	Grading	of	Recommendations,	Assessment,	
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Development	and	Evaluation	Tool	(GRADE)	to	assess	the	quality	of	evidence	(high,	
moderate,	low	or	very	low)	(155).		
4.6	Summary	
In	the	previous	sections,	I	explained	the	methods	used	to	generate	the	review,	
“Interventions	for	the	prevention	of	DIOS	in	cystic	fibrosis”.	To	do	this,	I	clarified	the	
eligibility	criteria	for	inclusion	of	studies	and	explained	the	process	of	searching	for	
studies	using	medical	databases	and	registries.	I	then	went	onto	to	describe	the	process	
of	data	collection	and	data	extraction,	in	which	I	gathered	detailed	information	from	the	
included	studies.	Next,	I	outlined	the	strategies	for	10	main	areas	of	data	analysis,	and	
explained	the	importance	of	each	method.	These	main	areas	were:	The	assessment	of	
bias	in	studies,	measuring	treatment	effects,	unit	of	analysis	issues,	dealing	with	missing	
data,	assessment	of	heterogeneity,	assessment	of	reporting	bias,	data	synthesis,	
subgroup	analysis,	sensitivity	analysis	and	summary	of	findings	table.		
In	the	next	section,	I	will	present	the	results	from	data	extraction	and	analysis.	These	will	
be	described	using	a	combination	of	text	and	figures.	I	will	then	discuss	the	importance	
and	significance	of	the	main	findings.		
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4.7	Results		
4.7.1	Description	of	studies			
a)	Results	of	the	search	
Of	the	2631	studies	 (after	588	duplicates	were	removed)	 identified	by	 initial	searches,	 I	
found	 8	 potentially	 eligible	 studies	 for	 inclusion.	Of	 these,	 1	 study	was	 included	 and	 7	
were	excluded.	The	study	flow	diagram	was	based	on	the	PRISMA	statement	(Preferred	
Reporting	Items	for	Systematic	Reviews	and	Meta-Analyses)	flow	diagram	(156)	and	was	
produced	on	RevMan®.	It	is	shown	below	in	Figure	4.3.		
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Figure	4.3:	Study	flow	diagram	for	the	review,	“Interventions	for	the	prevention	of	DIOS”		
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b)	Included	studies	
The	included	study	(n=17)	was	available	as	an	abstract	and	full	text	(157).	
c)	Trial	characteristics	
The	 study	 was	 a	 randomised,	 double-blind,	 placebo-controlled	 crossover	 trial.	 It	 was	
based	at	a	single	centre	in	Toronto,	Canada.		
The	 duration	 of	 the	 trial	 was	 12	 months.	 The	 participants	 were	 randomised	 into	 two	
groups	to	take	either	the	placebo	or	active	drug	and	then	swapped	to	the	opposite	group	
after	6	months.	The	potential	carry-over	effect	of	 the	drug	was	also	accounted	 for	 (see	
section	4.1.5)	(157).	
 
d)	Participant	characteristics	
The	number	of	participants	was	17.	The	trial	did	not	specify	the	recruiting	age,	but	
decided	to	recruit	both	male	and	female	participants.	The	mean	age	(years)	and	range	for	
the	age	of	participants	in	the	trial	was	21.0	(12.9	to	34.9)	and	there	were	5	female	and	12	
male	participants.	
In	terms	of	the	inclusion	criteria,	the	trial	required	participants	to	have	a	diagnosis	of	CF	
and	to	have	had	one	or	more	episodes	of	DIOS	in	preceding	12	months.	
The	trial	excluded	pregnant	participants,	those	with	current	gastrointestinal	obstruction	
and	with	serious	cardiovascular,	neurological,	renal	or	hepatic	disease.	Participants	with	
other	causes	of	abdominal	pain	e.g.	peptic	ulcer	disease	and	inflammatory	bowel	disease	
were	also	excluded,	as	were	those	who	regularly	used	metoclopramide,	domperidone	or	
an	anticholinergic	drug.		
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The	baseline	characteristics	for	participants	were	stated;	there	were	no	significant	
differences	in	the	clinical	characteristics	between	them	(157).	
	
e)	Intervention	
As	the	trial	had	a	crossover	design,	participants	served	as	their	own	controls.		
The	 active	 drug	 was	 cisapride.	 Participants	 were	 randomised	 into	 two	 groups	 and	
received	(in	a	blind	fashion)	placebo	or	cisapride	for	6	months	each.	They	then	switched	
to	the	other	treatment	arm	for	the	second	6	months	of	the	study.	Patients	between	40	
and	 50kg	 received	 7.5mg	 of	 either	 placebo	 or	 cisapride	 3	 times	 per	 day	 and	 patients	
above	50kg	received	10mg	of	either	placebo	or	cisapride	3	times	per	day.		
The	trial	accounted	for	any	potential	carry-over	treatment	effect	of	the	active	drug.	The	
investigators	did	 this	by	analysing	 the	data	 in	 two	ways.	Measurements	were	 recorded	
twice	 for	 each	 6-month	 period:	 once	 every	 3	 months.	 Firstly,	 investigators	 took	 an	
average	of	the	two	measurements.	They	then	discarded	the	measurements	from	the	first	
3	months,	to	account	for	any	cumulative	effect	of	the	drug	(157).	
f)	Outcome	measures	
The	 radiological	 diagnosis	 of	 DIOS	 was	 measured	 in	 the	 trial	 using	 supine	 abdominal	
radiographs.	 Patients	 were	 interviewed	 for	 adverse	 effects	 and	 also	 reported	 any	
gastrointestinal	and	global	symptoms,	with	the	use	of	scoring	systems.	Other	outcomes	
included	the	number	of	participants	requiring	therapy	for	DIOS	and	stool	weight.	
Irrelevant	 outcomes	 for	 our	 review	 included:	 Anthropometric	measurements	 (e.g.	mid-
arm	 circumference,	 skin	 fold	 thickness),	 frequency	 of	 pulmonary	 infections,	 pulmonary	
	
93	
function	 (%FEV1),	 nutritional/calorie	 intake,	 routine	 laboratory	 tests	 (e.g.	 urinalysis,	
complete	blood	count)	and	number	of	hospital	admissions.		
g)	Excluded	studies	
I	excluded	7	studies	 for	various	reasons.	5	trials	were	excluded	because	the	active	drug	
was	used	for	the	wrong	indication	and	therefore	the	trials	had	irrelevant	outcomes.	In	4	
of	these,	N-acetylcysteine	was	used	as	a	mucolytic	for	lung	disease	in	CF,	rather	than	for	
the	prevention	of	DIOS	(158,	159,	160,	161).	 In	 the	other,	N-acetylcysteine	was	used	to	
improve	malabsorption	in	CF	rather	than	for	the	prevention	of	DIOS	(162).		
Another	 study	 was	 excluded	 because	 the	 intervention	 was	 for	 the	 treatment	 of	 DIOS,	
rather	than	the	prevention	of	DIOS	(163).	The	other	study	was	excluded	because	 it	was	
open-label	(i.e.	no	blinding	of	participants	and	personnel)	and	the	participants	were	non-
randomised.	The	risk	of	bias	was	too	high	for	this	study	to	be	reliable	(164).	
4.7.2	Risk	of	bias	in	included	studies		
I	constructed	a	risk	of	bias	summary	for	this	review	using	RevMan®,	which	is	shown	below	
in	Figure	4.4.	
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Figure	4.4:	Risk	of	bias	summary	for	the	included	study	(140)	in	this	review.	
a)	Allocation	
The	trial	stated	that	participants	were	randomly	allocated	to	start	with	either	cisapride	or	
placebo,	but	it	did	not	specify	how	the	sequence	was	generated	or	the	method	used	for	
concealment	of	allocation	(140).	I	therefore	ranked	the	study	as	having	an	unclear	risk	of	
bias	for	these	categories.	WC	and	I	initially	disagreed	on	the	ranking	for	this	domain;	he	
thought	it	should	have	a	low	risk	of	bias	because	the	study	authors	had	stated	that	
participants	were	“randomly	allocated”.	However,	I	argued	that	we	could	not	know	how	
the	participants	were	randomly	allocated;	truly	random	methods	may	well	have	been	
used	(such	as	a	random	computer	generator)	but	the	participants	could	have	been	quasi-
randomised,	(such	as	allocation	of	clinic	days).	Therefore,	because	the	study	authors	did	
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not	specify	how	exactly	participants	were	randomised,	we	ultimately	agreed	that	there	
was	an	unclear	risk	of	bias	for	this	domain.	 
b)	Blinding	
Participants	and	personnel	were	blinded	and	the	placebo	was	identical	in	taste	and	
appearance	to	cisapride	(140).	For	this	category,	I	ranked	the	trial	as	having	a	low	risk	of	
bias.	
For	the	blinding	of	outcome	assessors,	the	overall	risk	of	bias	was	unclear.	Only	three	
outcomes	stated	that	the	investigators	were	blinded.	The	first	of	these	was	
gastrointestinal	symptom	scores,	where	the	blinded	patients	acted	as	their	own	
assessors.	Second	was	for	the	assessment	of	supine	abdominal	radiographs,	where	a	
paediatric	radiologist	judged	these	in	a	blind	fashion.	Third	was	for	the	assessment	of	
nutritional	intake	and	stool	collection,	where	the	blinded	patients	recorded	their	own	
intake	and	investigators	also	worked	in	a	blind	fashion.		For	the	other	outcomes,	the	risk	
of	bias	was	unclear.	Although	blinded	patients	scored	their	own	global	symptoms,	
physicians	assessed	them	too	and	I	could	not	make	the	assumption	that	the	physicians	
were	blinded.	There	was	no	mention	of	blinding	for	the	other	outcomes	in	the	study:	
anthropometric	measurements,	number	of	hospital	admissions,	pulmonary	function	and	
frequency	of	pulmonary	infections,	laboratory	tests,	abdominal	circumference	and	
intestinal	lavage	therapy.	This	was	another	area	of	disagreement	between	WC	and	
myself.	WC	sensibly	pointed	out	that	the	blinding	of	outcome	assessors	would	not	make	
much	difference	for	certain	outcomes	that	were	very	objective	in	nature,	such	as	
anthropometric	measurements,	number	of	hospital	admissions,	laboratory	tests	and	
pulmonary	function	testing.	However,	the	assessment	of	global	symptoms	was	a	more	
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subjective	outcome	and	one	in	which	blinding	of	outcome	assessors	would	be	important.	
Therefore,	as	there	was	no	mention	of	blinding	for	this,	we	agreed	to	rank	this	domain	as	
having	an	unclear	risk	of	bias.		
c)	Incomplete	outcome	data	
For	gastrointestinal	symptom	scores,	global	symptom	scores	and	intestinal	lavage	
therapy,	there	was	no	missing	data.	For	nutritional	intake	and	stool	losses,	only	10	out	of	
17	participants	were	represented	in	the	results.	This	was	because	3	participants	had	
refused	to	perform	quantitative	food	intake	protocols	and	stool	collections	and	4	
participants	were	excluded	due	to	incomplete	or	inaccurate	food	records	or	stool	
collections.	Although	the	investigators	gave	reasons	for	the	missing	data,	there	was	no	
mention	of	an	ITT	analysis.	For	anthropometric	measurements,	adverse	effects,	
pulmonary	function,	frequency	of	pulmonary	exacerbations,	number	of	hospital	
admissions,	radiological	signs	of	DIOS	and	laboratory	values,	there	was	insufficient	
information	to	judge	whether	there	was	missing	outcome	data	(140).	For	these	reasons,	I	
ranked	this	category	as	having	an	unclear	risk	of	bias.		
d)	Selective	reporting	
I	did	not	have	access	to	the	protocol,	so	could	not	compare	the	list	of	outcomes	in	the	
protocol	with	the	results	reported	in	the	study.	However,	I	compared	the	outcomes	listed	
in	the	Methods	section	with	the	outcomes	reported	in	the	Results	section.		
The	investigators	stated	that	they	would	calculate	the	difference	in	weight	and	
percentage	of	ideal	weight	for	height	during	the	two	periods,	using	t	tests	for	comparison.	
However,	these	changes	and	results	of	t	tests	were	not	reported	in	the	results.	Pulmonary	
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function	testing	and	radiological	findings	were	measured	at	baseline	and	after	6	months,	
but	the	results	were	unreported.	Anthropometric	measurements	(e.g.	mid-arm	
circumference	and	skin	fold	thickness),	physical	examination	findings,	number	of	hospital	
admissions	and	frequency	of	pulmonary	infections	were	measured	every	3	months	but	
insufficiently	reported.	Laboratory	test	results	(blood	and	urine	analysis)	were	also	
measured	but	not	reported	(140).		
Due	to	multiple	incidences	of	selective	reporting,	I	ranked	the	study	as	having	a	high	risk	
of	bias	for	this	category.	
e)	Other	potential	sources	of	bias	
There	was	insufficient	information	to	judge	whether	there	was	a	risk	of	bias	from	other	
sources.	In	terms	of	publication	bias,	the	pharmaceutical	company,	“Janssen	
Pharmaceutica	Incorporated”,	supported	the	trial,	but	there	was	no	evidence	to	suggest	
that	they	had	any	part	in	sponsorship	or	funding.	There	was	also	no	indication	to	suggest	
conflicts	of	interest	from	the	authors,	but	this	was	not	explicitly	stated	(140).		Therefore,	I	
could	not	assume	that	the	risk	of	bias	was	low.	
Due	to	insufficient	information	regarding	other	sources	of	bias	in	the	study,	I	decided	to	
rate	this	category	as	having	an	unclear	risk	of	bias.	
4.7.3	Effects	of	interventions	
In	this	section,	I	will	compare	the	main	outcomes	from	our	protocol	with	the	outcomes	in	
the	included	trial.			
a)	Summary	of	Findings	table	
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Please	 see	 Appendix	 3	 for	 the	 Summary	 of	 Findings	 table	 for	 oral	 cisapride	 versus	
placebo.		
b)	Oral	cisapride	versus	placebo	
Oral	cisapride	versus	placebo	was	the	only	comparison	used	in	the	included	trial	(140).	No	
other	active	drugs	were	assessed.		
i)	Primary	outcomes	
1. Complete	or	incomplete	DIOS	diagnosed	either	clinically	(e.g.	abdominal	masses,	
or	distension	or	pain)	or	radiologically	(e.g.	dilated	bowel	or	faecal	mass).	
The	radiological	diagnosis	of	DIOS	was	an	outcome	measure	for	this	trial.	It	was	measured	
using	a	scoring	system	for	the	total	radiological	severity	and	severity	of	each	criterion	
(e.g.	degree	and	distribution	of	faecal	retention,	presence	of	bubbly	granularity	in	the	
right	iliac	fossa,	degree	of	small	bowel	dilatation	and	nodularity	of	the	intestinal	mucosa).	
However,	the	numerical	data	was	not	reported	in	the	results.		The	investigators	stated	
that	there	was	no	significant	difference	between	cisapride	and	placebo	(140).		
2. Adverse	effects	from	treatments	
i.	Serious	adverse	effects	of	treatment	regimens	(including,	but	not	limited	
to,	rectal	bleeding,	intestinal	perforation,	mucosal	erosions,	anaphylactic	
reaction,	vomiting	with	electrolyte	disturbance)	
ii.	Other	adverse	effects	of	treatment	(e.g.	diarrhoea	or	soiling,	abdominal	
distension,	loss	of	continence	or	pain)	
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Participants	were	interviewed	for	adverse	effects	every	3	months.	The	trial	reported	that	
no	adverse	effects	were	noted	(140).	
ii)	Secondary	outcomes	
1. Time	to	hospital	admission	
i.	All	causes	
ii.	Due	to	DIOS	
This	outcome	was	not	assessed	or	reported	in	the	trial	(140).	
2. Patient-reported	quality	of	life	(QoL)	scores	
This	outcome	was	not	assessed	or	reported	in	the	trial	(140).	
3. Patient-reported	symptom	scores	
Two	different	symptom	scores	were	assessed	and	reported	by	participants	in	this	trial:	
gastrointestinal	symptoms	and	global	symptoms.		
For	gastrointestinal	symptoms,	a	lower	score	signified	a	better	score.	Participants	scored	
the	severity	and	frequency	of	10	different	gastrointestinal	symptoms	and	total	
gastrointestinal	symptoms	at	3	monthly	intervals.	The	trial	reported	results	for	a	6-month	
period,	where	the	scores	ranged	from	2-20	for	individual	symptoms	and	20-100	for	the	
total	gastrointestinal	symptom	score	(140).		
As	the	data	came	from	a	crossover	trial	where	individuals	acted	as	their	own	controls,	the	
number	of	participants	for	each	group	was	automatically	doubled	in	RevMan®.	Due	to	the	
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way	the	data	were	presented,	I	needed	to	calculate	the	mean	difference	and	standard	
error	in	order	to	analyse	the	average	symptom	score	using	the	generic	inverse	variance	
(GIV).	I	used	the	fixed	effects	model	because	there	was	a	single	study	in	the	review,	so	
there	would	be	no	heterogeneity	(I	planned	to	use	the	fixed	effects	model	for	an	I2	value	
below	40%	and	use	a	random	effects	model	for	an	I2	value	of	above	40%).		The	results	
favoured	cisapride	over	the	placebo.	The	total	gastrointestinal	symptom	score	was	
statistically	significant	at	6	months	with	an	MD	of	-7.60	(95%	CI	-14.73	to	-0.47)	using	the	
fixed	effects	model.	Individual	symptom	scores	of	interest	were	abdominal	distension	and	
abdominal	pain,	as	they	related	to	the	symptoms	of	DIOS.	
There	was	no	significant	difference	between	cisapride	and	placebo	for	abdominal	
distension	or	abdominal	pain	at	6	months.	Abdominal	distension	showed	a	MD	of	-0.90	
(95%	CI	-2.39	to	0.59)	and	abdominal	pain	showed	a	MD	of	-0.4	(95%	CI	-2.05	to	1.25).		
	
The	figures	below	are	screenshots	from	the	RevMan®	software	(131).	They	show	the	
statistical	analysis	for	the	relevant	gastrointestinal	symptom	scores,	including	the	total	
gastrointestinal	score	and	the	scores	for	abdominal	distension	and	for	abdominal	pain.		
Figure	4.5:	Statistical	analysis	for	patient-reported	total	gastrointestinal	symptom	
scores	for	cisapride	versus	placebo.		
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There	is	no	I2	value	because	there	is	no	heterogeneity,	as	there	is	only	one	study	(The	
definition	of	I2	can	be	found	in	section	4.5.5).		The	weight	of	the	study	is	100%	because	
there	are	no	other	studies	in	the	review.	The	p	value	is	statistically	significant	(<0.05)	and	
so	it	rejects	the	null	hypothesis	(that	there	is	no	difference	between	cisapride	and	
placebo).	The	confidence	interval	does	not	include	1,	which	also	reflects	a	significant	
result.		
Figure	4.6:	Forest	plot	for	patient-reported	total	gastrointestinal	symptom	scores	for	
cisapride	versus	placebo.		
	
	
The	significance	of	the	p	value	is	supported	by	the	black	diamond	(the	pooled	results)	not	
overlapping	with	the	line	of	no	effect.		
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Figure	4.7:	Statistical	analysis	for	patient-reported	abdominal	distension	symptom	
scores	for	cisapride	versus	placebo.		
	
	
Here,	the	p	value	is	not	statistically	significant,	which	implies	that	there	is	no	difference	
between	cisapride	and	placebo.	
	
	
Figure	4.8:	Forest	plot	for	patient-reported	abdominal	distension	symptom	scores	for	
cisapride	versus	placebo.		
	
	
The	pooled	result	is	now	touching	the	line	of	no	effect,	which	reflects	the	non-significant	
p	value.		
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Figure	4.9:	Statistical	analysis	for	the	patient-reported	abdominal	pain	symptom	scores	
for	cisapride	versus	placebo.	
	
	
Again,	the	p	value	shows	no	statistical	significance	between	cisapride	and	placebo.	
	
Figure	4.10:	Forest	plot	for	patient-reported	abdominal	pain	symptom	scores	for	
cisapride	versus	placebo.		
	
	
The	black	diamond	is	touching	the	line	of	no	effect,	which	supports	the	p	value	of	a	non-
significant	result.		
The	precision	of	the	results	is	discussed	later	in	this	chapter.		
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Participants	also	recorded	global	symptom	scores	at	the	end	of	each	6-month	period	(i.e.	
after	the	full	course	of	either	cisapride	or	placebo).	The	data	was	reported	as	the	number	
of	participants	who	fell	into	3	categories:	those	who	felt	better,	the	same	or	worse	with	
the	treatment	(140).	Due	to	the	way	in	which	the	data	was	reported,	I	was	unable	to	
measure	this	outcome	as	continuous	or	dichotomous.	On	advice	from	the	CRG,	I	
presented	the	data	in	a	simple	table	on	RevMan®	(131)	to	show	the	numbers	of	
participants	for	each	category.	The	study	reported	that	the	results	favoured	cisapride	and	
were	statistically	significant	(p<0.05).	
	I	have	taken	a	screenshot	of	the	table,	shown	below	in	Figure	4.9:	
Figure	4.11:	Alterations	in	patient-reported	global	symptom	scores	with	cisapride	and	
placebo.	
	
4. Tolerability	(participant-	or	investigator-reported	rates	of	concordance)	
This	outcome	was	not	assessed	or	reported	in	the	trial	(140).	
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4.8	Discussion		
4.8.1	Main	findings	
There	was	only	one	included	study	in	this	review	that	compared	cisapride	to	placebo	for	
the	prevention	of	DIOS.		The	results	found	that	cisapride	improved	the	total	
gastrointestinal	symptoms	for	patients	during	the	study	period.	Patients	generally	felt	
better	taking	cisapride	and	those	with	worse	symptom	scores	benefitted	most	from	the	
drug.	There	were	also	no	side	effects	noted	from	cisapride.	There	were	no	significant	
differences	between	cisapride	and	placebo	for	radiological	diagnosis	of	DIOS	and	
individual	symptom	scores	that	were	relevant	to	the	review,	such	as	abdominal	
distension	and	abdominal	pain.	The	findings	of	the	review	were	limited	and	
demonstrated	that	overall,	there	is	a	huge	lack	of	evidence	for	the	prevention	of	DIOS	in	
CF.	
4.8.2	 Overall	 completeness,	 relevance	 and	 applicability	 of	 the	
evidence	
My	objective	was	to	compare	various	laxative	agents	for	the	prevention	of	DIOS	in	
children	and	adults	with	CF.	As	there	was	only	one	comparison	in	the	review	(cisapride	
versus	placebo),	I	could	not	perform	a	meta-analysis	of	the	data.	Hence,	I	was	unable	
compare	the	relative	efficacies,	safety	and	adverse	effects	of	different	laxative	agents	as	I	
had	intended.	The	following	sections	detail	that	the	evidence	for	the	prevention	of	DIOS	
is	only	based	on	one	low	quality	study	(see	section	4.8.3)	that	was	conducted	nearly	30	
years	ago	with	a	drug	that	can	no	longer	be	prescribed	in	the	UK;	therefore,	the	findings	
are	incomplete,	irrelevant	and	largely	inapplicable.		
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a.)	Outcome	measures	
I	was	unable	to	report	several	important	outcome	measures	that	I	had	set	out	in	the	
protocol.	My	primary	outcome	was	to	measure	the	diagnosis	of	complete	or	incomplete	
DIOS	(diagnosed	either	clinically	or	radiologically).	In	the	trial,	the	radiological	diagnosis	of	
DIOS	was	measured	and	the	investigators	reported	a	non-significant	difference	between	
cisapride	and	placebo.	However,	the	trial	results	were	not	fully	reported	so	I	could	not	
analyse	the	data.	
The	measure	of	adverse	effects	from	treatments	was	another	primary	outcome.	The	trial	
stated	that	there	were	no	adverse	effects	from	treatments,	but	did	not	expand	on	this.	
The	trial	also	failed	to	assess	nearly	all	of	my	secondary	outcomes.	The	unreported	
outcomes	were:	time	to	hospital	admission,	patient-reported	quality	of	life	scores	and	
tolerability.	The	number	of	hospital	admissions	was	described	as	an	outcome	in	the	trial,	
but	I	judged	it	to	be	irrelevant,	as	it	was	not	reported	as	time-to-event	data	and	did	not	
specify	the	reason	for	each	hospital	admission.		
However,	the	trial	managed	to	assess	and	report	one	of	my	secondary	outcomes:	the	
patient	reported	symptom	scores.	There	were	two	types	of	symptom	scores	used	in	the	
trial:	gastrointestinal	symptom	scores	and	global	symptom	scores.	There	is	reliable	
evidence	to	support	the	use	of	patient	reported	outcome	measures	(PROMs)	in	
healthcare.	A	2013	systematic	review	demonstrated	that	effective	PROMs	improve	
patient-provider	communication,	patient	satisfaction,	the	monitoring	of	treatment	
response	and	the	detection	of	unrecognised	problems	(165).	These	findings	could	
therefore	be	applicable	to	clinical	practice.	
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b.)	Participants	
They	participants	were	relevant	to	the	review	because	all	had	a	diagnosis	of	CF	and	
included	both	children	and	adults.	However,	the	population	size	was	very	small,	which	
limited	the	precision	of	the	effect	estimates	(see	section	4.8.3iv).	In	addition,	the	age	
range	only	included	older	children	and	young	adults.	There	were	no	findings	to	
demonstrate	the	safety	and	efficacy	of	cisapride	in	CF	patients	of	other	age	ranges.	There	
were	also	12	male	participants	compared	to	only	5	female	participants,	which	could	have	
unfairly	affected	the	results.	In	2016,	Munck	found	that	female	gender	was	associated	
with	recurrent	DIOS	(75%	vs.	52%,	p	=	0.04)	(111).	If	this	is	the	case,	the	results	for	the	
radiological	diagnosis	of	DIOS	may	not	be	accurate,	since	the	data	mostly	represents	male	
participants.		
	
c.)	Intervention	
The	study	intervention	was	cisapride.	Cisapride	is	not	categorised	as	a	laxative	agent,	so	it	
is	debatable	whether	it	meets	the	criteria	for	“types	of	interventions”	according	to	the	
protocol.	It	is	typically	used	a	gastro-prokinetic	agent.	I	could	argue	that	cisapride	
functioned	as	a	laxative	agent	in	the	trial	and	so	should	therefore	be	accepted.	However,	
cisapride	has	since	been	withdrawn	from	the	UK	market	due	to	its	cardiac	side	effects	
(see	section	4.8.5	for	more	detail).	Therefore,	the	drug	has	no	applicability	in	clinical	
practice	unless	it	can	be	re-approved	for	licence.		
4.8.3	Quality	of	the	evidence	
a.)	Strengths	
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There	were	some	methodological	strengths	of	the	included	study.	The	design	of	a	
crossover	trial	meant	that	participants	acted	as	their	own	controls,	which	eliminated	
clinical	differences	between	the	two	treatment	arms.	The	investigators	also	considered	
and	eliminated	the	potential	carry-over	treatment	effect	that	could	occur	with	this	study	
design.	As	the	trial	had	also	measured	the	mean	and	standard	deviation	for	the	active	
drug	and	placebo,	I	was	also	able	to	carry	out	a	paired	analysis	using	the	generic	inverse	
variance	method	in	RevMan®	(131).	This	is	more	accurate	at	estimating	a	treatment	
effect	than	an	unpaired	analysis,	as	it	makes	comparisons	between	the	same	subjects,	
hence	taking	advantage	of	the	crossover	design	(151).	
	
	Certain	domains	of	the	Risk	of	Bias	Tool	demonstrated	a	high	quality	study	design,	such	
as	the	blinding	of	participants	and	personnel.	Some	outcomes	also	reported	blinding	of	
the	assessors	e.g.	supine	abdominal	radiography.	
b.)	Weaknesses	
The	review	demonstrated	far	more	examples	of	low	quality	evidence,	as	based	on	the	
GRADE	criteria	(166).	The	Summary	of	Findings	table	in	Appendix	3	illustrates	this.	First	
and	foremost,	there	was	only	one	included	study	that	had	a	small	number	of	participants.	
The	trial	was	also	conducted	almost	30	years	ago,	so	its	results	have	limited	relevance	
today.	
Having	a	single	study	review	meant	that	I	could	not	perform	the	meta-analysis	
methodology.	Hence,	I	was	unable	to	assess	for	heterogeneity,	construct	funnel	plot	for	
assessment	of	reporting	bias,	perform	a	subgroup	analysis	(this	would	only	be	done	if	
results	showed	>40%	heterogeneity),	use	the	random	effects	model	(this	would	only	be	
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compared	against	the	fixed	effects	model	if	results	showed	>40%	heterogeneity)	or	
undertake	a	sensitivity	analysis.	A	lack	of	meta-analysis	meant	that	I	was	unable	to	fully	
evaluate	the	robustness	of	the	review’s	findings,	or	comment	on	the	consistency	of	the	
results.		
	
i)	Risk	of	Bias	
For	the	outcomes	in	the	Summary	of	findings	table	(Appendix	3),	I	downgraded	them	in	
quality	for	unclear	methods	in	sequence	generation	and	allocation	concealment,	as	the	
investigators	stated	that	the	participants	were	randomised	but	did	not	specify	how.	There	
was	also	risk	of	selective	reporting	for	the	radiological	diagnosis	of	DIOS,	as	the	
investigators	did	not	fully	report	the	results.		
In	addition	to	the	outcomes	in	the	Summary	of	Findings	table,	there	were	missing	data	for	
the	outcomes	measuring	nutritional	intake	and	stool	losses,	for	which	the	trial	reported	
results	from	10	participants	rather	than	17.	The	trial	gave	reasons	for	the	missing	data	
and	I	judged	that	it	was	missing	at	random,	but	the	investigators	did	not	(to	my	
knowledge)	conduct	an	ITT	analysis.		
The	trial	was	found	to	have	a	high	risk	of	bias	for	selective	reporting	for	other	outcomes	
in	addition	the	radiological	diagnosis	of	DIOS.		On	multiple	occasions,	the	authors	
explained	how	they	would	measure	an	outcome	in	the	Methods,	but	failed	to	fully	report	
the	findings	in	the	Results.	They	briefly	mentioned	some	findings	e.g.	“pulmonary	
function	testing	revealed	no	differences	between	the	placebo	and	cisapride	periods”	but	
did	not	report	the	data.	I	could	not	find	a	valid	reason	for	why	the	investigators	fully	
reported	some	results	but	not	others.	Consequently,	there	was	a	high	risk	of	selective	
reporting	bias	across	the	whole	study.		
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The	included	study	revealed	an	unclear	risk	of	bias	across	most	of	the	domains.	This	was	
because	the	report	did	not	provide	sufficient	information	required	for	the	risk	of	bias	
assessment.	The	most	prominent	areas	of	unclear	bias	were:	random	sequence	
generation,	allocation	concealment	and	incomplete	outcome	data.		
	
ii)	Inconsistency	
There	was	no	heterogeneity	as	there	was	just	one	included	study.	Therefore,	I	could	not	
downgrade	the	quality	of	the	findings	for	this	category.		
	
iii)	Indirectness	
Due	to	the	intervention	used	in	the	study,	there	was	a	great	deal	of	indirectness	shown	in	
the	review.	Firstly,	cisapride	is	not	a	typical	laxative	agent	and	so	does	not	meet	the	
specific	objectives	of	investigating	“different	laxative	agents”	for	the	review.	Secondly,	
the	study	was	conducted	in	1990	when	cisapride	still	prescribed	in	the	UK.	Since	then,	it	
has	been	removed	from	the	market	due	to	rare	but	serious	cardiac	effects	(see	section	
4.8.5)	and	is	no	longer	permitted	for	use.	These	issues	led	me	to	downgrade	the	evidence	
two	levels	for	the	directness	of	the	review.		
	
iv)	Imprecision	
Although	the	confidence	intervals	for	the	outcomes	in	the	Summary	of	Findings	table	did	
not	appear	to	be	wide	according	to	the	forest	plots,	I	downgraded	the	evidence	one	level	
for	precision	due	to	the	small	number	of	participants.	When	the	sample	size	is	small,	
there	is	less	information	about	the	treatment	effect,	resulting	in	more	uncertainty	and	
hence,	less	precision.	
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v)	Publication	bias	
I	was	unable	to	produce	funnel	plot	to	test	for	publication	bias	because	there	was	only	
one	study	in	the	review.	I	could	not	assume	that	one	study	meant	that	there	was	no	risk,	
but	equally	I	did	not	strongly	suspect	publication	bias.	I	therefore	rated	publication	bias	as	
“undetected”	in	the	Summary	of	Findings	table.		
4.8.4	Potential	biases	in	the	review	process	
a)	Strengths	
During	the	process	of	study	screening,	data	collection	and	extraction,	there	was	a	low	risk	
of	bias.	WC	and	I	independently	screened	the	studies	and	so	that	we	could	come	to	our	
own	conclusions.	Afterwards,	we	worked	out	disputes	mainly	by	discussion,	but	FG	acted	
as	an	external	arbiter	to	resolve	some	disagreements,	namely	on	ranking	domains	of	bias.	
I	also	endeavoured	to	be	very	thorough	as	I	collected	the	data.	I	did	this	by	collecting	it	in	
two	ways.	I	firstly	completed	the	data	collection	form	given	to	us	by	the	CRG,	which	
provided	a	good	foundation	for	each	important	area	e.g.	participants,	interventions,	
outcomes.	Secondly,	I	used	the	more	detailed	data	extraction	form	on	Covidence©	to	
obtain	any	other	important	information.	I	also	completed	the	risk	of	bias	assessment	on	
Covidence©.		
For	the	searching	of	studies,	the	risk	of	bias	was	very	low.	NH	(a	Cochrane	information	
specialist)	assisted	me	in	developing	a	comprehensive	strategy	to	ensure	that	all	relevant	
trials	were	obtained.	I	ran	each	search	twice	and	checked	that	the	number	of	results	was	
the	same	for	each	(i.e.	to	account	for	typing	errors).		
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None	of	the	authors	for	the	review	(myself,	WC	and	FG)	had	any	conflicts	of	interest	to	
declare.		
b)	Weaknesses	
i)	Differences	between	protocol	and	review	
Potential	risks	of	bias	in	the	review	process	included	some	differences	between	the	
protocol	and	review.	I	stated	that	the	review	would	compare	different	laxative	agents	for	
the	prevention	of	DIOS,	but	the	included	study	assessed	the	efficacy	and	safety	of	
cisapride,	which	is	not	classed	as	a	laxative	agent.	In	hindsight,	I	should	have	mentioned	
that	other	agents	could	sometimes	be	used	to	prevent	DIOS.	This	would	have	improved	
the	transparency	of	the	Methods	and	prevented	the	potential	risk	of	bias.	However,	it	
was	a	team	decision	to	include	the	study	in	the	review	and	in	all	other	aspects	(e.g.	the	
types	of	participants,	indication	and	study	design),	I	believed	it	to	meet	the	inclusion	
criteria.	The	lack	of	evidence	on	the	review	topic	may	have	also	motivated	me	to	look	
further	afield	for	other	interventions	used	for	the	prevention	of	DIOS.		
	
ii)	Unsuitable	trials		
The	motivation	to	perform	a	meta-analysis	led	me	to	be	overly	optimistic	in	the	
assessment	of	one	particular	trial	(164).	Originally,	I	intended	to	include	this	trial	in	the	
review	and	completed	the	process	of	data	extraction	for	it.	However,	after	corresponding	
with	the	CRG,	I	later	removed	it	for	having	a	high	risk	of	bias	in	multiple	domains.	The	trial	
had	a	non-randomised,	open	label	design	and	was	therefore	not	suitable	for	inclusion.		
iii)	Additional	outcomes	
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Although	our	outcomes	were	pre-specified	in	the	protocol	for	the	review,	there	were	
some	outcomes	from	the	included	study	that	I	thought	were	clinically	relevant	to	the	
review	question.	Initially,	I	wished	to	include	these	additional	outcomes.	The	first	was	
stool	weight.	Stool	weight	is	a	relevant	outcome	because	it	illustrates	the	quantity	and	
relative	ease	of	bowel	movements	in	participants.	Lower	stool	weight	suggests	smaller,	
harder	stools	that	can	cause	faecal	impaction	and	therefore	bowel	obstruction;	higher	
stool	weight	means	participants	are	passing	a	substantial	quantity	of	stool,	suggesting	
normal	bowel	movements	with	no	obstruction.	This	outcome	correlates	with	the	efficacy	
of	the	intervention.		
The	second	outcome	I	considered	to	be	clinically	relevant	was	the	number	of	patients	
requiring	intestinal	lavage	therapy	for	DIOS	during	the	study	period.	I	considered	this	to	
be	applicable	because	it	would	demonstrate	differences	in	efficacy	between	the	active	
drug	and	placebo.	That	is,	the	higher	the	number	of	participants	requiring	lavage	during	
the	study	period,	the	less	effective	the	intervention	in	preventing	DIOS.	Furthermore,	this	
outcome	would	highlight	the	safety	of	the	intervention.	Patients	who	require	immediate	
treatment	for	DIOS	may	be	at	risk	of	developing	complete	bowel	obstruction,	so	if	
participants	taking	the	active	drug	required	immediate	treatment	or	invasive	therapy	
during	the	study	period,	it	may	raise	concerns	about	the	safety	of	the	study	drug.		
	
However,	after	communicating	with	the	NJ	and	FG,	I	came	to	the	conclusion	that	the	
inclusion	of	these	additional	outcomes	would	strongly	indicate	reporting	bias.	Although	I	
considered	these	outcomes	to	be	clinically	relevant,	they	were	not	identified	at	protocol	
stage	by	any	of	the	clinical	experts	or	brought	to	our	attention	in	the	peer	review	
	
114	
comments.	It	could	appear	that	I	was	adapting	the	review	to	suit	the	study	outcomes,	
rather	than	basing	the	review	on	the	rationale	of	the	original	clinical	question.		
4.8.5	 Agreements	 and	 disagreements	 with	 other	 studies	 or	
reviews	
The	included	trial	was	published	in	1990	when	cisapride	was	a	fully	licenced	drug	in	the	
UK.	It	was	commonly	used	to	treat	gastric	and	digestive	disorders	in	children	and	adults.	
However	in	July	2000,	the	Medicines	Control	Agency	suspended	the	use	of	cisapride	in	
the	UK	due	to	the	rare	but	serious	cardiac	effects	associated	with	the	drug.	These	effects	
were	associated	with	ventricular	arrhythmias	and	in	some	cases,	sudden	death.	Between	
1988	and	2000,	the	UK	received	reports	of	60	adverse	cardiovascular	reactions	of	the	
drug,	5	of	which	resulted	in	death.	Worldwide,	there	were	125	fatal	reactions	to	
cisapride,	which	led	to	many	other	countries	suspending	the	marketing	for	the	drug	e.g.	
USA,	Canada	and	Germany	(167).		
4.9	Summary	
In	this	chapter,	I	have	presented	the	methods,	results	and	discussed	the	main	findings	for	
the	 Cochrane	 Review:	 “Interventions	 for	 preventing	 DIOS	 in	 CF”.	 	 The	most	 significant	
outcome	from	this	review	was	that	there	is	a	severe	lack	of	evidence	for	the	prevention	
DIOS	in	CF.	After	carefully	constructing	the	eligibility	criteria	and	outcomes	for	the	review,	
and	 running	 extensive	 searches	 on	 medical	 databases	 and	 registries,	 it	 was	 very	
discouraging	 to	 find	 that	 there	was	a	single	study	 for	 inclusion.	Furthermore,	 this	study	
failed	to	address	any	of	my	primary	outcomes.	It	also	had	an	unclear	risk	of	bias	for	most	
domains	and	was	very	poor	 in	quality.	But	most	 importantly,	 the	study	drug	 (cisapride)	
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can	no	longer	be	prescribed	in	the	UK,	which	renders	any	findings	irrelevant	for	current	
clinical	practice.		
In	 the	 next	 chapter,	 I	 will	 present	 and	 discuss	 the	 findings	 from	 the	 review	 on,	
“Interventions	 for	 the	 treatment	 of	 DIOS”.	 In	 chapter	 6,	 I	 will	 present	 and	 discuss	 the	
findings	 from	 a	 nationwide	 survey	 about	 the	 current	management	 of	 constipation	 and	
DIOS.	In	chapter	7,	I	will	draw	my	conclusions	from	all	the	main	findings	of	this	thesis	(the	
two	Cochrane	reviews	and	the	survey).	From	there,	I	will	propose	implications	for	future	
clinical	practice	and	research.		
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Chapter	5:	Cochrane	Systematic	Review	for	
Interventions	for	the	treatment	of	DIOS	in	
CF.	
5.1	Objective	
• To	assess	the	effectiveness	and	safety	of	different	groups	of	laxative	agents	for	
treating	distal	intestinal	obstruction	syndrome	(incomplete	and	complete)	in	
children	and	adults	with	CF.		
5.2	Writing	the	Protocol	
Before	the	academic	year	started,	FG	drafted	the	protocol	and	after	attending	the	first	
part	of	Cochrane	training,	I	added	content	and	references	to	the	background	section	(the	
introduction,	description	of	the	condition	and	description	of	the	intervention).	For	the	
section,	“description	of	the	intervention”,	I	grouped	and	defined	the	different	types	of	
laxative	and	specified	the	comparisons	between	laxative	agents	(e.g.	osmotic	laxative	
versus	stimulant	laxatives).	I	also	drafted	the	section	on	“types	of	outcome	measures”.	I	
also	made	amendments	to	the	section	entitled	“electronic	searches”	with	the	help	of	a	
Cochrane	information	specialist,	NH.		
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As	I	was	not	able	to	design	the	protocol	for	my	own	review,	I	decided	to	involve	myself	in	
the	development	of	the	protocol	for	the	prospective	MPhil	student.	This	was	beneficial	
because	it	completed	my	“Cochrane	experience”.		
I	submitted	the	protocol	on	27/02/2017	and	it	was	sent	back	with	peer	review	comments	
on	20/06/2017.	I	responded	to	the	peer	review	comments	and	edited	the	protocol	
accordingly.	As	we	are	awaiting	approval,	the	protocol	is	not	yet	published	and	I	could	
therefore	not	include	it	in	the	Appendices	of	this	thesis.			
5.3	Eligibility	criteria	
Although	 the	 nature	 of	 the	 intervention	 for	 this	 review	 was	 different	 to	 that	 of	 the	
previous	review	(treatment	versus	prevention	of	DIOS),	many	areas	of	the	PICOS	criteria	
were	the	same	for	both	reviews,	such	as	 the	types	of	participants,	 types	of	studies	and	
largely,	the	types	of	 interventions.	Therefore	 in	the	sections	below,	 I	will	 regularly	refer	
back	to	the	PICOS	criteria	of	the	previous	review	as	described	in	Chapter	4.			
a)	Participants	
I	searched	for	studies	including	children	and	adults	with	CF	(with	all	stages	and	severity	of	
lung	disease	and	with	or	without	pancreatic	sufficiency)	(See	Chapter	4	for	more	detail).	
b)	Intervention	and	Comparison	
i)	Types	of	interventions	
Laxatives	form	the	basis	of	the	medical	management	of	DIOS,	whether	that	is	prevention	
or	treatment	of	DIOS.	In	this	case,	I	wanted	to	assess	laxatives	for	the	treatment	of	acute	
incomplete	or	complete	bowel	obstruction.		
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In	addition,	I	included	surgery	as	a	type	of	intervention	for	this	review.	Although	seen	as	
last	resort,	surgery	is	nevertheless	a	treatment	for	complete	DIOS	in	cases	where	medical	
management	has	failed.		
ii)	Categorising	the	difference	types	of	laxative	
As	with	the	previous	Cochrane	review,	I	decided	to	group	the	laxatives	according	to	their	
mode	of	actions:	osmotic	laxatives,	stimulant	laxatives	and	mucolytics.		
In	DIOS,	osmotic	laxatives	may	soften	the	viscid	stool	(caused	by	the	combination	of	
mucus	and	faeces)	that	has	accumulated	in	the	bowel.		
Stimulant	laxatives	are	effective	are	stimulating	peristalsis	(104),	so	could	reduce	gut	
transit	time	and	flush	the	mucofaeculant	material	that	has	adhered	to	the	bowel	wall.		As	
depicted	in	the	name,	Mucolytics	work	by	disintegrating	the	mucus	produced	in	CF.	They	
could	therefore	breakdown	existing	mucofaeculant	material.	
Please	see	Chapter	4	for	more	detail	on	the	grouping	of	laxatives.	
iii)	Types	of	comparisons	
I	decided	to	compare	various	laxative	therapies	at	any	dose	to	placebo,	no	treatment	or	
alternative	laxatives	for	the	treatment	of	DIOS.		
c)	Outcomes	
As	 this	 review	 was	 assessing	 laxatives	 for	 treatment	 of	 DIOS	 rather	 than	 for	 the	
prevention	of	DIOS,	the	outcomes	had	to	be	specific	to	this	objective	and	were	therefore	
different.		
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Primary	outcomes:	
I	aimed	to	assess	the	following	primary	outcomes	for	the	review,	“Interventions	for	the	
treatment	of	DIOS”:	
1. Time	taken	from	start	of	treatment	until	the	resolution	of	DIOS	(diagnosed	
clinically	or	radiologically)	
2. Treatment	failure	rate	(e.g.	clinician-determined	need	to	change	medical	regimen	
or	need	for	surgical	intervention)	
The	first	primary	outcome	for	this	review	is	useful	for	measuring	the	effectiveness	of	
various	laxatives	for	the	treatment	of	DIOS.	This	type	of	outcome	is	commonly	known	in	
statistics	as	“time-to-event”	data.	However,	the	event	i.e.	resolution	of	DIOS,	may	not	
occur	for	various	reasons.	Some	participants	could	be	lost	in	the	follow-up	process,	or	
suffer	from	a	serious	adverse	effect	that	may	worsen	their	condition	(133).		
There	are	various	ways	of	assessing	time-to-event	data.	The	resolution	of	DIOS	could	be	
measured	by	allocating	an	agreed	period	of	time	in	which	the	patient	should	be	
successfully	treated.	When	that	period	of	time	ends,	the	participants	who	do	not	have	
resolution	of	DIOS	could	fall	into	the	“treatment	failure”	category,	the	other	primary	
outcome	for	the	review.	However	in	this	case,	we	did	not	relate	“treatment	failure	rate”	
to	a	period	of	time.	Instead,	“treatment	failure”	would	be	assigned	to	those	participants	
who	required	a	different	medical	regimen	or	surgical	intervention,	according	to	the	
expert	opinion	of	a	clinician.		
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Secondary	outcomes:	
I	aimed	to	assess	the	following	secondary	outcomes	for	the	review,	“Interventions	for	the	
treatment	of	DIOS”:	
1.	Recurrence	rate	of	DIOS	(diagnosed	clinically	or	radiologically)	after	successful	
treatment	
2.	Adverse	effects	
i)	Serious	adverse	effects	of	treatment	regimens	(including	but	not	limited	to	
rectal	bleeding,	intestinal	perforation,	mucosal	erosions,	anaphylactic	
reaction,	vomiting	with	electrolyte	disturbance)	
ii)	Other	adverse	effects	of	treatment	(e.g.	abdominal	distension,	soiling,	loss	
of	continence	or	pain)	
							3.	Adherence	
1.	It	is	widely	recognised	that	patients	who	have	had	a	previous	diagnosis	of	DIOS	are	
more	likely	to	be	diagnosed	with	it	again,	compared	to	patients	who	have	never	had	
DIOS.	I	thought	it	would	be	useful	to	ascertain	the	exact	figures	of	this	by	using	study	data	
of	patients	who	were	successfully	treated	for	DIOS,	hence	why	it	is	listed	as	the	first	
secondary	outcome	for	the	review.			
2.	Adverse	effects	are	listed	in	this	review	as	a	secondary	outcome	rather	than	a	primary	
outcome.	One	of	the	primary	outcomes	of	this	review,	“treatment	failure	rate”	may	
already	address	some	of	the	potential,	adverse	effects	of	a	treatment.	This	is	because	the	
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treatment	may	have	to	be	altered	in	cases	where	the	patient	finds	it	intolerable	or	has	a	
serious	adverse	reaction.		Adverse	effects	are	also	listed	as	a	secondary	outcome	due	to	
the	nature	of	the	intervention.	For	the	prevention	of	DIOS,	patients	would	most	likely	
receive	laxative	treatment	over	a	long	period	of	time,	in	which	adverse	effects	would	
have	a	more	significant	impact	on	the	patient.	Conversely,	the	treatment	of	DIOS	involves	
a	short	course	of	laxative(s),	so	it	is	likely	that	adverse	effects	will	have	a	lesser	impact	on	
the	patient	(obviously	depending	on	the	nature	of	the	adverse	effects).		
3.	Adherence	is	listed	as	a	secondary	outcome	because	it	can	greatly	influence	the	results	
of	a	particular	treatment	regimen.	Non-adherence	is	an	issue	in	medicine	and	it	would	be	
useful	to	ascertain	the	scale	of	the	problem-	especially	in	CF	patients,	who	already	carry	a	
substantial	treatment	burden.	It	reflects	the	patient’s	perspective	of	a	particular	
intervention;	for	example,	a	significant	rate	of	non-adherence	may	highlight	issues	
regarding	treatment	tolerability	and	quality	of	life.		
d)	Study	Design	
I	chose	to	include	RCTs,	quasi-RCTs	and	crossover	trials	for	this	review.	The	reasoning	for	
this	is	discussed	in	the	“Study	Design”	section	in	Chapter	4.		
5.4	Search	methods		
Due	to	the	similarities	between	the	two	reviews,	I	decided	(with	the	advice	of	the	
Cochrane	information	specialist,	NH)	that	it	was	possible	to	use	one	search	strategy	to	
find	eligible	studies	for	either	review.	This	meant	that	throughout	the	screening	process,	I	
was	able	to	accept	titles	and	abstracts	that	matched	the	eligibility	criteria	for	either	
review.	Thereafter,	I	sorted	through	the	chosen	studies	and	allocated	them	to	the	most	
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suitable	review.	For	this	review,	I	searched	the	same	medical	databases	and	online	
registries	as	described	in	Chapter	4.		
5.4.1	Examination	of	full	text	reports	
After	searching	the	medical	databases	and	online	registries,	there	were	8	titles	and	
abstracts	that	appeared	to	match	the	criteria	for	either	review.	This	meant	that	I	could	go	
on	to	the	next	stage	of	screening	the	full-text	copies	of	these	studies.		
5.5	Estimated	Results	and	Discussion	
As	of	early	May	2017	(when	full-text	screening	took	place),	 the	protocol,	“Interventions	
for	the	treatment	of	DIOS”	had	not	yet	been	approved	for	publication.	Having	the	same	
search	strategy	as	the	review	for	prevention	of	DIOS	meant	that	I	could	go	through	the	8	
studies	to	assess	their	eligibility	for	this	review,	but	I	did	not	have	permission	to	progress	
to	full	data	extraction	and	analysis.		
However,	 my	 estimation	 was	 that	 there	 would	 be	 only	 1	 study	 eligible	 for	 inclusion;	
furthermore,	 the	 study	 was	 only	 available	 as	 an	 abstract.	 It	 was	 a	 double-blinded,	
randomized	crossover	trial	(163)	conducted	in	1992	that	investigated	the	use	of	high	and	
low	doses	of	PERT	for	the	treatment	of	DIOS.		The	abstract	indirectly	addressed	one	of	my	
primary	outcomes:	 the	 treatment	 failure	 rate	 (measured	 in	 the	study	as	 the	number	of	
episodes	of	acute	DIOS),	but	did	not	present	the	actual	data	for	this	outcome.	Overall,	the	
abstract	gave	very	little	information	about	PERT	for	the	treatment	of	DIOS.		
The	 results	 so	 far	 for	 this	 Cochrane	 review	 demonstrate	 that	 there	 is	 a	 great	 lack	 of	
evidence	for	the	treatment	of	DIOS,	as	proven	by	the	fact	that	there	is	only	a	single	study	
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which	was	conducted	25	years	ago	and	is	only	available	as	an	abstract.	As	with	the	review	
on	the	prevention	of	DIOS,	I	find	these	results	extremely	disappointing.	I	will	not	be	able	
to	conduct	a	meta-analysis	 for	 this	 review	and	 therefore	will	not	be	able	 to	 investigate	
the	effectiveness	and	safety	of	various	laxatives	for	the	treatment	of	DIOS.	I	will	draw	my	
conclusions	from	these	results	and	the	results	from	the	previous	review	(the	prevention	
of	DIOS)	 in	chapter	7	of	 this	 thesis,	but	 in	summary-	 this	unmistakable	 lack	of	evidence	
should	alert	clinicians	to	this	poorly	studied	area	of	CF	and	will	hopefully	highlight	an	area	
for	further	research.		
	
	
	
	
	
	
	
	 	
	
124	
Chapter	6:	The	Management	of	
Constipation	and	Distal	Intestinal	
Obstruction	Syndrome	at	CF	Centres	in	the	
UK.	
6.1	Introduction	
In	addition	to	undertaking	a	Cochrane	Systematic	Review,	we	thought	it	would	be	useful	
to	determine	the	current	UK	practice	for	the	treatment	of	constipation,	incomplete	DIOS	
and	complete	DIOS	in	children	and	adults	with	CF.	We	suspected	that	there	may	be	
differences	in	opinion	and	practice,	due	to	limited	evidence	found	in	the	literature	search	
and	also	in	the	Cochrane	review.	We	thought	it	would	be	helpful	to	establish	the	extent	
of	these	differences	and	also	identify	the	management	strategies	that	clinicians	tend	to	
favour.		
To	investigate	this,	I	designed	and	distributed	two	online	surveys	that	were	sent	out	to	
paediatricians	and	adult	physicians	in	UK	CF	centres.	The	surveys	were	based	around	
patients	with	constipation,	incomplete	DIOS	or	complete	DIOS.	In	this	chapter,	I	will	
describe	the	methods	used	to	produce	and	distribute	the	survey.	I	will	then	summarise	
the	results	of	the	survey	and	discuss	the	significance	of	these	findings.	The	formal	report	
of	this	survey	can	be	found	in	Appendix	5.	
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6.2	Methods	
6.2.1	Audience		
Our	target	audience	consisted	of	paediatric	and	adult	consultants	from	the	main	CF	
centres	in	the	UK.	The	centres	were	found	on	the	CF	Trust	Directory	in	the	annual	data	
report	(8).	I	constructed	a	list	of	consultants	for	each	survey	by	using	the	CF	Trust	
directory	and	individual	trust	websites.	I	obtained	email	addresses	using	existing	contact	
lists	from	FG	or	WC,	hand-searched	the	name	of	consultant	and	their	base-centre.	
The	total	number	of	contacts	generated	for	the	paediatric	and	adult	surveys	were	82	and	
65	respectively.	These	contacts	came	from	29	different	CF	centres	across	the	UK.		
	
6.2.2	Survey	questions	
The	surveys	were	based	around	short	case	vignettes	about	patients	(either	a	child	or	
adult,	depending	on	the	survey)	with	constipation,	incomplete	DIOS	and	complete	DIOS.	
FG	and	WC	guided	me	in	the	patient	descriptions,	as	they	were	the	experts	in	the	field	of	
CF.	I	then	edited	the	phrasing	and	structure	of	questions	and	ensured	that	all	the	main	
laxatives	were	available	in	the	list	of	treatment	regimens.	Case	vignettes	were	chosen	in	
order	to	make	the	questions	more	clinically	relevant	and	to	obtain	more	accurate	
answers	about	how	clinicians	really	manage	their	patients.	I	thought	that	this	would	be	
more	effective	than	simply	asking	the	clinicians	for	the	management	of	constipation	and	
DIOS,	where	they	may	have	selected	the	option(s)	they	thought	were	correct,	rather	than	
what	they	would	actually	do.		
The	DIOS	questions	were	split	into	two	parts	to	ascertain	both	first-line	and	second-line	
treatments.	For	the	second-line	treatment	question,	the	consultants	were	given	four	
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options:	they	could	continue	the	existing	treatment	at	the	same	dose,	increase	the	dose	
of	the	existing	treatment,	add	in	another	treatment	or	replace	the	existing	treatment	
with	a	different	regimen.	If	the	consultants	chose	to	add	in	another	treatment	or	replace	
the	existing	treatment	with	another,	they	had	to	specify	what	these	new	treatments	
would	be.		
At	the	end	of	each	survey,	the	consultants	were	also	asked	about	the	clinical	features	
they	would	expect	to	find	if	the	patient	required	surgical	intervention	for	DIOS.		
	
The	survey	was	designed	so	that	the	questions	were	multiple-choice	in	style,	but	the	
consultants	could	select	however	many	options	they	deemed	necessary.	There	was	also	
an	opportunity	to	write	comments	in	an	additional	box	designated,	“other”	if	the	
consultants	required	an	option	that	was	not	already	listed.		The	reason	for	constructing	
these	surveys	in	such	an	open	manner	was	to	not	restrict	the	consultants	at	all	in	their	
treatment	plans.	I	hypothesised	that	the	results	would	be	more	honest	and	reflective	of	
current	clinical	practice	if	done	in	this	way.		
	
After	each	main	section	of	the	survey	(i.e.	constipation	or	DIOS),	a	follow-up	question	
enquired	whether	the	treatment	decisions	for	each	condition	were	based	on	personal	
experience,	local	guideline,	low	quality	evidence	(consensus,	expert	opinion,	case	reports)	
high	quality	evidence	(systematic	reviews,	randomised	control	trials)	or	a	combination	of	
these	options.	The	reason	for	including	this	question	was	to	establish	how	many	
consultants	had	a	good	quality	evidence	base	for	their	clinical	decisions.	
Extracts	from	the	Paediatric	survey	can	be	found	in	Appendix	4.	
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6.2.3	Use	of	software	
I	generated	the	surveys	using	the	Qualtrics©	software	(168)	a	website	that	enables	the	
user	to	collect	data	on	a	specific	subject	by	creating	their	own	survey.		
FG	showed	me	how	to	navigate	the	software	so	that	I	could	edit	the	survey.	For	example,	
the	“Look	and	Feel”	icon	allowed	me	to	alter	the	font,	colour	and	format	of	the	questions	
so	that	they	appeared	clearer	to	the	user.	The	“Survey	flow”	icon	helped	me	to	change	
the	order	and	add	in	extra	components	of	questions,	which	was	useful	for	follow-on	
questions	that	were	dependent	on	user’s	previous	answer.		For	the	distribution	of	
surveys,	I	generated	web	links	for	each	consultant	so	that	individual	responses	were	
recorded.	Qualtrics©	enabled	me	to	visualise	each	consultant’s	response	and	the	overall	
response	for	each	question.	These	various	tools	available	on	the	Qualtrics©	software	are	
shown	below	in	Figure	6.1:	
Figure	6.1:	The	editing	features	available	on	the	Qualtrics© software:	
	
	
The	icons	mentioned	e.g.	“Look	and	Feel”	and	“Survey	Flow”	can	be	seen	in	the	image.		
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6.2.4	Survey	distribution	
As	mentioned,	Qualtrics©	enabled	me	to	generate	individual	web	links	for	each	consultant	
using	their	email	addresses.	All	consultants	received	an	email	and	could	click	on	their	
personalised	web	link	to	complete	the	survey.	Their	responses	were	recorded	in	the	
results	and	data	analysis	section	of	Qualtrics©.	The	paediatricians	were	first	emailed	on	
07/02/2017.	Those	who	had	not	completed	the	survey	were	sent	reminder	emails	on	
20/02/2017.	The	adult	physicians	were	emailed	on	20/02/2017	and	reminder	emails	were	
sent	out	to	them	on	01/03/2017.		
6.3	Results		
6.3.1	Data	collection	
On	08/03/2017	(one	week	after	sending	out	the	final	reminder	emails),	I	collected	the	
survey	responses	from	Qualtrics©	and	constructed	two	spreadsheets	to	summarise	the	
data	from	either	survey.	I	calculated	two	different	percentages	for	each	treatment	
option:	how	often	the	treatment	was	used	as	a	single-drug	regimen	(i.e.	on	its	own)	and	
how	often	it	was	used	as	either	a	single-drug	or	in	a	multi-drug	regimen	(i.e.	more	than	
one	approach	was	used).		
20	different	CF	centres	contributed	to	the	results	of	the	children’s	survey	(out	of	a	
possible	28)	and	21	different	centres	contributed	to	the	results	of	the	adult’s	survey	(out	
of	a	possible	24).	In	total,	51%	(42/82)	paediatricians	and	60%	(39/65)	adult	physicians	
responded	to	the	survey.	However,	the	response	rates	for	the	questions	on	DIOS	were	
lower	than	this	(see	section	6.4	and	6.5).	
	
129	
6.3.2	Data	analysis		
After	I	completed	data	collection,	FG	used	STATA	version	12.0	(169)	for	data	analysis.	For	
tests	of	proportions	we	used	the	chi-squared	test	and	for	comparison	of	continuous	data	
we	used	student’s	t	test	or	the	Mann	Whitney	U	test	for	normally	distributed	and	non-
normally	distributed	data	respectively.	
The	statistical	analysis	of	the	results	is	shown	in	the	formal	report	of	the	survey	in	
Appendix	5.	In	the	sections	below,	I	will	describe	and	compare	the	responses	from	both	
surveys,	using	the	original	result	data	from	Qualtrics©	and	the	percentages	I	calculated	
from	Edexcel.	I	will	round	each	percentage	to	the	nearest	whole	number.	Later	in	this	
chapter,	I	will	discuss	and	the	main	findings	from	the	results.	
6.3.3	Constipation	
42	paediatric	consultants	and	39	adult	consultants	responded	to	the	question	on	the	first-
line	management	of	constipation.	The	paediatric	survey	recorded	9	different	treatment	
regimens,	compared	to	22	different	regimens	in	the	adult	survey.		
In	both	surveys,	Movicol®	was	the	most	commonly	used	treatment	option.		
	
a)	Constipation:	Paediatric	first-line	treatments	
When	used	as	a	single-	treatment	regimen,	Movicol	comprised	almost	59%	(24/42)	
responses	in	the	paediatric	survey.	In	total,	Movicol®	was	included	in	83%	(35/42)	
paediatric	regimens,	either	as	a	single-drug	or	as	part	of	a	multi-drug	regimen.	
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Lactulose	was	another	commonly	used	drug	in	the	paediatric	survey.	Nearly	22%	(9/42)	
consultants	included	it	in	their	treatment	plan	for	constipation,	either	on	its	own	or	
alongside	other	treatments.		
	
b)	Constipation:	Adult	first-line	treatments	
Movicol	was	used	in	nearly	21%	(8/39)	single	drug	regimens	and	in	69%	(27/39)	of	either	
single-drug	or	multi-drug	adult	regimens.		
Overall,	wide	ranges	of	treatments	were	used	to	treat	adult	constipation.	Some	
consultants	(7%,	3/39)	chose	to	use	lifestyle	modifications	as	a	single	treatment.	
However,	it	also	featured	considerably	as	part	of	treatment	regimens	with	other	drugs.	In	
total,	over	56%	(22/39)	adult	physicians	used	lifestyle	modifications	as	either	as	a	single-
treatment	or	as	part	of	a	larger	regimen.		
For	treatments	used	on	their	own	or	as	part	of	a	multi-drug	regimen,	Sodium	docusate	
featured	in	nearly	21%	(8/39)	of	responses,	Senna	was	in	over	15%	(6/39)	regimens	and	
N-acetylcysteine	was	chosen	on	two	occasions	(2/39).		Gastrografin®	was	used	once	
(1/39)	as	a	single-drug	treatment.	Unlike	the	paediatric	survey,	Lactulose	did	not	feature	
in	the	adult	treatments	at	all.		
In	the	box	designated,	“other”	(where	consultants	could	contribute	additional	comments)	
4/39	adult	physicians	decided	to	send	the	patient	for	an	abdominal	x-ray.		
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Figure	6.2:	First-line	treatment	for	constipation	
	
(Options	may	have	been	listed	on	their	own	or	in	combination	with	others)	
6.3.4	Incomplete	DIOS	
There	were	37	responses	from	the	adult	consultants	and	39	responses	from	the	
paediatric	consultants	for	the	questions	on	the	treatment	for	incomplete	DIOS.	The	
treatment	regimens	chosen	for	incomplete	DIOS	varied	greatly.	
In	the	adult	survey,	there	were	23	different	1st	line	treatment	plans	and	25	different	2nd	
line	treatment	plans	for	incomplete	DIOS.		
For	the	children’s	survey,	there	were	22	different	treatment	combinations	for	1st	line	
management	and	27	different	combinations	for	2nd	line	management	of	incomplete	DIOS.		
Incomplete	DIOS:	Paediatric	first-line	treatments	
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Movicol®	and	Gastrografin®	were	equally	common	for	a	single-drug	1st	line	management,	
each	used	on	their	own	in	15%	(6/39)	cases.	In	total	(either	in	a	single-drug	or	multi-drug	
regimen),	Movicol®	was	used	for	56%	(22/39)	1st	line	combinations	and	Gastrografin®	was	
used	in	26%	(10/39).		
Another	commonly	used	1st	line	drug	was	Lactulose,	featuring	21%	(8/39)	times,	either	in	
a	single	or	multi-drug	regimen.	In	total,	N-acetylcysteine	was	used	in	13%	(5/39)	1st	line	
cases	and	Sodium	picosulphate	and	Klean-Prep®	were	used	in	5%	(2/39)	1st	line	regimens.	
The	least	used	drugs	were	Senna	and	Sodium	docusate,	featuring	in	2%	(1/39)	regimens	
each.		
Incomplete	DIOS:	Adult	first-line	treatments	
16%	(6/37)	adult	consultants	decided	to	use	Gastrografin®	on	its	own	for	1st	line	
treatment,	which	accounted	for	the	largest	percentage	of	any	single	drug	regimen.		
In	total,	(as	a	single	drug	or	in	a	multi-drug	combination)	Gastrografin®	was	included	in	
54%	(20/37)	1st	line	treatment	regimens.	Another	commonly	used	drug	was	Movicol®,	
used	in	nearly	60%	(22/37)	1st	line	adult	treatment	regimens,	as	a	single	drug	or	in	a	
combination.		Lifestyle	modifications	featured	in	nearly	38%	(14/37)	1st	line	treatment	
regimens.	
Many	other	laxatives	were	also	chosen,	such	as	Sodium	docusate	(used	in	6/37	or	16%	
single	drug	or	multi-drug	combinations),	N-acetylcysteine	(in	4/37	or	11%	single	drug	or	
multi-drug	combinations)	and	Senna	(in	3/37	or	8%	single	drug	or	multi-drug	
combinations).	
The	drugs	least	used	were	Lactulose	(2/37	single	drug	or	multi-drug	combinations)	and	
Sodium	picosulphate	(1/37	single	drug	or	multi-drug	combinations).			
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4	consultants	(10.8%)	also	chose	to	add	imaging	to	their	regimen.	An	abdominal	
ultrasound	scan	was	chosen	on	two	occasions,	a	CT	scan	was	used	once	and	an	abdominal	
x-ray	was	also	used	once.		
Figure	6.3:	First-line	treatments	for	incomplete	DIOS:	
	
(Options	may	have	been	listed	on	their	own	or	in	combination	with	others).	
6.3.5	Complete	DIOS	
In	the	adult	survey,	36	consultants	answered	the	questions	on	1st	line	management	for	
complete	DIOS	and	35	answered	the	questions	for	2nd	line	treatment.	There	were	25	
different	1st	line	treatment	regimens	and	26	different	2nd	line	regimens.		
	
134	
In	the	children’s	survey,	38	answered	the	questions	on	1st	line	management	and	36	
consultants	answered	the	questions	on	2nd	line	management	for	complete	DIOS.	There	
were	17	different	1st	line	treatment	regimens	and	23	different	2nd	line	treatment	
regimens.		
Complete	DIOS:	Paediatric	first-line	treatment	
In	the	paediatric	survey,	the	most	common	intervention	was	surgical	review,	featuring	
21%	(8/38)	times	on	its	own	and	68%	(26/38)	times	as	part	of	a	larger	treatment	regimen.	
Gastrografin®	was	the	most	commonly	used	drug,	featuring	16%	(6/38)	times	as	a	single-
drug	regimen	and	53%	(20/38)	times	in	total	as	part	of	larger	regimens.	Klean-Prep®	was	
also	used	frequently.	It	was	chosen	in	29%	(11/38)	regimens,	either	in	a	single	or	multi-
drug	regimen.		
24%	(9/38)	consultants	used	some	or	all	parts	of	the	conventional	“drip	and	suck”	
management	for	bowel	obstruction	(intravenous	fluids,	nasogastric	tube,	nil	by	mouth).	
Less	common	interventions	included	N-acetylcysteine	(in	5%	or	2/38	regimens)	and	an	
enema	(1/38	regimens).		1	consultant	also	chose	to	include	antibiotics	in	their	1st	line	
management	for	complete	DIOS.	
Complete	DIOS:	Adult	first-line	treatment	
The	commonest	1st	line	single-drug	regimens	were	Gastrografin®	and	Klean-prep®,	each	
accounting	for	11%	(4/36).		However,	72%	(26/36)	1st	line	regimens	included	
Gastrografin®	and	50%	(18/36)	included	Klean-prep®	as	part	of	single-drug	or	multi-drug	
regimens.		
A	significant	number	(39%	or	14/36)	of	consultants	included	surgical	review	in	their	1st	
line	management	of	complete	DIOS.	28%	(10/36)	also	chose	to	include	some	or	all	parts	
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of	the	conventional	“drip	and	suck”	management	for	bowel	obstruction	(intravenous	
fluids,	nasogastric	tube,	nil	by	mouth	and	17%	(6/36)	consultants	decided	to	refer	the	
patient	for	a	CT	scan.		
More	invasive	methods	were	also	used:	6%	(2/36)	clinicians	chose	to	send	the	patient	for	
a	colonoscopy,	and	the	same	percentage	also	suggested	an	enema	as	part	of	the	1st	line	
management.		
Other	laxatives	were	less	commonly	used	in	1st	line	regimens.	N-acetylcysteine	and	
Movicol®	were	each	used	11%	(4/36)	times	as	a	single	or	multi-drug	regimen,	Sodium	
picosulphate	was	used	in	8%	(3/36)	regimens	and	Lactulose	was	used	in	3%	(1/36).		
Figure	6.4:	First-line	treatments	for	complete	DIOS:	
	
	
(Options	may	have	been	listed	on	their	own	or	in	combination	with	others).	
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6.3.6	Reasons	for	a	surgical	review	in	DIOS	
Towards	the	end	of	the	survey,	the	consultants	were	asked	which	clinical	features	in	
complete	DIOS	would	prompt	them	to	ask	for	a	surgical	review.	Again,	they	could	select	
as	many	options	as	they	deemed	necessary.	There	were	some	similarities	between	the	
two	surveys.	97%	(37/38)	paediatricians	and	89%	(32/36)	adult	physicians	selected	
rebound	tenderness	and	guarding.	Evidence	of	suspected	perforation	on	abdominal	
imaging	was	also	very	popular,	selected	94%	(34/36)	times	by	the	adults	and	100%	
(38/38)	times	in	the	paediatric	survey.	However,	there	was	a	great	disparity	between	
bilious	vomiting,	voted	33%	(12/36)	times	by	adult	physicians	and	95%	(36/38)	times	by	
paediatricians.	
Failure	to	improve	with	medical	therapy	after	24	hours	also	showed	a	big	difference	in	
opinion	between	the	two	surveys,	selected	17%	(6/36)	times	by	adult	consultants	and	
42%	(16/38)	times	by	paediatricians.	Failure	to	improve	after	48-72	hours	was	selected	
44%	(16/36)	times	by	the	adult	consultants	and	50%	(19/38)	times	by	the	paediatricians,	
failure	to	improve	after	96	hours	was	selected	17%	(6/36)	by	adult	consultants	and	11%	
(4/38)	by	the	paediatricians.		
	
6.3.7	Evidence	base	for	decisions	
The	adult	and	paediatric	consultants	were	asked	how	they	were	guided	to	make	decisions	
about	the	treatments	for	constipation	and	DIOS.		
Evidence	base	for	constipation	treatment	
For	the	decision	on	the	treatment	of	constipation,	100%	(39/39)	adult	consultants	and	
88%	(38/43)	paediatric	consultants	used	personal	experience	to	make	their	decision.	31%	
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(12/39)	adult	consultants	and	49%	(21/43)	paediatricians	used	local	guideline,	33%	
(13/39)	adult	consultants	and	42%	(18/43)	paediatricians	used	low	quality	evidence.	No	
consultants	used	high	quality	evidence	in	their	decisions	for	constipation	treatment.		
Evidence	base	for	DIOS	treatment	
For	the	treatment	of	DIOS,	100%	(36/36)	adult	consultants	and	87%	(33/38)	
paediatricians	used	their	personal	experience,	58%	(21/36)	adult	consultants	and	74%		
(28/38)	paediatricians	used	their	local	guideline	and	61%	(22/36)	adult	consultants	and	
58%	(22/38)	paediatricians	used	low	quality	evidence.	Only	3%	(1/38)	paediatricians	said	
they	would	use	high	quality	evidence	to	make	decisions	about	DIOS	management.		
	
	
	 	
	
138	
6.4	Discussion	
6.4.1	Main	findings	
The	results	of	the	survey	showed	that	there	is	a	huge	difference	of	approach	for	the	
treatment	of	constipation,	incomplete	DIOS	and	complete	DIOS	in	patients	with	CF,	with	
particular	variation	for	the	treatment	of	DIOS.	
a)	Constipation	
The	treatment	of	constipation	showed	moderate	variation,	which	was	particularly	
demonstrated	in	the	adult	survey,	where	physicians	used	22	different	combinations.		
However,	the	paediatricians	only	used	9	different	combinations.	It	is	also	important	to	
note	that	the	response	rate	for	the	questions	on	constipation	was	higher	than	the	
questions	on	DIOS,	which	may	reflect	in	the	number	of	combinations	used.	Movicol®	
featured	significantly	in	the	treatment	combinations	for	constipation	in	both	surveys.	It	
was	used	in	69%	adult	regimens	and	83%	paediatric	regimens.	However,	adult	physicians	
were	more	likely	to	use	lifestyle	modifications	than	the	paediatricians	and	also	used	a	
higher	mean	number	of	interventions	per	patient.	
b)	Incomplete	DIOS	
The	treatment	of	incomplete	DIOS	displayed	the	greatest	variation	out	of	all	the	
questions.	Paediatricians	used	22	different	1st	line	and	25	different	2nd	line	treatment	
combinations	and	adult	physicians	used	23	different	1st	line	and	27	different	2nd	line	
treatment	combinations.	In	both	surveys,	Movicol®	and	Gastrografin®	were	the	most	
commonly	used	drugs	for	1st	line	treatment.	However,	the	adult	physicians	used	more	
Gastrografin®	than	the	paediatricians.		
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c)	Complete	DIOS	
For	complete	DIOS,	adult	physicians	showed	the	most	variation,	using	25	different	1st	line	
and	26	different	2nd	line	combinations.	Paediatricians	also	displayed	a	fair	amount	of	
variation,	with	17	different	1st	line	and	23	different	2nd	line	treatment	combinations.	
Gastrografin®	and	Klean-Prep®	were	the	most	commonly	used	1st	line	treatments	for	the	
adult	survey,	but	paediatricians	opted	for	surgical	review	as	the	top	choice	for	1st	line	
treatment,	follow	by	Gastrografin®.		
6.4.2	Strengths	of	the	survey	
FG,	WC	and	I	designed	the	survey	so	that	the	average	respondent	would	take	less	than	5	
minutes	to	complete	the	questions.	Short	surveys	are	generally	favourable	because	the	
audience	do	not	have	to	sacrifice	a	great	deal	of	time	to	answer	questions.	After	
reviewing	all	the	questions	in	the	draft	survey,	I	also	helped	to	eliminate	some	non-
essential	questions	in	order	to	shorten	the	duration	time.		
The	questions	were	based	around	clinical	cases	similar	to	those	seen	in	real	patients	and	
we	used	terminology	that	the	consultants	would	be	familiar	with	e.g.	“right-iliac	fossa	
mass”.	I	helped	FG	and	WC	to	improve	the	phrasing	and	structure	of	the	questions	so	that	
they	were	clear	and	more	succinct.		
I	also	ensured	that	the	respondents	could	select	however	many	treatment	options	they	
deemed	necessary.	As	the	respondents	were	not	restricted	in	their	choices,	it	is	likely	that	
the	answers	were	more	accurate.		Adding	a	box	underneath	the	options	labelled,	“other”	
for	respondents	to	write	additional	options	or	comments,	enhanced	this.		
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Before	distribution,	WC	and	I	tested	the	survey	by	answering	the	questions	ourselves.	
This	gave	us	an	opportunity	to	amend	any	errors	and	rephrase	sentences	that	were	not	
clear.		
In	order	to	improve	the	response	rate,	I	sent	out	reminder	emails	one	week	after	the	first	
survey	distribution.	I	was	aware	that	emails	might	have	been	lost	in	the	many	
correspondences	of	some	consultants	and	others	were	on	annual	leave	at	the	time	of	the	
first	email.		
6.4.3	Survey	limitations	
This	survey	did	not	include	countries	outside	the	four	devolved	nations	of	the	UK.	
However,	given	the	disagreements	within	one	country	with	a	unified	training	program	
and	clinicians	who	all	follow	the	same	guideline,	it	is	unlikely	that	there	is	more	
agreement	elsewhere	in	the	world.		
Although	I	sent	emails	to	all	the	main	CF	centres	in	the	UK,	there	were	some	centres	that	
did	not	complete	the	survey.	For	the	adult	survey,	these	centres	were:	London	(South),	
Nottingham	and	Edinburgh.	For	the	paediatric	survey,	these	centres	were:	Leeds,	London	
(South),	Newcastle	upon	Tyne,	Sheffield,	Aberdeen,	Dundee,	Lanarkshire	and	Cardiff.	It	
would	have	been	preferable	to	have	at	least	one	response	from	each	centre,	but	I	
realised	that	this	would	have	been	difficult	to	achieve	in	practice.	Ultimately,	I	collected	
responses	from	21/24	adult	centres	and	20/28	paediatric	centres.	I	deemed	these	to	
sufficiently	represent	the	treatment	approaches	used	across	the	UK.				
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6.4.4	 Differences	 in	 approach:	 Paediatricians	 compared	 to	 adult	
physicians	
The	survey	revealed	obvious	differences	in	approach	between	paediatricians	and	adult	
physicians,	particularly	demonstrated	in	their	choice	of	laxatives	for	incomplete	DIOS	and	
in	their	approaches	to	surgical	review	for	complete	DIOS.		
Adult	physicians	were	more	likely	to	use	bowel	cleansers	such	as	Gastrografin®	to	treat	
incomplete	DIOS,	whereas	paediatricians	tended	to	use	Movicol®	and	treated	incomplete	
DIOS	as	they	would	for	constipation.	The	pathophysiology	and	clinical	diagnoses	for	
constipation	and	DIOS	are	distinct	(102),	so	I	believe	they	should	be	treated	as	separate	
conditions.	It	is	likely	that	adult	physicians	have	more	clinical	experience	in	treating	
patients	with	DIOS	(it	tends	to	be	more	common	in	adulthood)	(91)	so	they	may	recognise	
that	it	is	distinct	from	constipation	and	treat	it	with	a	bowel	cleanser	instead	of	an	
osmotic	laxative.	
The	second	big	difference	between	adult	physicians	and	paediatricians	was	the	extent	at	
which	they	relied	on	surgical	review	for	the	treatment	of	complete	DIOS.		68%	
paediatricians	chose	to	include	a	surgical	review	in	their	1st	line	management	for	
complete	DIOS,	compared	to	only	39%	adult	physicians.	Paediatricians	also	had	a	lower	
threshold	for	sending	their	patients	for	a	surgical	review,	with	95%	paediatricians	
requesting	a	surgeon	for	bilious	vomiting,	compared	to	33%	adult	physicians.	42%	
paediatricians	would	also	call	a	surgeon	if	their	patient	had	not	improved	on	medical	
therapy	after	24	hours,	compared	to	17%	adult	physicians.		
	
It	may	be	that	these	results	demonstrate	predictable	differences	in	approach	between	
paediatric	and	adult	medicine,	where	paediatricians	have	a	lower	threshold	for	surgical	
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intervention	due	to	pressure	put	on	them	from	anxious	parents.	However,	it	is	more	likely	
that	these	results	suggest	that	paediatricians	have	less	confidence	in	dealing	with	acute	
bowel	obstruction	than	their	adult	colleagues,	as	the	incidence	of	DIOS	is	reportedly	
lower	in	children	than	in	adults	(8).	These	findings	are	supported	by	the	literature,	as	
Munck	(111)	also	found	that	children	were	more	likely	to	receive	surgical	intervention	
than	adults.	
6.4.5	Lack	of	Consensus	
On	average,	the	treatment	for	incomplete	DIOS	showed	the	greatest	amount	of	variation,	
with	many	consultants	treating	incomplete	DIOS	the	same	as	they	would	for	constipation.	
This	highlights	an	area	of	insufficient	knowledge,	experience	(as	explained	above)	
compounded	by	the	fact	that	constipation	and	incomplete	DIOS	are	sometimes	difficult	
to	clinically	distinguish	from	one	another	in	practice.	Although	there	are	criteria	for	
differentiating	constipation	from	incomplete	DIOS	(102),	the	margins	between	them	are	
sometimes	blurred	when	faced	with	an	individual	patient.		
The	lack	of	certainty	in	treating	DIOS	is	also	driven	by	a	great	lack	of	evidence.		This	was	
reflected	in	the	survey	where	over	99%	consultants	recognised	the	scarcity	of	high-quality	
evidence.	There	are	no	national	or	international	evidence-based	guidelines	for	the	
treatment	of	DIOS,	but	there	are	evidence-based	guidelines	for	the	treatment	of	
constipation	(101),	which	could	be	a	reason	for	the	lower	number	of	combinations	used	
for	constipation.	However,	it	is	important	to	note	that	the	guidelines	for	constipation	do	
not	advocate	the	use	of	Movicol®	(the	most	common	constipation	treatment	in	this	
survey)	for	patients	with	CF.	Therefore,	caution	should	be	taken	when	extrapolating	these	
guidelines	to	include	the	use	of	Movicol®	for	CF	constipation.		
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Furthermore,	I	believe	that	the	variation	in	DIOS	management	is	precipitated	by	the	lack	
of	Patient	Reported	Outcome	Measures	(PROMs)	and	Magnetic	Resonance	Imaging	(MRI)	
scans,	which	comes	from	a	lack	of	evidence	on	these	resources.	If	these	were	commonly	
used,	they	may	well	advance	the	diagnostic	process	of	DIOS	and	provide	information	
about	the	quality	of	care	delivered	to	patients.		
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Chapter	7:		Conclusions	
7.1	Main	findings	from	thesis	
During	my	reading,	I	discovered	that	DIOS	is	a	common	condition	in	CF	(109,	110)	and	if	it	
progresses	to	complete	intestinal	obstruction,	can	also	be	a	life	threatening	condition.	It	
is	therefore	rational	to	expect	that	such	a	significant	problem	should	have	robust	
evidence	for	its	treatment	and	prevention.	However,	throughout	my	literature	review,	I	
could	not	find	any	set	guidelines	for	the	prevention	or	for	the	treatment	of	DIOS.	The	
ESPGHAN	CF	working	group	set	clear	criteria	regarding	the	clinical	diagnosis	of	DIOS	
(102),	but	the	information	for	the	management	of	DIOS	was	extremely	vague	and	only	
based	on	case	studies	and	anecdotal	evidence.		
Before	starting	the	Cochrane	review,	I	considered	that	the	scarcity	of	evidence	on	DIOS	
reflects	how	little	importance	is	placed	on	gastrointestinal	problems	in	CF.	
Conversely,	there	are	a	staggering	number	of	randomised	controlled	trials	on	the	
respiratory	complications	in	CF.	This	is	likely	the	case	because	CF	patients	predominantly	
suffer	from	respiratory	complications	and	are	most	likely	to	die	from	respiratory	failure.	
However,	as	explained	in	my	literature	review,	all	complications	in	CF	affect	the	overall	
health	of	the	patient.	If	gastrointestinal	problems	such	as	constipation	and	DIOS	are	not	
managed	effectively,	they	may	worsen	the	patient’s	quality	of	life,	nutritional	status,	
mobility,	and	ultimately	make	them	more	susceptible	to	respiratory	infections.	It	is	
therefore	imperative	that	these	problems	are	placed	at	a	higher	level	of	importance.				
After	these	findings	in	my	literature	review,	my	aim	for	this	thesis	was	to	determine	the	
current	evidence	and	practice	for	the	management	of	DIOS.	From	this,	I	had	two	
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objectives:	to	conduct	a	Cochrane	systematic	review	to	evaluate	the	evidence	and	create	
a	survey	to	evaluate	current	practice.		
	
The	Cochrane	review	revealed	a	huge	lack	of	evidence	for	the	prevention	of	DIOS	in	CF.	
Only	one	study	was	eligible	for	inclusion,	so	I	was	unable	to	compare	the	safety	and	
efficacies	of	different	interventions.		This	also	meant	that	I	was	unable	perform	a	meta-
analysis	to	assess	the	consistency	and	reliability	of	the	results.		In	addition,	the	included	
study	was	downgraded	in	quality	for	various	reasons,	did	not	assess	the	use	of	a	typical	
laxative	agent	and	drug	in	question	is	no	longer	licenced	for	use	in	the	UK.		
The	limited	findings	from	the	review	suggested	the	importance	of	patient-reported	
symptom	scores,	which	may	provide	information	about	the	tolerability	and	overall	effects	
of	an	intervention.	However,	this	was	poorly	demonstrated	in	such	a	small	number	of	
participants.		
The	unfinished	Cochrane	review,	“Interventions	for	the	treatment	of	DIOS”	also	showed	
that	there	is	most	likely	a	deficiency	of	evidence	for	the	treatment	of	DIOS	in	CF.	From	the	
full-text	screen,	I	judged	that	there	was	only	one	eligible	abstract	which	contributed	a	
limited	amount	of	data.		
The	survey	demonstrated	a	lack	of	consensus	and	therefore	a	lack	of	evidence	for	the	
treatment	of	incomplete	DIOS	and	complete	DIOS.	It	seems	that	many	clinicians	have	
difficulty	diagnosing	incomplete	DIOS	in	clinical	practice	(as	they	treated	incomplete	DIOS	
exactly	as	they	would	for	constipation)	and	nearly	all	have	acknowledged	the	lack	of	clear	
evidence	for	the	treatment	of	DIOS.	Furthermore,	there	are	differences	in	approach	
between	paediatricians	and	adult	physicians	in	their	choice	of	laxative,	with	adult	
physicians	more	likely	to	use	a	more	potent	bowel	cleanser	to	treat	incomplete	DIOS,	
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whereas	paediatricians	mostly	used	Movicol®.	In	addition,	paediatricians	were	far	more	
likely	to	request	a	surgical	review	than	adult	physicians.	These	differences	most	likely	
relate	to	their	degree	of	experience	in	treating	DIOS.			
7.2	Implications	for	future	practice	
The	results	of	the	survey	and	review	should	signal	that	there	is	no	consensus	or	evidence-
base	for	the	management	of	DIOS	in	clinical	practice.	As	mentioned,	there	is	a	great	deal	
of	importance	placed	on	respiratory	complications	in	CF,	but	not	enough	on	the	
gastrointestinal	problems	that	commonly	arise.	This	was	not	only	proven	by	the	results	of	
the	review;	the	survey	also	highlighted	the	confusion	that	can	occur	between	
constipation	and	incomplete	DIOS,	as	many	clinicians	treated	them	as	though	they	were	
the	same	complication.		
However,	one	must	appreciate	that	it	is	sometimes	difficult	to	distinguish	these	
complications	from	one	another	in	clinical	practice.	With	that	said,	I	believe	the	use	of	
abdominal	imaging	may	be	important	in	the	management	of	DIOS.	This	featured	as	an	
outcome	measure	in	the	review	and	was	mentioned	in	the	survey’s	discussion.	Abdominal	
imaging	e.g.	MRI	could	be	used	to	aid	the	diagnosis	of	DIOS	and	also	act	as	a	measure	of	
treatment	efficacy.	The	unclear	clinical	distinction	between	constipation	and	incomplete	
DIOS	could	be	alleviated	by	the	use	of	imaging.	Furthermore,	abdominal	imaging	could	be	
used	as	a	marker	for	the	treatment	of	DIOS;	clinicians	could	assess	the	efficacy	of	various	
laxative	agents	by	comparing	patients	imaging	results.	
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It	is	also	worth	noting	that	the	review	highlighted	the	use	of	patient-reported	symptom	
scores.	These	are	important	in	clinical	practice	for	understanding	how	patients	experience	
and	tolerate	their	treatments.	The	significance	of	patient	reported	outcome	measures	
was	also	highlighted	in	the	discussion	of	the	survey;	they	could	enhance	the	quality	of	
care	delivered	to	patients.	For	example,	PROMs	may	be	used	to	investigate	the	
palatability	of	various	laxative	agents	used	for	treating	constipation	and	DIOS,	which	
could	provide	important	information	about	their	tolerability.	Overall,	patient	feedback	
could	lead	to	better	communication	and	hence,	improve	patient	satisfaction	and	
adherence.		
	
7.3	Implications	for	future	research	
As	there	was	only	one	low	quality,	crossover	trial	eligible	for	inclusion	in	the	systematic	
review,	it	is	evident	that	there	is	a	great	need	for	more	research	in	this	area.	My	findings	
were	also	reflected	in	the	survey,	where	99%	clinicians	recognised	that	there	is	a	lack	of	
high	quality	evidence	for	the	treatment	of	incomplete	and	complete	DIOS.	Future	trials	
should	also	include	larger	numbers	of	participants	for	more	precision	and	be	designed	as	
placebo-controlled,	randomised-	controlled	trials	in	order	to	provide	robust	evidence.		
Following	on	from	the	limited	findings	of	the	review,	it	would	be	very	interesting	to	look	
at	the	role	of	prokinetics	for	the	prevention	or	treatment	of	DIOS.	Although	cisapride	has	
been	removed	from	the	UK	drug	market,	there	are	many	other	types	of	prokinetics	such	
as	domperidone	and	metoclopramide,	as	well	as	antibiotics	with	prokinetic	properties	
such	as	erythromycin	and	azithromycin.		Azithromycin	is	commonly	used	for	respiratory	
complications	in	CF,	so	it	would	be	interesting	to	see	whether	the	incidence	of	DIOS	in	
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patients	taking	azithromycin	is	significantly	different	to	those	not	taking	it.	An	
observational	study	using	data	from	the	UK	CF	registry	could	help	obtain	this	information.	
Of	course,	there	are	various	factors	that	may	affect	the	incidence	of	DIOS;	patients	who	
take	regular	azithromycin	arguably	have	a	lower	standard	of	health	and	may	be	more	
likely	to	suffer	from	gastrointestinal	complications,	such	as	DIOS.	However,	these	types	of	
factors	could	be	accounted	for	in	subgroup	analyses,	for	example,	grouping	patients	
according	to	their	%FEV1.	In	summary,	the	lack	of	evidence	on	this	subject	has	opened	up	
various	avenues	for	further	research.	After	the	Cochrane	review	demonstrated	the	use	of	
prokinetics	for	the	prevention	of	DIOS	(albeit	in	a	very	limited	way),	I	believe	the	next	
logical	step	is	to	further	investigate	their	role	in	the	management	of	DIOS.		
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Chapter	8:	Reflections	on	intercalating	
Before	starting	my	fourth	year	in	medical	school,	I	had	originally	planned	to	carry	on	to	
fifth	year	without	intercalating	because	I	had	not	found	a	course	that	had	sparked	my	
interest.	This	changed	after	I	did	some	further	research	and	discovered	the	MPhil	in	CF,	
led	by	Dr	Gilchrist.	I	was	delighted	that	the	MPhil	was	on	such	a	fascinating	and	complex	
subject	in	which	I	could	truly	immerse	myself.	During	my	previous	medical	school	
placements	I	had	also	developed	an	enthusiasm	for	paediatrics;	consequently	I	was	
pleased	that	the	MPhil	would	involve	working	closely	with	the	paediatric	department	at	
the	hospital.	But	above	all,	I	was	eager	to	learn	the	skills	involved	in	research	so	that	in	
my	future	career	I	could	add	value	and	contribute	to	a	subject	that	I	feel	passionately	
about.		
	
When	I	discovered	that	I	would	be	an	author	of	a	Cochrane	review,	my	initial	reaction	was	
that	of	surprise.	I	had	no	previous	experience	in	systematic	reviews	or	meta-analysis	
methods	other	than	the	few	lectures	I	had	attended	in	medical	school.	The	prospect	was	
rather	overwhelming.	I	remedied	my	lack	of	knowledge	by	attending	a	4-part	training	
course	on	Cochrane	reviews,	which	helped	me	gain	some	understanding.	However,	the	
course	provided	a	large	amount	of	information	in	a	relatively	short	period	of	time,	which	
meant	that	I	forgot	some	of	the	material.	It	was	really	when	I	began	working	on	the	
review	that	I	gained	a	better	understanding.	This	was	supplemented	by	the	countless	
questions	I	asked	our	managing	editor	(NJ)	and	I	will	be	eternally	grateful	for	her	patience	
and	support.	I	also	watched	several	Cochrane	webinars	and	attempted	to	gain	as	much	
knowledge	as	I	could	from	the	Cochrane	handbook.	Although	I	struggled	at	times	to	
	
150	
comprehend	these	new	skills,	in	retrospect	I	enjoyed	the	steep	learning	curve.	I	also	
valued	being	able	to	work	independently	and	in	depth	on	something	that	I	could	take	my	
time	over;	I	was	often	unable	to	do	this	during	the	hectic	life	of	medical	school.		
	
When	it	came	to	writing	the	thesis,	I	initially	found	the	process	to	be	quite	difficult.	I	have	
always	loved	writing	and	I	undoubtedly	underestimated	the	task	of	writing	such	a	long	
piece	of	work.	I	quickly	realized	that	a	thesis	requires	a	particular	style,	structure	and	
requires	a	great	deal	of	planning.	However,	after	careful	organisation	and	devoting	
sufficient	time	to	writing,	it	was	very	achievable.		
	
After	all	the	time	and	effort	I	had	devoted	to	gain	an	understanding	of	the	methodology	
involved	in	a	Cochrane	review,	I	found	it	very	frustrating	that	I	was	unable	to	perform	a	
meta-analysis	for	the	review.	This	initially	led	me	to	be	overly	optimistic	about	the	
inclusion	of	another	study.	In	hindsight,	I	was	so	eager	to	compare	two	studies	that	I	had	
overlooked	the	risk	of	bias	for	the	second	study.	Ultimately,	I	realised	that	there	is	no	
point	in	producing	a	review	if	it	includes	poor	studies	that	do	not	fit	the	review’s	
rationale.	And	although	I	had	not	been	able	to	perform	a	meta-analysis,	I	had	still	gained	
valuable	skills	that	could	be	used	for	future	reviews.	In	addition,	my	review	identified	
gaps	in	the	literature	that	would	highlight	areas	for	future	research.			
	
Overall,	I	have	gained	a	great	deal	of	knowledge	and	experience	from	this	MPhil.	I	now	
know	what	is	involved	in	a	Cochrane	review	and	learned	valuable	skills	from	being	part	of	
one.		After	helping	to	write	a	protocol	and	responding	to	peer	review	comments	on	it,	I	
now	understand	the	criteria	required	to	produce	an	effective	protocol.	I	have	learnt	what	
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makes	a	comprehensive	search	strategy	and	how	to	navigate	my	way	around	online	
medical	databases.	After	screening	studies,	extracting	data	and	assessing	studies	for	
quality,	I	have	vastly	improved	my	skills	for	critical	appraisal.		I	now	understand	the	
important	points	to	consider	when	analysing	data	e.g.	directness,	precision	and	
consistency	and	have	produced	a	Summary	of	Findings	table	to	illustrate	this.	Although	I	
did	not	perform	a	meta-analysis,	I	have	learnt	a	great	deal	about	the	tests	and	processes	
required	to	perform	one.	In	addition,	I	have	learnt	how	to	use	the	software	needed	
produce	a	Cochrane	review	e.g.	RevMan,	Covidence,	GRADE.		
Generally,	being	able	to	examine	intervention	studies	and	understand	areas	that	may	
downgrade	or	upgrade	evidence	has	given	me	a	useful	set	of	skills	for	my	future	practice.	
Towards	the	end	of	my	MPhil,	I	also	contributed	to	a	protocol	proposal	for	the	next	MPhil	
student	(who	will	be	in	the	department	from	September	2017).	I	found	this	to	be	a	
valuable	experience	because	I	did	not	have	the	opportunity	to	contribute	to	the	proposal	
for	my	own	review	protocol;	this	therefore	completed	my	holistic	“Cochrane	experience”.	
	
Furthermore,	in	contributing	to	the	production	and	distribution	of	a	survey,	I	now	
understand	the	important	points	to	consider	when	writing	a	questionnaire.	And	after	
distributing	and	collecting	a	large	amount	of	data,	I	now	have	a	greater	appreciation	of	
the	work	involved	in	generating	a	survey.	
Clinically,	I	had	almost	no	knowledge	of	DIOS	before	starting	this	academic	year.	After	
attending	weekly	CF	clinics	and	writing	my	literature	review,	I	now	have	a	far	greater	
understanding	about	DIOS	and	CF	in	general.	I	also	have	great	appreciation	and	
understanding	about	how	an	MDT	works.	I	found	that	talking	to	and	shadowing	different	
professionals	involved	in	CF	care	(other	than	physicians)	was	a	very	valuable	experience;	
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it	is	not	often	that	medical	students	get	to	spend	an	extended	period	of	time	with	
professionals	such	as	physiotherapists,	dieticians,	social	workers	and	psychologists.			
	
In	conclusion,	I	have	gained	much	knowledge	and	experience	from	my	year	as	an	MPhil	
student.	I	feel	proud	to	have	been	part	of	a	Cochrane	review	that	will	be	published	and	
provide	important	information	for	clinicians	and	will	highlight	areas	for	future	research.	I	
am	also	proud	to	have	been	part	of	a	nationwide	survey	that	has	revealed	significant	
information	about	the	current	treatments	used	for	DIOS.	I	am	optimistic	about	the	
publication	of	this	survey	report.	My	hard	work	has	given	me	confidence	and	motivation	
to	engage	in	more	academia	and	research	in	my	future	career.	Working	closely	with	the	
CF	team	has	also	furthered	my	passion	to	pursue	a	career	in	paediatrics.		
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Chapter	9:	Reflections	after	the	Viva	
Two	weeks	after	handing	in	my	thesis,	my	work	and	comprehension	of	the	subject	were	
assessed	in	a	viva.	I	was	unsure	about	what	to	expect	and	felt	rather	apprehensive	about	
it.	Dr	Carroll	led	me	through	a	mock	examination	beforehand,	which	really	helped	me	to	
prepare	for	potential	questions;	I	would	like	to	take	this	opportunity	to	thank	him	for	his	
guidance	and	support.		
On	the	day	of	the	viva,	my	feelings	of	apprehension	evaporated	as	I	was	called	into	the	
room.	The	examiners	were	warm,	friendly	and	seemed	genuinely	eager	to	discuss	my	
thesis	with	me.	This	made	me	feel	very	much	at	ease.	The	calm	atmosphere	meant	that	I	
felt	confident	enough	to	have	some	in-depth	discussions	with	the	examiners	and	
showcase	my	knowledge.	After	the	viva,	I	was	delighted	to	have	been	awarded	
recommendation	2,	an	indication	that	my	hard	work	had	paid	off.		
The	most	significant	learning	point	from	the	viva	was	how	important	it	is	to	improve	and	
enhance	my	work	to	make	it	the	best	it	can	be.	After	4	years	in	medical	school,	I	became	
more	familiar	with	sitting	one	exam	and	being	awarded	a	final	result.	It	was	refreshing	to	
be	able	to	re-visit	my	work	after	the	viva	and	look	at	it	through	new	eyes.		
A	specific	learning	point	from	the	viva	was	that	I	should	write	my	discussion	with	more	
conviction.	The	examiners	wanted	me	to	be	incisive	about	the	fact	that	there	is	no	
evidence	for	the	management	of	DIOS;	they	felt	that	I	was	“holding	back”	at	times	in	my	
writing.	This	point	led	me	to	reflect	on	my	overall	confidence	in	decision-making	and	it	
made	me	realise	that	I	can	sometimes	be	hesitant	in	making	bold	statements,	even	when	
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I	am	correct.	The	examiners	had	told	me	that	I	spoke	well	and	with	conviction	in	the	viva,	
so	I	wondered	why	I	had	not	done	so	in	my	writing.	This	is	obviously	something	I	need	to	
be	aware	of	in	the	future:	I	should	not	only	be	confident	when	defending	my	work,	but	
should	be	assertive	in	my	decision	from	the	outset.		
Another	interesting	topic	from	the	viva	was	discussing	the	implications	of	my	thesis	for	
future	research.	There	are	many	possibilities,	(since	the	Cochrane	review	proved	that	
there	was	a	serious	lack	of	evidence)	but	Dr	Carroll	and	I	had	already	discussed	the	
potential	role	for	prokinetics	in	the	management	of	DIOS,	following	on	from	the	limited	
findings	in	the	review.	It	was	exciting	to	propose	this	idea	in	the	viva	because	Professor	
Lenney,	Dr	Hurley	and	I	were	able	to	debate	the	practicalities	of	conducting	a	study	on	
this	topic.	For	example,	a	study	investigating	the	role	of	azithromycin	(an	antibiotic	with	
prokinetic	properties)	could	assess	the	patient’s	pulmonary	function	(e.g.	%FEV1)	as	a	
primary	outcome	and	assess	the	incidence	of	DIOS	as	a	secondary	outcome.	A	limitation	
of	this	study	would	likely	be	the	correlation	of	a	patient’s	poor	lung	function	and	declining	
health	with	their	chance	of	having	DIOS.	After	discussing	these	points	with	the	examiners,	
I	was	further	motivated	to	explore	the	role	of	prokinetics	in	DIOS.		
Overall,	the	viva	was	a	very	useful	experience.	It	gave	me	to	opportunity	to	challenge	
myself	and	openly	discuss	my	thoughts	on	the	work	I	had	done	and	its	implications	for	
future	research.	It	has	also	given	me	the	confidence	to	be	more	assertive	in	my	decisions,	
which	is	something	I	will	take	with	me	in	my	future	work.	I	would	like	to	thank	Professor	
Lenney	and	Dr	Hurley	for	taking	the	time	to	examine	me	and	making	me	feel	at	ease.	I	
would	also	like	to	thank	Professor	Pandyan	for	being	the	independent	chair	and	for	
welcoming	me	so	warmly	to	the	examination.			
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Chapter	11:	Appendices	
Appendix	1:	Search	strategies	for	the	databases	used	in	the	Cochrane	systematic	
review.		
	
This	appendix	contains	the	search	strategies	for	CENTRAL,	MEDLINE,	EMBASE,	
clinicaltrials.gov,	ISRCTN	registry,	WHO	ICTRP	and	OpenGrey.	
	
	
CENTRAL	
	
#1	Cystic	Fibrosis	[MeSH	descriptor]	 	
#2	cystic	fibrosis:ti,ab	 	
#3	fibrocystic	near/10	disease	near/10	pancreas		
#4	mucoviscidos*:ti,ab	 	
#5	cystic*	near/10	fibros*:ti,ab	 	
#6	#1	or	#2	or	#3	or	#4	or	#5	 	
#7	distal	intestinal	obstruction	syndrome*:ti,ab	
#8	dios	or	mie:ti,ab	 	
#9	Intestinal	Obstruction	[MeSH	descriptor]	 	
#10	meconium	ileus	equivalent:ti,ab	 	
#11	faecal	near/3	(obstruction	or	impact*):ti,ab		
#12	Constipation	[MeSH	descriptor]	 	
#13	constipat*:ti,ab	 	
#14	laxative*:ti,ab	
#15	Laxatives	[MeSH	descriptor]	
#16	lactulose:ti,ab	
#17	Lactulose	[MeSH	descriptor]	 	
#18	(macrogol	or	polyethylene	glycol*):ti,ab	
#19	Polyethylene	Glycols	[MeSH	descriptor]	 	
#20	movicol:ti,ab	
#21	klean*:ti,ab	
#22	diatriozate:ti,ab	
#23	gastrografin:ti,ab	 	
#24	sennati:ti,ab	 	
#25	docusate:ti,ab	
#26	picosulfate:ti,ab	
#27	acetylcysteine	or	fibrol:ti,ab	
#28	parvolex:ti,ab	
#29	fibre:ti,ab	
#30	picosulphate:ti,ab	 	
#31	#7	or	#8	or	#9	or	#10	or	#11	or	#12	or	#13	or	#14	or	#15	or	#16	or	#17	or	#18	or	#19	or	
#20	or	#21	or	#22	or	#23	or	#24	or	#25	or	#26	or	#27	or	#28	or	#29	#30	
#32	#6	and	#31	
	
MEDLINE	Ovid	(1946	onwards)	
	
1.	Cystic	Fibrosis/	 	
2.	cystic	fibrosis.tw.	 	
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3.	(fibrocystic	adj10	disease	adj10	pancreas).tw.		
4.	mucoviscidos$.tw.	 	
5.	(cystic$	adj10	fibros$).tw.	 	
6.	1	or	2	or	3	or	4	or	5	 	
7.	"distal	intestinal	obstruction	syndrome*".tw.	 	
8.	(dios	or	mie).tw.	 	
9.	Intestinal	Obstruction/	 	
10.	meconium	ileus	equivalent.tw.	 	
11.	(faecal	adj3	(obstruction	or	impact*)).tw.	 	
12.	Constipation/	 	
13.	"constipat*".tw.	 	
14.	"laxative*".tw.	 	
15.	Laxatives/	 	
16.	lactulose.tw.	or	Lactulose/	 	
17.	(macrogol	or	polyethylene	glycol*).tw.	or	Polyethylene	Glycols/	 	
18.	movicol.tw.	 	
19.	klean*.tw.	 	
20.	diatriozate.tw.	 	
21.	gastrografin.tw.	 	
22.	senna.tw.	 	
23.	docusate.tw.	 	
24.	picosulfate.tw.	 	
25.	acetylcysteine	or	fibrol.tw.	 	
26.	parvolex.tw.	
27.	fibre.tw.	 	
28.	picosulphate.tw.	
29.	7	or	8	or	9	or	10	or	11	or	12	or	13	or	14	or	15	or	16	or	17	or	18	or	19	or	20	or	21	or	22	or	
23	or	24	or	25	or	26	or	27	or	28	 	
30.	6	and	29	
	
Embase	Ovid	(1974	onwards)	
	
1.	CYSTIC	FIBROSIS/	 	
2.	cystic	fibrosis.tw.	 	
3.	(fibrocystic	adj10	disease	adj10	pancreas).tw.		
4.	mucoviscidos$.tw.	 	
5.	(cystic$	adj10	fibros$).tw.	 	
6.	1	or	2	or	3	or	4	or	5	 	
7.	"distal	intestinal	obstruction	syndrome*".tw.	 	
8.	(dios	or	mie).tw.	 	
9.	INTESTINE	OBSTRUCTION/	 	
10.	meconium	ileus	equivalent.tw.	 	
11.	(faecal	adj3	(obstruction	or	impact*)).tw.	 	
12.	CONSTIPATION/	 	
13.	"constipat*".tw.	 	
14.	"laxative*".tw.	 	
15.	LAXATIVE/	 	
16.	lactulose.tw.	or	LACTULOSE/	
17.	(macrogol	or	polyethylene	glycol*).mp,hw.		
18.	movicol.tw.	 	
19.	klean*.tw.	 	
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20.	diatriozate.tw.	 	
21.	gastrografin.tw.	 	
22.	senna.tw.	 	
23.	docusate.tw.	 	
24.	picosulfate.tw.	 	
25.	acetylcysteine	or	fibrol.tw.	 	
26.	parvolex.tw.	
27.	fibre.tw.	
28.	picosulphate.tw.	 	
29.	7	or	8	or	9	or	10	or	11	or	12	or	13	or	14	or	15	or	16	or	17	or	18	or	19	or	20	or	21	or	22	or	
23	or	24	or	25	or	26	or	27	or	28	 	
30.	6	and	29	
	
Clinicaltrials.gov	
	
ADVANCED	SEARCH	
	
Search	1	
Search	terms:	laxative	OR	laxatives	OR	lactulose	OR	macrogol	OR	polyethylene	OR	movicol	OR	
klean	OR	diatriozate	OR	gastrografin	OR	senna	OR	docusate	OR	picosulfate	OR	acetylcysteine	
OR	fibrol	OR	parvolex	OR	picosulphate	OR	fibre	
Study	type:	Interventional	Studies	
Conditions:	cystic	fibrosis	
	
Search	2	
Search	terms:	intestinal	OR	DIOS	OR	constipation	OR	constipated	OR	faecal	OR	meconium		
Study	type:	Interventional	Studies	
Conditions:	cystic	fibrosis	
	
	
ISRCTN	Registry	
	
ADVANCED	SEARCH	
Condition:	cystic	fibrosis	
	
	
WHO	ICTRP	
	
BASIC	SEARCHES	
	
Search	1:	cystic	fibrosis	AND	intestinal	
Search	2:	cystic	fibrosis	AND	constipation	
Search	3:	cystic	fibrosis	AND	faecal	
Search	4:	cystic	fibrosis	AND	meconium	
Search	5:	mucoviscidose		
	
ADVANCED	SEARCH	
	
Condition:	cystic	fibrosis	
Intervention:	laxative	OR	laxatives	OR	lactulose	OR	macrogol	OR	polyethylene	OR	movicol	OR	
klean	OR	diatriozate	OR	gastrografin	OR	senna	OR	docusate	OR	picosulfate	OR	acetylcysteine	
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OR	fibrol	OR	parvolex	OR	picosulphate	OR	fibre	
Recruitment	Status:	All	
	
Open	Grey	
(cystic	fibrosis	OR	cf	OR	mucoviscidos*)	AND	(intestin*	OR	constipat*	OR	faecal	OR	meconium	
OR	laxative*	OR	lactulose	OR	macrogol	OR	polyethylene	OR	movicol	OR	klean*	OR	diatriozate	
OR	gastrografin	OR	senna	OR	docusate	OR	picosulfate	OR	acetylcysteine	OR	fibrol	OR	
parvolex	OR	picosulphate	OR	fibre)	
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Appendix	2:	Protocol	for	the	Interventions	for	Preventing	Distal	Intestinal	Obstruction	
Syndrome	in	Cystic	Fibrosis.	
This	protocol	can	also	be	accessed	online	at:	
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012619/full	
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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review aims to evaluate the effectiveness and safety of laxative agents of differing types for preventing DIOS (complete and
incomplete) in children and adults with CF. If possible, we aim to assess the optimal laxative regimen by comparing the evidence for
osmotic laxatives, stimulant laxatives and mucolytic agents.
B A C K G R O U N D
Cystic fibrosis (CF) is an important genetic disorder. It is life-
limiting and affected individuals have dysfunction of several or-
gan systems which results in morbidity and reduced quality of life
(QoL). To be affected a person must possess two faulty copies of
the gene that encodes a protein called the cystic fibrosis transmem-
brane conductance regulator (CFTR). About 1 in 25 of the UK
white population carry a single faulty copy of this gene and one
in 2500 newborns in the UK are born with CF (Tobias 2011).
Worldwide the condition affects approximately 70,000 children
and adults (CF Foundation 2016).
Although respiratory symptoms are prominent, and often the fo-
cus of clinical care, CF is a multifaceted disease which also has
important effects on the gastrointestinal and endocrine systems.
The CFTR is expressed in many cell types throughout the body;
it regulates chloride transport and thus indirectly influences wa-
ter transport across the cell membranes. Absent or dysfunctional
CFTR leads to thickened, dehydrated mucus.
Description of the condition
Intestinal obstruction in CF
Distal intestinal obstruction syndrome (DIOS) is a well-recog-
nised morbidity in CF. It is the result of the accumulation of thick
and sticky material within the bowel (both mucus and faeces) par-
ticularly in the final part of the small intestine (the terminal ileum
and caecum). This mass becomes connected to the bowel wall it-
self and the finger-like projections of the small bowel (intestinal
villi) making it fixed in position and difficult to remove (Colombo
2011). The bowel may be completely blocked (complete DIOS)
or only partially blocked (incomplete DIOS), e.g. when a persis-
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tent mass is found low down on the right-hand side (right iliac
fossa). Previously DIOS was known as meconium ileus equivalent
(MIE), and affects between 10% to 22% of individuals with CF
(Davidson 1987; Dray 2004; Penketh 1987; Rubinstein 1986).
The reported incidence increases with age, with almost 80% of
new cases occurring in adults (Dray 2004). Once an individual
has had DIOS the recurrence risk is about 50% (Dray 2004). A
number of factors contribute to the occurrence of DIOS. It occurs
more commonly in individuals who have pancreatic enzyme defi-
ciency (Munck 2016) and anecdotally is more common in those
who do not adhere to pancreatic enzyme replacement therapy. In
part, it occurs due to the loss of CFTR function in the intestine,
where CFTR regulates chloride, bicarbonate and sodium trans-
port.
Distinguishing DIOS from other causes of bowel
obstruction in CF
The CF gut is prone to obstruction from other causes due to its
altered pathophysiology (van der Doef 2011). A small but sig-
nificant proportion of newborns with CF present either at birth
or shortly afterwards with bowel obstruction - meconium ileus.
Meconium ileus occurs in 13% to 17% of the CF population (van
der Doef 2011). Throughout life, children and adults with CF
are prone to constipation, with almost half of all children studied
(47%) having evidence of constipation (van der Doef 2010). How-
ever, it is possible to distinguish between constipation and DIOS
both clinically and radiologically. One widely-used definition of
DIOS is an acute complete or incomplete faecal obstruction in the
ileocecum; whereas constipation is defined as gradual faecal im-
paction of the total colon (Houwen 2010). Using this definition
in individuals under 18 years of age, 51 episodes of DIOS in 39
individuals were recorded, giving an overall incidence of 6.2 (95%
confidence interval (CI) 4.4 to 7.9) episodes per 1000 patient-
years. Although there is undoubtedly overlap between constipa-
tion and incomplete DIOS, the clinical definition proposed by
Houwen permits the effectiveness of treatments to be monitored
clinically (Houwen 2010).
Description of the intervention
Treatment of constipation and the prevention of complete bowel
obstruction is required as part of optimal care for individuals with
CF. DIOS is predominantly an ileocaecal pathology (Houwen
2010). Many strategies are currently used in clinical practice and
there is a lack of consensus about what the best preventative mea-
sures are likely to be. In addition to ensuring adequate hydration
and adherence with pancreatic enzyme supplementation, different
centres use different combinations of laxatives to prevent DIOS
including lactulose, senna, polyethylene glycol (e.g. Movicol®),
sodium docusate, sodium picosulphate and fibre.
Although most children and adults with CF are prescribed inter-
ventions to prevent DIOS at some stage, there is significant het-
erogeneity observed between clinicians in their choices of agent.
With the advent of newer laxative agents, e.g. Movicol®, some
centres have changed their approach.
This review will focus upon the use of laxative agents (aperients) for
the prevention of DIOS. There are three main groups of laxatives
based upon their primary mechanism of action (although there is
overlap between the mechanism of action for some agents).
1. Osmotic laxatives
Osmotic laxatives are faecal softeners which work by increasing
water in the large bowel, either by drawing fluid from the body
into the bowel or by retaining the fluid they were administered
with.
Lactulose
Lactulose is given orally; it is widely used, but may cause flatulence
or abdominal pain in high doses (Colombo 2011).
Macrogol 3350
Macrogol 3350 is also known as polyethylene glycol, or under
the brand names Movicol®, Laxido® or Klean-Prep®. Movicol®
is recommended as first-line treatment for constipation (NICE
2015). It is commonly given to children for chronic constipation
or at a higher dose in faecal impaction. It can be given as an oral
solution or powder (BNFc 2016). Laxido® is a very similar prod-
uct which is also recommended for treatment of chronic constipa-
tion or impaction. Klean-Prep® can also be used, with the aim to
cleanse the bowel. The solution is given until clear fluid is passed
per rectum. As larger volumes are required, it is often necessary to
administer via gastrostomy or nasogastric tube (Colombo 2011;
NICE 2015).
Diatrizoate
Oral diatrizoate (also known as Gastrografin®) is used by many
centres to treat DIOS. It is given as a single dose, which can be
repeated after 24 hours. Rectal diatrizoate can also be used in more
severe cases (Colombo 2011). As diatrizoate is highly osmotic, the
individual must be adequately hydrated prior to administration in
order to avoid complications such as shock and perforation of the
bowel (Tuldahar 1999).
2. Stimulant laxatives
Senna
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Senna acts by stimulating peristalsis and increases the emptying of
the bowel. Senna is therefore useful when the individual has soft
stools, but finds it difficult to pass them (NICE 2015).
Sodium docusate
Sodium docusate acts both as a stimulant and also as a stool soft-
ener. It can be administered orally, but if this does not relieve faecal
impaction, the drug can also be given as an enema (NICE 2015).
Sodium picosulphate
Sodium picosulphate acts by stimulating the mucosa of the large
bowel, increasing its motility; it is given as an oral solution (BNFc
2016).
3. Mucolytics
Oral N-acetylcysteine
N-acetylcysteine (also known as Parvolex® ) is indicated for ab-
normal or impaired mucus production. It can be given as a single
oral dose for treatment of meconium ileus or DIOS. It is typically
diluted in a sweet drink, such as orange juice or cola, to mask the
strong and bitter taste (BNFc 2016).
How the intervention might work
Different aperients have different mechanisms of action. Histori-
cally these have been divided into three broad categories as stated
above. In clinical practice it has been helpful to titrate the doses
of these to achieve a reduction in abdominal pains and a nor-
mal physical examination, e.g. resolution of right iliac fossa mass.
Some newer agents (e.g. Movicol®) combine these effects provid-
ing both softening and stimulation.
For preventing DIOS, laxatives are likely to work by increasing
stool volume and reducing gut transit time or by softening muco-
faeculant material that has built up in the gut. The passage of larger
volumes of more liquid stool may have a mechanical effect on any
adherent mucofaeces. However, the use of high doses of laxatives
are likely to lead to other undesirable consequences including the
unacceptable frequency of stooling, soiling, abdominal distension,
flatulence and abdominal pain.
Why it is important to do this review
Intestinal obstruction is an important and common problem in
CF. Incomplete DIOS is relatively common and there is consider-
able variation in practice. In our clinical experience, prophylaxis
for DIOS is given to individuals who have had an episode of com-
plete DIOS, those who have clinical signs consistent with incom-
plete DIOS or those with pancreatic insufficiency and clinical or
radiological manifestations of constipation (e.g. faecal masses pal-
pable on clinical examination or reported abdominal pain). The
evidence base for this practice is unclear and there is no clear ev-
idence base for any preventative therapies for DIOS (Colombo
2011).
Individuals with CF undergo a very large treatment burden. In dis-
cussing the risks and benefits of preventative treatment for DIOS
it is important that we give clear information about the likely side
effects and tolerability of any proposed therapy.
O B J E C T I V E S
This review aims to evaluate the effectiveness and safety of laxa-
tive agents of differing types for preventing DIOS (complete and
incomplete) in children and adults with CF. If possible, we aim to
assess the optimal laxative regimen by comparing the evidence for
osmotic laxatives, stimulant laxatives and mucolytic agents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised-controlled trials (RCT) and quasi-
RCTs. We will assess quasi-RCTs on their merit using the
Cochrane risk of bias tool and if both reviewers are satisfied that
the groups were similar at baseline, we will include them.
We will also assess cross-over trials for possible inclusion on an
individual basis. If we deem the treatment to alter the condition
to the extent that, on entry to subsequent phases, the participants
differ from their initial state, we will exclude the trial unless we
can use data from the first phase only (see Unit of analysis issues).
Types of participants
Children and adults with CF diagnosed by sweat test or genetic
testing, with all stages and severity of lung disease and with or
without pancreatic sufficiency.
Types of interventions
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We will compare the different treatment groups of enteral laxative
therapy for preventing DIOS (including osmotic agents, stimu-
lants, mucolytics and substances which have more than one ac-
tion) at any dose to placebo, no treatment or an alternative oral
laxative therapy.
As some treatments have significant overlap in their mechanisms
of action (e.g. Movicol® is a osmotic agent which also has a stim-
ulant effect), it is proposed that initial analysis will attempt to ex-
amine whether any preventative treatment is effective. The relative
effectiveness of different classes of agents will be examined as a
subgroup analysis.
Types of outcome measures
Primary outcomes
1. Complete or incomplete DIOS diagnosed either clinically
(e.g. abdominal masses, or distension or pain) or radiologically
(e.g. dilated bowel or faecal mass).
2. Adverse effects from treatments
i) serious adverse effects of treatment regimens
(including, but not limited to, rectal bleeding, intestinal
perforation, mucosal erosions, anaphylactic reaction, vomiting
with electrolyte disturbance)
ii) other adverse effects of treatment (e.g. diarrhoea or
soiling, abdominal distension, loss of continence or pain)
Secondary outcomes
1. Time to hospital admission
i) all causes
ii) due to DIOS
2. Patient-reported quality of life (QoL) scores
3. Patient-reported symptom scores
4. Tolerability (participant- or investigator-reported rates of
concordance)
Search methods for identification of studies
Electronic searches
We will identify relevant studies from the Group’s Cystic Fibrosis
Trials Register using the terms: distal intestinal obstruction syn-
drome [DIOS]. There will be no restrictions regarding language
or publication status.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group website.
We will search the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
www.thecochranelibrary.com;
• MEDLINE Ovid (1946 onwards);
• Embase Ovid (1974 onwards).
We will also search the following trials registries and other re-
sources:
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• International Standard Randomised Controlled Trial
Number (ISRCTN) Registry (www.isrctn.com);
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch);
• Open Grey (www.opengrey.eu/).
For details of our search strategies, please see the appendices (
Appendix 1).
Searching other resources
We will check the bibliographies of included trials and any rele-
vant systematic reviews identified for further references to relevant
trials.
Data collection and analysis
Selection of studies
Once we have the complete list of identified references, one au-
thor (WC) will check for and remove any duplicates. Two authors
(WC and JG) will then review all titles and abstracts and discard
references which clearly do not meet the inclusion criteria. We will
attempt to resolve any disagreements by discussion, but if we can
not reach a decision, we will ask the third author (FG) of the re-
view to mediate until we can reach a final decision. Once we have
discarded trials on the basis of title and abstract, we will obtain
full copies of the remaining references and screen these using a
standardised screening form customised for this review.
We will consider trials in any language and will translate them as
necessary. We will include trials published as full texts, but if where
there is only an abstract available, we will include it if it presents
results. If there are no results presented within the abstract or on
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any trials registry sites, then we will classify the trial as ’Awaiting
assessment’ until more information is available. Similarly with un-
published trials, if a trial meets our inclusion criteria and quality
assessment then we will include it.
We will present the results of the search using a standardised flow
chart.
Data extraction and management
Two authors (WC and JG) will independently extract data using a
specially designed data extraction form developed by the Cochrane
Cystic Fibrosis and Genetic Disorders Review Group and adapted
to this review. We will collect data on:
• participant characteristics;
• trial characteristics and trial design;
• intervention and comparator;
• outcome data - we will report data for each outcome
separately.
One author (WC) will check the independent data extraction
forms for discrepancies and if there are any which we can not re-
solve by discussion, a third author (FG) will arbitrate.
We will enter the extracted data into the Review Manager software
for analysis (RevMan 2014). We initially will carry out the a com-
parison of any laxative agent versus placebo or usual treatment and
then, if possible, undertake subgroup analysis by type of laxative
(see Subgroup analysis and investigation of heterogeneity).
Assessment of risk of bias in included studies
We will use the risk of bias tool as described in the Cochrane Hand-
book for Systematic Reviews of Interventions to assess the risk of bias
across six domains (sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting and other
potential sources of bias) (Higgins 2011).
If the trial describes the methods of randomisation and allocation,
including the concealment of the allocation sequence from the
researchers, and we deem these to be adequate, then we will rank
the trial as having a low risk of bias for this domain. Where these
are inadequate, we will rank the trial as being at a high risk and
where it is unclear from the description given, then we will rank
it as having an unclear risk of bias.
Similarly for blinding, we will look at the method used and who
was blinded to determine the risk of bias.
We will extract information on missing data and how the inves-
tigators recorded participant withdrawals and loss to follow up.
We will also look at whether missing data were equally distributed
between the intervention and control groups. If all review authors
agree that missing data have been accounted for adequately, then
we will judge the trial to be at a low risk of bias. We will record
the trial as having a high risk of bias if the missing data have not
been reported adequately and will record it as having an unclear
risk of bias if we are unable to see how the missing data have been
reported. Two authors will assess each included trial to determine
whether the investigators used an intention-to-treat (ITT) analysis
and again, once we have reached an agreement, we will rank the
trials as being at a high, low or unclear risk of bias.
If the trial investigators report all outcomes in the paper, the review
authors will record a low risk of bias from selective reporting. If
the paper states that investigators measured outcomes, but they
do not report the results of these, the review authors will rank the
paper as being at high risk. If it is unclear to the review authors
whether the trial reports all outcomes measured, then we will state
this and rank it as unclear for this domain. We will search for
trial protocols to be able to assess outcome reporting. If we can
not locate the protocol, we will assess outcome reporting based on
a comparison between the methods section of the full published
paper and the results section.
The review authors will look for any other potential sources of
bias in the included trials and will record what they find. If neither
author can find any other source of bias, then we will rank the trial
as having a low risk for this domain and high risk if the opposite
is true.
We will present the results of the risk of bias assessment both
individually and in a summary table.
Measures of treatment effect
For dichotomous data (complete DIOS, incomplete DIOS,
pooled adverse effects, failure to tolerate treatment and adherence),
we will calculate a pooled estimate of the treatment effects for each
outcome across trials using the risk ratio (RR) and 95% confidence
intervals (CIs) where appropriate. For individual adverse events,
e.g. reported soiling, then 99% CIs will be reported.
For continuous data (patient-reported QoL, symptom scores) we
plan to record the mean change and standard deviation (SD) from
baseline for each group. We intend to calculate a pooled estimate
of treatment effect using the mean difference (MD) and 95% CIs.
Where trials use different units of measurement or measurement
scales for reporting the same outcome (which is likely to be true
for QoL and symptom scores) we will use the standardised mean
difference (SMD) to report the results. Where trials only report
only a pre-intervention mean (SD) and post-intervention mean
(SD) then we can calculate the mean change but not the SD of
the change. We will report these results narratively.
For time-to-event data (e.g. time to hospitalisation) we will express
the intervention effect as a hazard ratio (HR) with 95% CIs using
the generic inverse variance method.
Where end-points are semantically different but report to similar
outcomes then we will group outcomes. Thus, synonymous terms
will be considered jointly. We will consider:
• abdominal distension (reported) to be synonymous with
bloating, swelling or gaseous distension;
• pain to be synonymous with discomfort or ache;
• vomiting to be synonymous with emesis;
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• constipation to be synonymous with straining or dyschezia.
Unit of analysis issues
We will assess any trials using a cross-over design to establish how
much data we can include in the analysis. Where the authors have
taken account of the cross-over design in the analysis, any carry-
over effect and within-person differences, we will be able to include
the trial. Where the data have not been analysed appropriately, we
may be able to include data from the first phase of the cross-over
trial as if it were a parallel design; although the advantage of the
cross-over design (using participants as their own controls) would
be lost (Elbourne 2002).
If we find trials which are multi-arm they will possibly fall into
more than one comparison. In such cases, where the two active
treatment arms are different types of laxative regimen, e.g. Movi-
col® versus lactulose and senna versus placebo, each treatment
arm will be analysed separately against placebo and where appro-
priate included in a meta-analysis. If the two active treatment arms
are of the same type of laxative (e.g. softening agents), but em-
ploy a different laxative or dose, we will combine them against the
placebo arm to look at the effect of the type of laxative rather than
an individual drug.
If there is heterogeneity between trials looking at different types of
laxative regimen, we will carry out a subgroup analysis to look at
the effect of individual drugs (Subgroup analysis and investigation
of heterogeneity).
Dealing with missing data
We will attempt to request additional data from the trial author(s)
if there are insufficient data in the published paper or uncertainty
about data we are able to extract from the included trials. We
will undertake an ITT analysis wherever possible throughout the
review.
We will also assess the extent to which trial authors have employed
an ITT analysis and we will report the numbers of participants
who dropped out of each arm of the trial, where possible.
Where data is incomplete but partially available we will use the
last available measurement to determine effectiveness.
Assessment of heterogeneity
Where there are trials reporting the same outcomes which we
are able to include in a meta-analysis, we will assess the level of
heterogeneity using the I² statistic. We will look at the overlap of
the CIs on the forest plots to gauge the significance of the I² value.
We will base our definitions of different levels of heterogeneity
on the levels described in the Cochrane Handbook for Systematic
Reviews of Interventions:
• low (might not be important) - 0% to 40%;
• moderate - 30% to 60%;
• substantial - 50% to 90%; and
• considerable - 75% to 100%.
The Cochrane Handbook for Systematic Reviews of Interventions
states that this is a rough guide because the importance of incon-
sistency depends on several factors (Deeks 2011).
Assessment of reporting biases
Where we are able to include at least 10 trials, we will generate
a funnel plot to attempt to identify any publication bias in the
included trials (Sterne 2011). We will also attempt to identify any
selective reporting in the included publications, by comparing the
trial protocols with the final papers and by careful examination
of the trial publications and consideration of reporting of both
positive and negative effects of the intervention. Where trial pro-
tocols are not available, we will compare the outcomes reported
in the results section against the methods section of the paper.
We will extract information on the sponsors, sources of funding
and competing interests of the authors to determine the role of
external bias being introduced. To minimise publication bias, we
will search trial registries and contact pharmaceutical companies
for unpublished data.
Data synthesis
Where we are able to combine trials in a meta-analysis, we will
use the data from the selected trials to generate forest plots using
the Review Manager software (RevMan 2014). We plan to carry
out an initial combined analysis of all types of laxative agent) fol-
lowed by separate meta-analyses for different groups of laxative
agents (e.g. osmotic laxatives, stimulants and those with a com-
bined mechanism of action) and mucolytics. We will examine the
level of heterogeneity to determine which type of analysis model
to use. If there is low heterogeneity (less than 40%) then we will
use a fixed-effect model and if the I² statistic is greater than 40%
then we will use a random-effects model to summarize the data.
Subgroup analysis and investigation of heterogeneity
If there is greater than 40% heterogeneity among the included
trials, we will undertake subgroup analyses to look at the following:
• children (18 years and under) versus adults;
• type of laxative (osmotic agent (e.g. lactulose) versus
stimulant laxative regimes (e.g. senna) versus mucolytic (e.g. N-
acetylcysteine));
• single regimens versus combined regimens (e.g. lactulose
and senna)
• effectiveness of regimen in preventing complete versus
incomplete DIOS* (Houwen 2010)
*The following definitions of complete and incomplete DIOS are
taken from (Houwen 2010).
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1. Complete intestinal obstruction as evidenced by vomiting
of bilious material and/or fluid levels in small intestine on an
abdominal radiography.
2. Faecal mass in ileo-caecum.
3. Abdominal pain or distension (or both).
Complete DIOS is defined as when all three of the above criteria
are present, whereas incomplete or impending DIOS is defined as
only the second and third criteria being present.
Sensitivity analysis
Where we have performed a meta-analysis, we will carry out sen-
sitivity analyses to look at the effect of the risk of bias findings. We
will look at the effect of adding in and taking out trials where there
is high risk of bias. We will also attempt to examine the effect of
cross-over trials on the results by carrying out a sensitivity analysis
to include and exclude them.
Summary of findings table
We will report summary of findings information, with a separate
table for each treatment comparison, for our chosen outcomes
comparing laxative agents versus control, placebo or alternate reg-
imens for the outcomes: prevention of complete or incomplete
DIOS, adverse events, hospitalisation for any cause, hospitalisa-
tion for DIOS, QoL, symptom score, and tolerability. Where no
data for individual outcomes are available then a row in the table
will identify this by entry of the notation: ’data not reported’.
For each outcome we will report the illustrative risk with and with-
out the intervention, magnitude of effect (RR or MD), numbers
of trials and participants addressing each outcome and a grade
of the overall quality of the body of evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) with comments (Schunemann 2006).
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Appendix 1. Search strategies
Database/Resource Strategy
Cochrane Central Register of Controlled Trials (CENTRAL) #1 Cystic Fibrosis [MeSH descriptor]
#2 cystic fibrosis:ti,ab
#3 fibrocystic near/10 disease near/10 pancreas
#4 mucoviscidos*:ti,ab
#5 cystic* near/10 fibros*:ti,ab
#6 #1 or #2 or #3 or #4 or #5
#7 distal intestinal obstruction syndrome*:ti,ab
#8 dios or mie:ti,ab
#9 Intestinal Obstruction [MeSH descriptor]
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(Continued)
#10 meconium ileus equivalent:ti,ab
#11 faecal near/3 (obstruction or impact*):ti,ab
#12 Constipation [MeSH descriptor]
#13 constipat*:ti,ab
#14 laxative*:ti,ab
#15 Laxatives [MeSH descriptor]
#16 lactulose:ti,ab
#17 Lactulose [MeSH descriptor]
#18 (macrogol or polyethylene glycol*):ti,ab
#19 Polyethylene Glycols [MeSH descriptor]
#20 movicol:ti,ab
#21 klean*:ti,ab
#22 diatriozate:ti,ab
#23 gastrografin:ti,ab
#24 sennati:ti,ab
#25 docusate:ti,ab
#26 bicosulfate:ti,ab
#27 acetylcysteine or fibrol:ti,ab
#28 parvolex:ti,ab
#29 fibre:ti,ab
#30 picosulphate:ti,ab
#31 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #
16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27 or #28 or #29 #30
#32 #6 and #31
MEDLINE Ovid (1946 onwards) 1. Cystic Fibrosis/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. Intestinal Obstruction/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
12. Constipation/
13. “constipat*”.tw.
14. “laxative*”.tw.
15. Laxatives/
16. lactulose.tw. or Lactulose/
17. (macrogol or polyethylene glycol*).tw. or Polyethylene Glycols/
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
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(Continued)
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Embase Ovid (1974 onwards) 1. CYSTIC FIBROSIS/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. “distal intestinal obstruction syndrome*”.tw.
8. (dios or mie).tw.
9. INTESTINE OBSTRUCTION/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
12. CONSTIPATION/
13. “constipat*”.tw.
14. “laxative*”.tw.
15. LAXATIVE/
16. lactulose.tw. or LACTULOSE/
17. (macrogol or polyethylene glycol*).mp,hw.
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 6 and 29
Clinicaltrials.gov ADVANCED SEARCH
Search 1
Search terms: laxative OR laxatives OR lactulose OR macrogol OR
polyethylene OR movicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Study type: Interventional Studies
Conditions: cystic fibrosis
Search 2
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(Continued)
Search terms: intestinal OR DIOS OR constipation OR constipated
OR faecal OR meconium
Study type: Interventional Studies
Conditions: cystic fibrosis
ISRCTN Registry ADVANCED SEARCH
Condition: cystic fibrosis
WHO ICTRP BASIC SEARCHES
Search 1: cystic fibrosis AND intestinal
Search 2: cystic fibrosis AND constipation
Search 3: cystic fibrosis AND faecal
Search 4: cystic fibrosis AND meconium
Search 5: mucoviscidose
ADVANCED SEARCH
Condition: cystic fibrosis
Intervention: laxative OR laxatives OR lactulose OR macrogol OR
polyethylene OR movicol OR klean OR diatriozate OR gastrografin
OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Recruitment Status: All
Open Grey (cystic fibrosis OR cf OR mucoviscidos*) AND (intestin* OR con-
stipat* OR faecal OR meconium OR laxative* OR lactulose OR
macrogol OR polyethylene OR movicol OR klean* OR diatriozate
OR gastrografin OR senna OR docusate OR bicosulfate OR acetyl-
cysteine OR fibrol OR parvolex OR picosulphate OR fibre)
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol WC
Review stage: select which trials to include (2 + 1 arbiter) JG + WC + FG as arbiter
Review stage: extract data from trials (2 people) JG + WC
Review stage: enter data into RevMan JG
Review stage: carry out the analysis JG + WC
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(Continued)
Review stage: interpret the analysis JG + WC
Review stage: draft the final review JG + WC
Update stage: update the review WC
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Appendix	3:	Summary	of	Findings	table	for	the	review:	Interventions	for	Preventing	
Distal	Intestinal	Obstruction	Syndrome	in	Cystic	Fibrosis	
Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
placebo 
Risk with Cisapride 
Radiological 
diagnosis of 
DIOS 
(Diagnosis of 
DIOS) 
assessed with: 
Physician 
measured 
radiological 
scores 
follow up: 
range baseline 
to 6 months  
No significant difference between cisapride and 
placebo.  
 
34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
a,b,c 
Radiologist scored for 
radiographic signs of DIOS  
Adverse 
effects 
assessed with: 
Patient 
interviews 
follow up: 
range 3 
months to 12 
months  
No adverse effects were noted.  
 
34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,d 
 
Total 
gastrointestinal 
symptom 
scores 
assessed with: 
Patient 
reported 
symptom 
scores 
Scale from: 20 
to 100 
follow up: 
range 3 
months to 12 
months  
The mean total 
gastrointestinal 
symptom 
scores was 
39.2  
The mean total 
gastrointestinal symptom 
scores in the intervention 
group was 7.6 lower (14.73 
lower to 0.47 higher)  
-  34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,d 
Made up of 10 different 
gastrointestinal symptoms: 
heartburn, flatulence, 
regurgitation, fullness, 
abdominal distension, 
abdominal pain, diarrhoea, 
nausea, vomiting, anorexia.  
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Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
placebo 
Risk with Cisapride 
Abdominal 
pain symptom 
scores 
assessed with: 
Patient 
reported 
symptom 
scores 
Scale from: 2 
to 10 
follow up: 
range 3 
months to 12 
months  
The mean 
abdominal 
pain symptom 
scores was 5.9  
The mean abdominal pain 
symptom scores in the 
intervention group was 0.4 
lower (2.05 lower to 1.25 
higher)  
-  34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,d 
 
Abdominal 
distension 
symptom 
scores 
assessed with: 
Patient 
reported 
symptom 
scores 
Scale from: 2 
to 10 
follow up: 
range 3 
months to 12 
months  
The mean 
abdominal 
distension 
symptom 
scores was 4.4  
The mean abdominal 
distension symptom scores 
in the intervention group was 
0.9 lower (2.39 lower to 0.59 
higher)  
-  34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,d 
 
Alterations in 
global 
symptom 
scores (Global 
symptom 
scores) 
assessed with: 
Patient 
reported 
symptoms 
scores 
follow up: 
range baseline 
to 6 months  
With placebo: 3 felt better, 2 felt the same, 12 
felt worse. With cisapride: 12 felt better, 2 felt 
the same, 3 felt worse. p<0.05  
 
34 
(1 RCT)  ⨁◯◯◯ 
VERY LOW 
b,c,e 
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference  
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Summary of findings:  
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic 
fibrosis 
Patient or population: preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis  
Setting: Tertiary Centre  
Intervention: Cisapride  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
placebo 
Risk with Cisapride 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Selective reporting may have occurred with this outcome. Allocation concealment and sequence generation was unclear  
b. Cisapride is a prokinetic, not a typical laxative agent (Different to protocol). The study was conducted in 1990 when cisapride was still prescribed. It 
has now been taken out of the UK market and other international markets due to its rare but serious cardiac effects.  
c. Very small number of participants in the study does not give sufficient information to give a precise effect estimate.  
d. Allocation concealment and sequence generation ranked as unclear risk of bias  
e. Allocation concealment and sequence generation ranked as unclear risk of bias. Physicians were also outcome assessors for this outcome, but 
there was no mention of blinding of the physicians.  
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Appendix	4:	Survey	questionnaire	for	the	Management	of	Constipation	and	DIOS	in	
Children	with	CF	
	
Management	of	Constipation	and	DIOS	in	Children	with	CF	
	
	
Q1	Are	you:	
	
m A	consultant		
m A	doctor	in	training		
m A	doctor	in	a	non-training	post		
m A	specialist	CF	nurse		
	
Q2	 Siobhan	 is	 an	 8-year	 old	 girl	with	 CF.	She	 is	 homozygous	 Phe508del	 and	 pancreatic	
insufficient.	She	has	intermittently	been	constipated	for	3	years.		Mum	tells	you	that	she	
is	passing	small,	hard,	pellet-like	stools	(Bristol	stool	chart	-	type	1).	Her	diet	is	generally	
good	and	she	is	thriving.	Her	reported	adherence	to	Creon	is	good.		She	is	not	currently	
taking	any	laxatives.		A	small	faecal	mass	is	palpable	in	the	left	 iliac	fossa.	 	What	is	your	
first	step	in	management?	Select	all	that	apply.		
	
q Watchful	waiting		
q Lifestyle	modification	
q Start	lactulose		
q Start	senna		
q Start	paediatric	Movicol®	(macrogol	3350	sachets)		
q Start	sodium	docusate		
q Start	sodium	picosulphate		
q Start	Gastrografin®	(diatrizoate	sodium	solution)		
q Start	Klean-Prep®	(macrogol	3350	formulated	as	bowel-prep)		
q Start	N-acetylcysteine	
q Other	(please	specify)		____________________	
	
Q3	What	has	helped	you	make	these	choices	about	a	treating	Siobhan's	
constipation?	Select	all	that	apply.		
	
q Personal	experience		
q Local	guideline		
q Low	quality	evidence	e.g.	consensus,	expert	opinion,	case	reports		
q High	quality	evidence	e.g.	randomised	control	trials,	systematic	review	
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Q4	Warren	 is	 a	 10-year	 old	 boy	with	 CF.	 He	 is	 homozygous	 Phe508del	 and	 pancreatic	
insufficient.		 	He	has	 intermittent	 lower	abdominal	pain.	He	 reports	opening	his	bowels	
twice	 per	 day,	 passing	 normal,	 formed	 stools	without	 difficulty.	 His	 adherence	with	 all	
treatments	is	good.			On	examination	you	identify	a	6x4cm,	indentable	mass	in	the	right	
iliac	 fossa.	 His	 abdomen	 is	 not	 distended	 and	 bowel	 sounds	 are	 normal.	 You	 make	 a	
diagnosis	 of	 incomplete	 DIOS.	What	 is	 your	 first	 step	 in	 management?	Select	 all	 that	
apply.				
	
q Watchful	waiting		
q Lifestyle	modification		
q Start	lactulose		
q Start	senna		
q Start	paediatric	Movicol®	(macrogol	3350)		
q Start	sodium	docusate		
q Start	sodium	picosulphate		
q Start	Gastrografin®	(diatrizoate	sodium	solution)		
q Start	Klean-Prep®	(macrogol	3350	formulated	as	bowel-prep)		
q Start	N-acetylcysteine		
q Other	(please	specify)	____________________	
	
Q5	Your	treatment	is	unsuccessful.		Warren	is	admitted	to	the	paediatric	ward	with	
abdominal	distension,	pain	and	vomiting.	The	mass	is	still	present	in	the	right	iliac	fossa.	
An	abdominal	x-ray	confirms	bowel	obstruction.		You	make	a	diagnosis	of	complete	distal	
intestinal	obstruction	syndrome	(DIOS).		What	is	your	next	step	in	management?	Select	all	
that	apply.	
	
q Start	lactulose		
q Start	senna		
q Start	Paediatric	Movicol®	(macrogol	3350)		
q Start	sodium	docusate		
q Start	sodium	picosulphate		
q Start	Gastrografin®	(diatrizoate	sodium	solution)		
q Start	Klean-Prep®		
q Start	N-acetylcysteine		
q Request	a	surgical	review		
q Other	(please	specify)		____________________	
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Q6	If	Warren	fails	to	improve	with	this	treatment	regimen,	what	would	you	do?	Select	all	
that	apply.		
	
q Continue	the	same	dose	of	treatment(s)	
q Increase	dose	of	current	treatment(s)		
q Add	in	an	additional	treatment(s)		
q Replace	the	existing	treatment(s)	with	a	different	regimen		
	
	
Q7	Which	of	the	following	clinical	features	would	prompt	you	to	ask	for	a	surgical	review?	
Select	all	that	apply.	
	
q Bilious	vomiting		
q Rebound	tenderness	and	guarding		
q Evidence	of	suspected	perforation	on	repeat	abdominal	imaging		
q Failure	to	improve	with	medical	therapy	after	24	hours		
q Failure	to	improve	with	medical	therapy	after	48-72	hours		
q Failure	to	improve	with	medical	therapy	after	96	hours		
q Other	(please	specify)	____________________	
	
	
Q8	What	has	helped	you	make	the	above	choices	about	a	child	with	CF	and	DIOS?	Select	
all	that	apply.		
	
q Personal	experience		
q Local	guideline		
q Low	quality	evidence	e.g.	consensus,	expert	opinion,	case	reports		
q High	quality	evidence	e.g.	randomised	control	trials,	systematic	review		
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Appendix	5:	Survey	report	for	The	Management	of	Constipation	and	Distal	Intestinal	
Obstruction	Syndrome	at	Cystic	Fibrosis	Centres	in	the	UK.	
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Highlights:	
• There	 is	 significant	 variation	 in	 treatment	 strategies	 for	DIOS	 reported	 by	 cystic	
fibrosis	clinicians.	
• For	incomplete	DIOS,	nine	different	interventions	were	combined	into	22	different	
treatment	regimens.	
• The	variation	in	the	management	of	DIOS	is	likely	to	be	a	reflection	on	the	paucity	
of	good	quality	evidence.	
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• By	comparison,	there	is	far	less	variation	in	the	management	of	constipation	with	
Movicol®	and	lifestyle	modification	accounting	for	>70%	proposed	interventions.	
	
Abstract	
	
We	surveyed	consultants	from	paediatric	and	adult	cystic	fibrosis	centres	in	the	UK	about	
constipation	and	distal	 intestinal	obstruction	 syndrome	 (DIOS)	management.	 	 Response	
rate	was	 55%	 (81/147).	Movicol®	 and	 lifestyle	modification	 accounted	 for	 >70%	of	 the	
interventions	 used	 for	 constipation.	 Adult	 physicians	 used	 a	 higher	 median	 (range)	
number	 of	 interventions	 for	 constipation	 per	 patient;	 2	 (1-3)	 vs	 1	 (1-2),	 p=0.006.	 	 For	
incomplete	 DIOS,	 nine	 interventions,	 combined	 into	 22	 different	 regimens	 were	 used.		
The	 most	 common	 were	 Movicol®,	 Gastrografin®	 and	 lifestyle	 modification.	 	 Adult	
physicians	 were	 more	 likely	 to	 use	 Gastrografin®	 (p=0.01).	 For	 complete	 DIOS,	
Gastrografin®,	 KleanPrep®	 and	 surgical	 review	 were	 the	 most	 common	 interventions.		
Paediatricians	were	more	 likely	 to	 request	 surgical	 review	 (p=0.01).	 	 In	 summary,	 there	
was	 relatively	 little	 variation	 in	 the	management	 of	 constipation.	 	 However,	 there	was	
significant	 variation	 in	 the	management	 of	 DIOS,	 particularly	 incomplete	 DIOS.	 	 This	 is	
likely	to	be	influenced	by	the	lack	of	good	quality	evidence.	
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Introduction:	
Intestinal	 complications	 are	 common	 in	 children	 and	 adults	 with	 cystic	 fibrosis	 (CF).[1]		
Constipation	affects	up	to	half	of	all	patients[2]	and	DIOS	affects	around	5%	of	patients	in	
any	one	year[3].	Although	these	two	conditions	share	symptomatology	and	treatments,	
the	pathogenesis	is	different.		DIOS	is	acute	complete	or	incomplete	faecal	obstruction	in	
the	 ileocaecum	whereas	 constipation	 is	 gradual	 faecal	 impaction	 of	 the	 total	 colon.[4]	
Despite	 the	 high	 prevalence	 of	 constipation	 and	 DIOS	 in	 patients	 with	 CF	 there	 is	 no	
consensus	regarding	their	treatment.		We	wanted	to	establish	current	UK	practice	at	both	
adult	and	paediatric	CF	centres.	
Materials	and	Methods:	
Separate	electronic	 surveys	were	devised	 to	clarify	 the	 first	and	second-line	 treatments	
for	 constipation,	 partial	 DIOS	 and	 complete	 DIOS	 used	 by	 paediatricians	 and	 adult	
physicians.	These	were	based	around	case	vignettes	of	patients	who	met	the	diagnostic	
criteria	 for	 these	 conditions	 as	 defined	 by	 the	 European	 Society	 for	 Paediatric	
Gastroenterology,	 Hepatology	 and	 Nutrition	 CF	 Working	 Group.[4]	 The	 surveys	 are	
available	 in	 Appendix	 1.	 	 A	 link	 to	 the	 appropriate	 surveys	was	 sent	 via	 email	 to	 each	
consultants	 listed	 on	 the	 UK	 CF	 Trust	 directory	 (2013).	 	 Consultants	 not	 listed	 on	 this	
directory	were	identified	using	each	UK	CF	Centre’s	website.		In	total,	links	were	sent	to	
82	Paediatricians	and	65	Adult	CF	Physicians.		If	responses	were	not	received	within	one	
week	a	single	reminder	email	was	sent	out.	 	The	Chi-squared	test	was	used	to	compare	
the	response	between	paediatricians	and	adult	physicians.	A	p	value	<0.05	was	deemed	
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significant.	 	 All	 statistical	 analyses	 were	 undertaken	 using	 STATA	 version	 12.0	 (STATA	
Corp,	 Texas,	 USA).	 	 The	 UK	 NHS	 Health	 Research	 Authority	 ethics	 tool	 confirmed	 that	
ethical	 approval	 was	 not	 required	 (http://www.hra.nhs.uk/resources/before-you-
apply/is-nhs-rec-review-required/).		
Results:	
Response	Rate	
We	received	responses	from	51%	(42/82)	Paediatricians	and	60%	(39/65)	Adult	Physicians	
giving	an	overall	response	rate	of	55%	(81/147).			
Summarising	Free-Text	Responses	
Free	 text-responses	 related	 to	 fluid	 intake,	 exercise	 and	 adherence	 were	 grouped	 as	
“lifestyle	modification”	 and	 those	which	 included	 nil	 by	mouth,	 IV	 fluids	 or	 nasogastric	
tube	were	grouped	into	“drip	and	suck”.	
Constipation	
All	 respondents	 completed	 this	 question.	 	 The	 adult	 physicians	 used	 a	 higher	 median	
(range)	 number	 of	 interventions	 per	 patient	 than	 paediatricians;	 2	 (1-3)	 vs	 1	 (1-2),	
p=0.006.	 	Responses	are	summarised	 in	Figure	1.	 	Sachets	of	Macrogol	3350	(Movicol®)	
and	lifestyle	modifications	accounted	for	>70%	of	the	responses	from	both	paediatricians	
and	adult	physicians.	 	 Lactulose	was	 the	only	other	 intervention	used	by	paediatricians	
whereas	 the	 adult	 physicians	 also	 documented	 the	 use	 of	 sodium	 docusate,	 senna,	 N-
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acetylcysteine	and	Gastrografin®.	 	Adult	physicians	were	more	 likely	than	paediatricians	
to	recommend	lifestyle	modification	(p=0.006).					
	
	
Figure	1:	First	line	management	for	constipation.	
Incomplete	DIOS	
Complete	responses	to	this	question	were	received	from	39	paediatricians	and	37	adult	
physicians.		Responses	are	summarised	in	Figure	2.		The	nine	options	were	combined	into	
22	 different	 regimens	 by	 the	 paediatricians	 and	 23	 different	 regimens	 by	 the	 adult	
physicians.	 	The	three	most	commonly	used	interventions	were	Movicol®,	Gastrografin®	
and	 lifestyle	 modification.	 	 Adult	 physicians	 were	 more	 likely	 to	 use	 Gastrografin®	
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(p=0.01)	 and	 there	was	a	non-significant	 trend	 for	paediatricians	 to	use	more	 lactulose	
(p=0.051).		
	
Figure	2:	First	line	management	for	incomplete	DIOS.	
	
	
Complete	DIOS	
Complete	responses	to	this	question	were	received	from	38	paediatricians	and	36	adult	
physicians.		Responses	are	summarised	in	Figure	3.		The	four	most	common	interventions	
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were	 surgical	 review,	 Gastrografin®,	 KleanPrep®	 and	 “drip	 and	 suck”.	 	 There	was	 non-
significant	trend	for	adult	physicians	to	use	more	Gastrografin®	(p=0.08)	and	Klean-Prep®	
(p=0.06)	than	paediatricians.		Paediatricians	were	more	likely	than	their	adult	colleagues	
to	ask	for	a	surgical	review	as	part	of	the	initial	management	plan	(p=0.01).		When	asked	
about	signs	and	symptoms	 that	would	prompt	asking	 for	 surgical	 review,	paediatricians	
had	a	 lower	threshold	with	36/38	referring	 if	bilious	vomiting	was	present	compared	to	
12/36	adult	physicians	(p=0.0001).	
	
Figure	3:	First	line	management	of	complete	DIOS.	
	
Quality	of	Evidence	
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All	of	the	adult	physicians	and	all	but	one	of	the	paediatricians	 identified	a	 lack	of	good	
quality	 evidence	 on	 which	 to	 base	 their	 management	 decisions	 for	 patients	 with	
incomplete	and	complete	DIOS.	
Discussion	
This	survey	has	identified	the	first	line	treatment	regimens	for	constipation	and	DIOS	used	
for	 children	 and	 adults	 with	 CF	 across	 the	 UK.	 	 The	 surveys	 were	 distributed	 to	 the	
majority	of	paediatricians	and	adult	physicians	working	at	 tertiary	CF	centres	 in	 the	UK.		
The	 wide	 distribution	 and	 satisfactory	 response	 rate	means	 that	 we	 are	 confident	 the	
survey	accurately	reflects	current	UK	practice.			
There	 was	 relatively	 little	 variation	 in	 the	management	 of	 constipation	 in	 CF	 amongst	
both	adult	physicians	and	paediatricians.	 	Although	eight	different	therapies	were	 listed	
the	 vast	majority	of	 respondents	used	macrogol	 3350	and	 /	or	 lifestyle	modification	as	
their	first	line	treatment.		Paediatricians	only	listed	one	additional	treatment	option.		This	
consensus	 is	 likely	 to	be	 influenced	by	 the	national	 guidance	available	 for	 constipation,	
informed	by	randomised	controlled	trials.[5]	Although	the	NICE	guideline	is	not	specific	to	
cystic	fibrosis,	there	is	no	reason	to	think	that	this	guidance	cannot	be	extrapolated	to	CF.		
Interestingly,	 adult	 physicians	 were	 more	 likely	 to	 recommend	 lifestyle	 changes	 than	
paediatricians.		The	reasons	for	this	are	unclear	but	may	reflect	adult	patients	being	more	
willing	or	able	to	make	such	changes.	
Although	the	respondents	listed	a	large	number	of	different	regimens	for	the	treatment	
of	complete	DIOS,	Gastrografin®	and	Klean	Prep®	were	the	only	commonly	used	medical	
therapies.	 This	 is	 in	 keeping	 with	 published	 guidelines.[6,7]	 Paediatricians	 were	 more	
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likely	to	request	a	surgical	review	than	adult	physicians.			Surgical	intervention	is	generally	
accepted	as	a	last	resort.[8]	The	different	thresholds	for	surgical	intervention	may	relate	
to	 the	 increased	 prevalence	 of	 DIOS	 in	 adults	 resulting	 in	 adult	 physicians	 being	more	
used	to	seeing	and	managing	such	patients.			
The	widest	variation	in	practice	was	seen	in	the	management	of	incomplete	DIOS	with	a	
large	number	of	therapies	being	combined	into	multiple	different	regimens.	This	variation	
was	 noted	 amongst	 both	 the	 paediatricians	 and	 adult	 physicians.	 	 The	 listed	 medical	
therapies	 included	both	 laxatives	used	 for	 constipation	and	 the	bowel	 cleansing	agents	
used	to	treat	complete	DIOS.		Previously	published	guidelines	have	advocated	the	use	of	
Movicol®	as	first	line	treatment	for	incomplete	DIOS	and	gastrografin®	as	second	line.[7]				
This	 survey	 has	 highlighted	wide	 variation	 in	 the	 treatment	 regimens	 used	 in	 DIOS	 for	
children	and	adults.		This	was	most	noticeable	for	incomplete	DIOS.		A	lack	of	good	quality	
evidence	 in	 this	 area	 is	 likely	 to	 be	 the	 underlying	 cause	 for	 this	 variation	 in	 practice.		
There	is	an	urgent	need	for	further	research	to	clarify	the	optimal	treatment	of	DIOS	and	
develop	patient	reported	outcome	measures	to	assist	in	such	studies.	
Figure	legends:	
Figure	1:	First	line	management	for	constipation.	
Options	may	have	been	listed	on	their	own	or	in	combination	with	others.	*	p<0.05.			
Figure	 2:	 First	 line	 management	 for	 incomplete	
DIOS.	
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Options	may	have	been	listed	on	their	own	or	in	combination	with	others.	*	p<0.05	
	
Figure	3:	First	line	management	of	complete	DIOS.	
Options	 may	 have	 been	 listed	 on	 their	 own	 or	 in	 combination	 with	 others.	 “Drip	 and	 suck”	
includes	mention	of	nil	by	mouth,	intravenous	fluids	or	nasogastric	tube.		*	p<0.05	
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Appendix	6:	Certificates	of	attendance	from	the	Cochrane	Review	Author	
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